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1
iNtroDUctioN
Since 1991, our research group and others have been investigating children born small 
for gestational age (SGA) with persistent short stature, both before and during treat-
ment with biosynthetic growth hormone (GH). Knowledge about different aspects of 
being born SGA and about effects of GH treatment has vastly increased over the past 25 
years, but new questions emerged and needed further evaluation. This doctoral thesis 
describes the long-term effects of GH treatment, with or without additional gonadotro-
pin-releasing hormone analog (GnRHa) treatment, in children born SGA, and illustrates 
that there is more to GH treatment than meets the eye.
SMall for geStatioNal age
Small for gestational age (SGA) refers to the size of an infant at birth. Accurate informa-
tion on gestational age, birth weight, and birth length is required to determine if a child 
is born SGA. SGA is defined as a birth length and/or weight of at least two standard de-
viation scores (SDS) below the median for gestational age, based on data derived from 
an appropriate reference population (1, 2). Children born SGA can be born full-term or 
premature. The term intrauterine growth retardation (IUGR) is often used synonymously 
with the term SGA. IUGR, however, refers to a deceleration of intrauterine fetal growth 
and the diagnosis is based on ultrasound measurements during pregnancy. IUGR does 
not always result in SGA birth and being born SGA does not necessarily mean that IUGR 
occurred, e.g. the fetus is small from the beginning of gestation (Figure 1). 
The etiology of SGA encompasses a broad spectrum of maternal, environmental, pla-
cental, and fetal factors (Table 1) (3), but in a significant proportion of cases, the reason 
for being born SGA remains unclear. 
Short StatUre
Most children born SGA experience spontaneous catch-up growth during the first years 
of life and reach a normal weight and height above -2 SDS. However, approximately 
10-15% of children born SGA fail to show sufficient catch-up growth and remain short 
throughout life (height below -2 SDS) (4, 5). The reason for this insufficient catch-up 
growth is poorly understood but disturbances in the GH-axis have been postulated to 
play an important role (6-8). Short stature after SGA birth accounts for approximately 
20% of all cases of short stature (9). 
In 2015, 170.510 infants were live-born in the Netherlands (Central Bureau of Statis-
tics, The Hague, the Netherlands). According to the definition that 2.3% of all live born 
neonates are born SGA, approximately 3922 of them fulfilled the definition of being 
born SGA. Since 10-15% of children born SGA show insufficient catch-up growth, 392-
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588 of the live-born children in 2015 will have persistent short stature during childhood 
due to SGA birth.
Figure 1. Fetal growth chart showing various intrauterine growth patterns.
growth
Several factors infl uence postnatal growth including hormones, genetics, and the 
physical, emotional and social environment. The growth hormone axis (GH-axis) is the 
main hormonal axis involved in human growth and is very complex (Figure 2) (10). The 
anterior pituitary gland produces GH in a pulsatile pattern. Secretion of GH is under the 
control of the hypothalamic hormones GH-releasing hormone (GHRH) and somatosta-
tin. GHRH binds to its receptor in the pituitary and stimulates GH secretion, whereas 
somatostatin inhibits GH release. Most of the eff ects of GH are mediated by insulin-like 
growth factors (IGFs). GH infl uences the production of IGF-I, which is synthesized in the 
liver and secreted into the blood under the control of GH, insulin and nutritional status. 
Next to growth, IGFs together with insulin and GH, regulate glucose metabolism, lipid 
metabolism, and body composition.
Growth assessment requires accurate measurements of height and weight over time, 
measurement of parental height, pubertal staging, and selection of appropriate growth 
references. Normal growth has periods of spurts and plateaus, and being familiar with nor-
mal patterns of growth allows practitioners to recognize and manage abnormal variations.
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Table 1. Factors associated with reduced fetal growth (3)
Genetics
Height of parents
Chromosomal disorders of the child Down syndrome
Turner syndrome
Genetic disorders of the child Silver Russell syndrome
Maternal factors
Medical conditions Acute or chronic hypertension
Pre-eclampsia 
Severe chronic disease 
Severe chronic infection 
Systemic lupus erythematosus 
Antiphospholipid syndrome 
Anemia 
Malignancy 
Abnormality of the uterus 
Social conditions Malnutrition
Low pregnancy body mass index 
Low maternal weight gain during pregnancy 
Delivery at age <16 years or >35 years 
Low socioeconomic status 
Drug use (smoking, alcohol, illicit drugs) 
Fetal factors
Intrauterine infections Toxoplasmosis
Rubella 
Cytomegalovirus 
Herpes Simplex 
Syphilis 
Congenital defects
Inborn errors of metabolism
Placental factors
Reduced blood flow
Reduced area for exchange of nutrients and oxygen Infarcts
Haematomas 
Partial abruption 
Environmental factors
High altitude
Toxic substances
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Pubertal growth
Height and age at onset of puberty, as well as the magnitude and duration of pubertal 
growth, are important determinants of adult height, explaining 15-20% of adult height 
(11). The median age of pubertal onset in the Dutch population is 10.7 years for girls 
and 11.5 years for boys (12). During puberty, the hypothalamic-pituitary-gonadal axis 
is reactivated, which results in the development of secondary sexual characteristics, 
the pubertal growth spurt, and epiphyseal maturation (Figure 3). In girls, the pubertal 
growth spurt starts during the first year of breast development. In boys, the pubertal 
growth spurt occurs later, during the second year of puberty, when the testicular size 
has increased to >10 ml. 
Although reported study results are difficult to compare due to the use of various 
definitions for the milestones of puberty, most authors seem to agree that short children 
born SGA have a normal pubertal onset and development, but relatively early for their 
short stature (13-20). In short children born SGA, height gain during puberty is often 
reduced (18, 21). They, therefore, have a poor adult height prognosis when they enter 
puberty with a height below -2.5 SDS.
SOMATOSTATIN
HYPOTHALAMUS
PITUITARY
IGF-I
GH
+
GHRH
Figure 2. Physiology of the GH-IGF-I axis. Adapted from Kumar et al. (10).
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growth horMoNe treatMeNt 
Recombinant GH has been used since 1986 and has replaced GH extracted from human 
pituitaries in the treatment of children with GH defi ciency. The indications have gradu-
ally extended from replacement therapy in children with GH defi ciency to an increasing 
number of conditions in which short stature is not due to classic GH defi ciency, such as 
short stature after SGA birth. Since 2005, recombinant GH treatment is reimbursed for 
short children born SGA in the Netherlands. In Europe, the recommended dose for short 
children born SGA is 1 mg/m2/day (~0.033 mg/kg/day) (The European Agency for the 
Evaluation of Medicinal Products, 2001).
The aim of GH treatment in short children born SGA is achieving an adult height in the 
normal range and/or in the target height range of the child. Studies have shown that 
GH treatment eff ectively induces catch-up growth and improves adult height in most 
short children born SGA (22-25). The GH-induced growth response is, however, highly 
variable (24). Several studies have been conducted to determine clinical predictors for 
growth response to GH treatment (22, 26-29). Patient characteristics found to be related 
with adult height SDS were: age and height SDS at start of GH treatment, target height 
SDS, GH dose, bone age delay at start of treatment, and baseline IGFBP-3 SDS, together 
explaining approximately 40% of the variability in adult height SDS. 
HPG axis Inhibition of the HPG axis
+
+
+
+
- - - -
- -
-
Inhibition by 
GnRH agonist treatment
HPG axis Inhibition of the HPG axis
+
+
+
+
- - - -
- -
-
Inhibition by 
GnRH agonist treatment
Figure 3. The hypothalamic-pituitary-gonadal (HPG) axis.
Abbreviations: GnRH, gonadotropin-releasing hormone analog; LH, luteinizing hormone; FSH, follicle-stim-
ulating hormone.
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Start of gh treatMeNt iN early PUberty
GH treatment is most effective when started at a young age (22, 30, 31). However, some 
children come to medical attention at an older age, even when pubertal development 
has started. In 2003, the Dutch SGA study (Appendix A) was initiated to evaluate the 
effectiveness and safety of GH treatment in children born SGA, who start treatment at 
the age of 8 years or older. When GH treatment is started in early puberty, the epiphyseal 
maturation has been activated which might result in a limited effect of GH treatment 
(32). Gonadotropin-releasing hormone analogs (GnRHa) delay the epiphyseal matura-
tion by suppressing the pubertal axis (Figure 3), and GnRHa treatment in addition to 
GH treatment might therefore further improve adult height in children who start GH 
treatment in early puberty. 
At start of the Dutch SGA study, the efficacy and safety of GH treatment for short 
SGA children who start treatment above the age of 8 years, with or without additional 
postponement of puberty, was unknown. Besides, the optimal GH dose during puberty 
and/or postponement of puberty was unknown. Our research group recently reported 
adult height data of the Dutch SGA study, showing that short SGA adolescents can still 
have impressive catch-up growth, even when GH was started when they had already 
entered puberty (33). Besides, 2 years of GnRHa treatment in early puberty in addition 
to GH treatment further improved adult height in children born SGA who were relatively 
short at onset of puberty (33). In boys, a higher GH dose of 2 mg/m2/day during puberty 
resulted in a better adult height, compared with the standard GH dose of 1 mg/m2/day 
(33). 
Since both GH and GnRHa treatment might influence body composition and insu-
lin sensitivity, combining these treatments had raised concerns. Our research group 
showed short-term metabolic effects during 2 years of combined GH/GnRHa treatment 
in short SGA children participating in the Dutch SGA study (34). However, the long-term 
effects of this combined treatment, as well as the GH-dose effects on metabolic health 
and glucose metabolism, remained unknown. 
A previous study of our group assessed the effect of GH treatment on pubertal de-
velopment in short children born SGA and showed that GH had no effect on pubertal 
onset, progression of puberty, age at menarche, and the interval between the onset of 
breast development and menarche (19). Besides, no GH-dose effect was found on the 
onset or duration of puberty. At start of the Dutch SGA study, the effects of 2 years of 
GnRHa treatment, in addition to GH treatment, on pubertal development and growth, 
were unknown. 
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geNeS iNvolveD iN Short StatUre
Adult height is one of the most heritable human traits (35), but until now only a small 
number of genetic mutations (<1%) explain short stature in children born SGA (36-38). 
Children born SGA comprise a heterogeneous group with a broad spectrum of clinical 
characteristics (1, 2). Uncovering the genetic basis of short stature is important for health 
prognosis, genetic counseling, and treatment options. Some short children born SGA 
have accelerated bone age maturation during childhood, resulting in early closure of the 
epiphyseal growth plates and cessation of growth at a young age, with a disappointing 
short adult height. Heterozygous mutations in the ACAN gene have been described in 
children with idiopathic short stature and advanced bone age (39, 40), but the presence 
in children born SGA with persistent short stature was unknown. Due to the variance 
in clinical characteristics, the identification of appropriate patients for genetic testing 
remained a challenge. A clinical scoring system to identify children most likely to test 
positive for a mutation in the ACAN gene, and for distinguishing these children from 
those not likely to test positive, would therefore be useful. Besides, the response to GH 
treatment in children with an ACAN gene mutation was unknown.
Metabolic aND carDiovaScUlar riSK factorS iN Sga
Epidemiological studies reported an inverse association between birth weight and risk 
for diabetes mellitus type 2, hypertension, and cardiovascular disease in adult life (41-
43). In short children born SGA, reduced insulin sensitivity and an increased prevalence 
of cardiovascular risk factors have been described (44, 45). Short adults born SGA have 
a lower lean body mass than those born appropriate for gestational age (AGA), but a 
similar fat mass percentage, insulin sensitivity measured by frequently sampled intra-
venous glucose tolerance (FSIGT) tests, and lipid profile (46-49). Systolic and diastolic 
blood pressure in short adults born SGA is higher compared to adults born AGA (25). In 
contrast, adults born SGA with spontaneous catch-up growth to a normal adult height, 
have a higher fat mass percentage and lower insulin sensitivity compared to adults born 
AGA (46, 50, 51). Thus, particularly young adults born SGA with early and spontaneous 
catch-up in weight, show an unfavorable body composition and lower insulin sensitivity 
as opposed to those who remain short (52-55). Long-term studies on metabolic and car-
diovascular risk factors in these predisposed children born SGA, either with or without 
spontaneous catch-up growth, are scarce, but recognizing metabolic and cardiovascular 
diseases at an early stage is very important.
effects of gh treatment on metabolic and cardiovascular risk factors 
Besides the positive effects on linear growth, GH has well-documented lipolytic, ana-
bolic, and insulin-antagonistic effects. Long-term GH treatment results in an increase 
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in lean body mass due to its anabolic effects on muscle mass, and a decline in fat mass 
due to the lipolytic effects on fat mass (56-60). Short children born SGA have reduced 
insulin sensitivity before receiving GH treatment (44). GH has well-documented insulin-
antagonistic effects and treatment results in a further decline in insulin sensitivity and 
a compensatory increase in insulin secretion in children born SGA (57, 61-64). During 
long-term GH-treatment, blood pressure SDS and cholesterol levels decrease in GH-
treated SGA children and become lower than in untreated SGA children (25, 56, 57, 65, 
66). There are, however, only limited data on the longitudinal effects after cessation of 
GH treatment in adults born SGA (25, 46, 67). During 6 months after cessation of GH 
treatment, fat mass increases whereas lean body mass decreases (67). Studies on insu-
lin sensitivity after cessation of GH treatment reported conflicting results, with some 
describing an increase in insulin sensitivity and others reporting no change in insulin 
sensitivity after cessation of treatment (61, 62). The number of subjects in these studies 
was, however, too low to draw conclusions. Our own research group showed that the 
GH-induced lower insulin sensitivity increased during 6 months after cessation of GH 
treatment (67). It remained, however, to be elucidated how body composition, insulin 
sensitivity, blood pressure, and lipid levels would change during several years after ces-
sation of GH treatment.
Recent preliminary French data of the Safety and Appropriateness of Growth hor-
mone treatments in Europe (SAGhE) project suggest that there might be an increased 
cardiovascular mortality in adults with isolated GH deficiency or adults born SGA who 
were treated with GH during childhood (68). These data have raised concerns about 
the long-term safety of GH treatment. Sävendahl et al. reported preliminary data on 
long-term vital status and causes of death in patients treated with GH in Belgium, the 
Netherlands and Sweden, and reported no deaths due to any form of cardiovascular dis-
ease (69). These data originate from the SAGhE project, in which eight European Union 
countries participate to evaluate long-term mortality in patients treated with GH during 
childhood. The main limitation of the SAGhE project is that data of ex-patient groups are 
compared with national reference values and not with an appropriate control group of 
untreated short SGA patients. To study the effect of GH treatment on the risk of diabetes 
mellitus type 2 and cardiovascular diseases, it is necessary to evaluate the risk for these 
diseases in children born SGA, and to compare data of GH-treated young adults born 
SGA with those of untreated young adults born SGA. We set out to study longitudinal 
data on metabolic and cardiovascular risk factors after cessation of GH treatment, and 
compared these data to age-matched untreated SGA control groups (Appendix B-C).
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DeterMiNaNtS of Metabolic aND carDiovaScUlar DiSeaSeS
To evaluate metabolic and cardiovascular risk factors, it is important to use appropriate 
measurements. The various measurements used in the studies were:
body composition
It is well known that a higher fat mass percentage in adulthood results in an increased 
risk for metabolic and cardiovascular diseases. The amount of fat mass and lean body 
mass, components of body composition, can be measured by dual-energy X-ray absorp-
tiometry (DXA), which is explained in appendix D. 
glucose homeostasis
Reduced insulin sensitivity plays an important role in the pathogenesis of diabetes mel-
litus type 2 and usually precedes the first symptoms of the disease by many years. Insulin 
sensitivity and insulin secretion should be balanced; reduced insulin sensitivity leads 
to an increased insulin secretion by the β-cells in the pancreas. When insulin secretion 
does not increase in relation to reduced insulin sensitivity, impaired glucose tolerance 
and eventually diabetes mellitus type 2 will develop. One of the best ways to accurately 
measure insulin sensitivity and β-cell function is by means of a frequently sampled 
intravenous glucose tolerance (FSIGT) test with Tolbutamide (Appendix D). 
blood pressure and lipid profile
Increased blood pressure, total cholesterol, low-density lipoprotein, and apolipoprotein 
B together with reduced serum levels of high-density lipoprotein and apolipoprotein 
A-I, are determinants of cardiovascular disease. Fasting blood samples are needed to 
evaluate serum lipid levels.
carotid intima media thickness
Atherosclerosis is a contributor to cardiovascular disease. The presence of atheroscle-
rotic changes in the carotid arteries can be determined by investigating the intima me-
dia thickness (IMT) of the vessel wall of the carotid arteries by non-invasive ultrasound 
measurements (Appendix D). A greater thickness is associated with the development of 
atherosclerotic plaques and is correlated with cardiovascular events. Because develop-
ment of atherosclerosis already starts in childhood, determining carotid IMT in early 
adulthood might give more insight in the risk of cardiovascular events in later life. 
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aiMS of the theSiS 
This thesis presents a detailed description of the studies that were performed to improve 
the knowledge about and the care for short children born SGA. The study populations 
consisted of GH-treated children and young adults born SGA, participating in the Dutch 
SGA study (Appendix A) or the IUGR studies (Appendix B), and untreated young adults 
born SGA or AGA (Appendix C). The aims of the studies described in this thesis are pre-
sented below.
Metabolic and cardiovascular health during gh treatment with or without gnrha 
Body composition, blood pressure, and lipid profile were investigated from start of GH 
treatment until adult height, to determine the long-term effects of combined GH/GnRHa 
treatment versus GH treatment only. Frequently sampled intravenous glucose tolerance 
(FSIGT) tests were used to assess the long-term effects of combined GH/GnRHa treat-
ment versus GH treatment only on insulin sensitivity and β-cell function.
Pubertal development and growth during gh treatment with or without gnrha
Pubertal onset, pubertal duration, and pubertal growth were assessed in GH-treated 
children born SGA with or without 2 years of additional GnRHa treatment, to investigate 
whether 2 years of additional GnRHa treatment affects pubertal development after ces-
sation of GnRHa treatment.
Metabolic and cardiovascular risk factors after cessation of gh treatment
Body composition, insulin sensitivity, β-cell function, blood pressure, lipid profile, and 
carotid intima media thickness were investigated during 5 years after cessation of GH 
treatment to assess the long-term effects of GH treatment on metabolic and cardiovas-
cular risk factors. 
To determine the effect of GH treatment during childhood on metabolic and cardio-
vascular risk factors in early adulthood, the data at 5 years after cessation of GH treat-
ment were compared to untreated young adults born SGA with or without spontaneous 
catch-up growth, and to young adults born AGA.
acaN gene mutations in short children born Sga
ACAN-sequencing was performed in children born SGA with advanced bone age matu-
ration during GH treatment, to determine the occurrence of ACAN gene mutations in 
children born SGA. The clinical characteristics and response to GH treatment in children 
with an ACAN gene mutation were investigated. 
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oUtliNe of thiS theSiS 
Chapter 1 gives an introduction on the topics described in this thesis.
Chapter 2 describes the effects of GH treatment with or without 2 years of additional 
GnRHa on metabolic health in short children born SGA.
Chapter 3 describes the effects of GH treatment with or without 2 years of additional 
GnRHa on insulin sensitivity and β-cell function in short children born SGA.
Chapter 4 describes the effects of GH treatment with or without 2 years of additional 
GnRHa on puberty and pubertal growth in short children born SGA.
Chapter 5 shows longitudinal data on body composition and glucose homeostasis until 
5 years after cessation of GH treatment in adults born SGA.
Chapter 6 shows longitudinal data on blood pressure, lipid levels, and carotid intima 
media thickness until 5 years after cessation of GH treatment in adults born SGA.
Chapter 7 reports on ACAN gene mutations in children born SGA and growth response 
during GH treatment.
Chapter 8 discusses our results and conclusions in relation to the current literature and 
comments on the clinical implications and conclusions of our study results.
Chapter 9 contains an English and Dutch summary of the results described in this thesis.
Chapter 10 summarizes the results of Dutch GH trials in patients born SGA.
Chapter 11 contains a list of abbreviations, a list of publications, and a list of co-authors 
affiliations. It further contains the PhD portfolio, acknowledgments, and curriculum 
vitae.
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aPPeNDiX a
the Dutch Sga study
Design
The Dutch SGA study is a longitudinal, randomized, dose-response GH trial involving 
short SGA children of at least 8 years of age. All children received somatropin sc daily 
(Genotropin). Every 3 months, GH dose was adjusted to calculated body surface area. 
Prepubertal children received GH 1 mg/m2/day (Figure 4). When these children entered 
puberty or when children were in early puberty at the start of treatment, they were 
randomly assigned to treatment with either GH 1 or 2 mg/m2/day after stratification for 
gender, pubertal stage, and parental height (one or two parents with a height less than 
−2 SDS vs. both parents with a height of at least −2 SDS). Because no model is known 
to predict AH accurately at the start of puberty, we used a pragmatic, arbitrary cutoff 
level. A height of less than 140 cm at the start of puberty was used to identify children 
with an AH expectation of less than −2.5 SDS, based on Dutch reference values (12, 70); 
these children received GnRHa (leuprolide acetate depots, 3.75 mg sc every 4 weeks) for 
2 years in addition to GH treatment.
GH 1 mg/m2/day Puberty
Start treatment
before puberty
Start treatment in
early puberty
Height <140 cm
Height >140 cm
GnRHa +
GH 1 mg/m2/day
GnRHa +
GH 2 mg/m2/day
GH 1 mg/m2/day
GH 2 mg/m2/day
Randomization of GH dose
Figure 4. Flowchart of treatment regimen of the Dutch SGA study.
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Inclusion and exclusion criteria
The Dutch SGA study included children when they met de following inclusion criteria:
1) Birth length and/or birth weight SDS for gestational age less than -2.0 (71)
2) Chronological age of 8 years or older
3) Prepubertal stage (Tanner stage I) or early pubertal stage (breast stage II-III in girls 
and or testicular volume less than 10 ml in boys (72), with a GnRHa-stimulating test 
indicating central puberty (73)) 
4) Height SDS less than -2.5 SDS or a predicted adult height less than -2.5 SDS (defined 
as height at start of puberty below 140 cm), according to Dutch references (12)
5) Well-documented growth data from birth to start of treatment
6) Informed consent
Children were excluded in case of:
1) Turner syndrome in girls, known syndromes or chromosomal disorders, or serious 
dysmorphic symptoms suggestive for a syndrome that has not yet been described, 
except for Silver Russell syndrome
2) A complicated neonatal period with severe asphyxia (defined as Apgar score ≤ 3 
after 5 minutes), or long-term complications of respiratory ventilation (bronchopul-
monary dysplasia or other chronic lung disease)
3) Celiac disease and other chronic or serious diseases of the gastrointestinal tract, 
heart, genito-urinary tract, liver, lungs, skeletal or central nervous system
4) Chronic or recurrent major infectious diseases or nutritional and/or vitamin deficien-
cies
5) Endocrine or metabolic disorders, e.g. diabetes mellitus, diabetes insipidus, hypo-
thyroidism, or inborn errors of metabolism
6) Medications or interventions during the previous 6 months that might have in-
terfered with growth, such as corticosteroids (including high dose corticosteroid 
inhalation), sex steroids, growth hormone, or major surgery (particularly of the spine 
or extremities)
7) Use of medication that might interfere with growth during GH treatment, such as 
corticosteroids, sex steroids, GnRH analog
8) Active or treated malignancy or increased risk of leukemia
9) Serious suspicion of psychosocial dwarfism (emotional deprivation)
10) Expected non-compliance
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Participating centers and physicians
The Dutch SGA study is a multicenter trial coordinated by the Dutch Growth Research 
Foundation, Rotterdam, the Netherlands. Every 3 months, the PhD fellow and a research 
nurse visit 10 hospitals throughout the Netherlands to examine children in collaboration 
with the local pediatrician or pediatric endocrinologist. Standardized measurements 
take place according to schedule at the Erasmus University Medical Center – Sophia 
Children’s Hospital Rotterdam, the Netherlands.
Participating centers and pediatricians are:
Erasmus University Medical Center – Sophia Children’s Hospital Rotterdam
A.C.S. Hokken-Koelega, MD PhD
M. van der Steen, MD
J. Bontenbal-van de Wege, research nurse
A.J. Lem, MD PhD (previously)
D.C.M. van der Kaay, MD PhD (previously)
J. van Houten, research nurse (previously)
Admiraal de Ruyter Hospital, Vlissingen  E.J. Sulkers, MD PhD
Canisius Hospital, Nijmegen   C. Westerlaken, MD PhD
Catharina Hospital, Eindhoven   R.J. Odink, MD
Isala Clinics Amalia, Zwolle   E.J. Schroor, MD PhD
Leiden University Medical Center, Leiden  W. Oostdijk, MD PhD
Radboud University Medical Center, Nijmegen C. Noordam, MD PhD
Rijnstate Hospital, Arnhem   F. Neijens, MD
University Medical Center Groningen, Groningen  W.M. Bakker-van Waarde, MD PhD
Zaans Medical Center, Zaandam   J.P.C.M. van der Hulst, MD
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aPPeNDiX b
iUgr studies
The IUGR studies were started before 2003, and included children born SGA with per-
sistent short stature. At that time, the term intrauterine growth retardation (IUGR) was 
still used synonymously with the term SGA. Therefore, these initial Dutch GH studies 
were named ‘IUGR studies’. Later on, a difference in the definitions of IUGR and SGA was 
made, as discussed on page 11. By that time, however, the IUGR studies were already 
nationwide known and their name was, therefore, not changed. 
Inclusion and exclusion criteria
Children were included when they met de following inclusion criteria:
1) Birth length and/or birth weight SDS for gestational age less than -2.0 (71)
2) An uncomplicated neonatal period without signs of severe asphyxia (defined as 
Apgar score ≤ 3 after 5 minutes), sepsis or long-term complications of respiratory 
ventilation such as bronchopulmonary dysplasia 
3) Chronological age between 3 and 8 years at start of the study 
4) Height SDS less than -2.5 SDS, according to Dutch references (12)
5) Height velocity SDS below zero to exclude children with spontaneous catch-up 
growth (12)
6) Prepubertal stage, defined as Tanner stage I or testicular volume less than 4 ml in 
boys (72)
7) Normal liver, kidney and thyroid functions 
8) Well-documented growth data from birth to start of treatment
9) Informed consent
Children were excluded in case of:
1) Endocrine or metabolic disorders, e.g. diabetes mellitus, diabetes insipidus, hypo-
thyroidism, or inborn errors of metabolism
2) Celiac disease and other chronic or serious diseases of the gastrointestinal tract, 
heart, genito-urinary tract, liver, lungs, skeletal or central nervous system
3) Chromosomal disorders or serious dysmorphic symptoms suggestive for a syndrome 
that has not yet been described, except for Silver Russell syndrome
4) Chondrodysplasia
5) Active or treated malignancy or increased risk of leukemia
6) Serious suspicion of psychosocial dwarfism (emotional deprivation)
7) Use of medication that might interfere with growth during GH treatment, such as 
corticosteroids, sex steroids, GnRH analog
8) Expected non-compliance
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PrograM and PreMS study cohorts
The PROgramming factors for Growth And Metabolism (PROGRAM) study consists of 
healthy young adults born term, whereas the Prematurity and Small for Gestational Age 
(PREMS) study cohort consists of healthy young adults born preterm (gestational age 
less than 36 weeks). In these participants, several parameters for metabolic and cardio-
vascular diseases were determined.
Inclusion and exclusion criteria
Inclusion criteria:
1) Chronological age at inclusion between 18 and 24 years
2) Neonatal period without signs of severe asphyxia (defined as Apgar score ≤ 3 after 
5 minutes), sepsis, or long-term complications of respiratory ventilation, such as 
bronchopulmonary dysplasia 
3) Well-documented growth data 
4) Caucasian
5) Born singleton
6) Signed informed consent
7) PROGRAM study: gestational age of 36 weeks or more
8) PREMS study: gestational age of less than 36 weeks
Exclusion criteria:
1) Chromosomal disorders or serious dysmorphic symptoms suggestive for a syndrome 
that has not yet been described, except for Silver Russell syndrome
2) Any disease, endocrine or metabolic disorders, that could interfere with growth 
during childhood (e.g. diabetes, growth hormone deficiency, malignancies, severe 
chronic disease)
3) Treatment that could have interfered with growth (such as radiotherapy or growth 
hormone treatment)
4) Serious suspicion of psychosocial dwarfism (emotional deprivation) during child-
hood
General introduction 27
Chapter
1
aPPeNDiX D
Dual energy X-ray absorptiometry (DXa)
DXA is a machine used to measure body composition (fat mass and lean body mass) and 
bone mineral density. The person being assessed lies still for approximately 15 minutes 
while a scanner slides over the participant. DXA uses X-rays to assess these measure-
ments, but the radiation dose is about 1/10th of a chest X-ray. 
frequently Sampled intravenous glucose tolerance (fSigt) test 
Several values regarding glucose homeostasis can be measured by FSIGT tests: insulin 
sensitivity, which quantifies the capacity of insulin to promote glucose disposal; glucose 
effectiveness, which reflects the capacity of glucose to mediate its own disposal; acute 
insulin response, which is an estimate of insulin secretory capacity; and the disposition 
index, which indicates the β-cell function. These indicators of glucose regulation were 
determined by the Bergman’s minimal model, calculating paired glucose and insulin 
data obtained during an FSIGT test with Tolbutamide (74, 75).
When insulin sensitivity varies in healthy subjects, these changes are compensated 
proportionally by insulin secretion; reduced insulin sensitivity leads to increased insulin 
secretion by the β-cells (Figure 5, (76)). If insulin secretion does not change appropriately, 
impaired glucose tolerance and eventually diabetes mellitus type 2 will develop (77). 
Figure 5. Hyperbolic association between insulin secretion and insulin sensitivity. Adapted from Kahn et al. 
(76). Abbreviations: IGT, impaired glucose tolerance; T2DM, diabetes mellitus type 2.
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carotid intima Media thickness
Intima media thickness (IMT) is the thickness of the two inner layers of an arterial wall. 
The thickness of the intima media of the carotid artery is related to atherosclerosis in 
later life (78, 79). Carotid IMT (cIMT) was measured in the supine position using carotid 
ultrasonography of both the left and right carotid artery using a 7.5 MHz linear array 
transducer. A longitudinal 1 cm segment of the common carotid artery, proximal to the 
bifurcation, was identified for measurements and the images were transferred to a com-
puter. The B-mode of Art Lab, a special intima-media thickness assessment program, 
was used to measure the intima media thickness. This measurement was repeated 6 
times for each common carotid artery (left and right side) and the mean was calculated. 
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Context Previously we showed that pubertal children born small for gestational age 
(SGA) with a poor adult height (AH) expectation can benefit from treatment with growth 
hormone (GH) 1 mg/m2/day (~0.033 mg/kg/day) in combination with 2 years of GnRH 
analog (GnRHa) and even more so with a double GH dose. GnRHa treatment is thought 
to have negative effects on body composition and blood pressure. Long-term effects 
and GH-dose effects on metabolic health in children treated with combined GH/GnRHa 
are unknown. 
Objective This study aimed to investigate body composition, blood pressure, and lipid 
profile during GH treatment, either with or without 2 years of additional GnRHa. To 
assess whether GH 2 mg/m2/day (~0.067 mg/kg/day) results in a similar or even more 
favorable metabolic health at AH than GH 1 mg/m2/day.
Methods This was a longitudinal, randomized, dose-response GH trial involving 107 
short SGA children (58 girls) treated with GH until AH (GH randomized 1 or 2 mg/m2/
day during puberty). Sixty-four children received additional GnRHa. At AH, metabolic 
parameters were compared between children treated with combined GH/GnRHa and 
those with only GH. The GH-dose effect on metabolic health was evaluated in a sub-
group of 47 children who started GH treatment in early puberty (randomized 1 or 2 mg/
m2/day) with 2 years of GnRHa. 
Results At AH, fat mass percentage (FM%) SD score (SDS), lean body mass (LBM) SDS, 
blood pressure SDS, and lipid profile were similar between children treated with com-
bined GH/GnRHa and those with only GH. In the pubertal subgroup, FM% SDS was lower 
during treatment with GH 2 mg/m2/day. There was no GH dose-dependent effect on 
LBM SDS, blood pressure, and lipid profile. 
Conclusions Combined GH/GnRHa treatment has no long-term negative effects on 
metabolic health compared with only GH. Started in early puberty, a GH dose of 2 mg/
m2/day results in a similar metabolic health at AH and a more favorable FM% than GH 1 
mg/m2/day.
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Being born small for gestational age (SGA) has been associated with a higher prevalence 
of diabetes mellitus type 2, hypertension, and hyperlipidemia at a relatively young adult 
age (1). Because 10% of children born SGA have persistent short stature (2-4), many of 
them are treated with growth hormone (GH) to increase adult height (AH) (5-10). Long-
term GH treatment results in an increase in lean body mass (LBM), a decline in fat mass 
(FM), and a decrease in blood pressure (BP) and lipid profile (11-13). 
Some short SGA children only come to medical attention around onset of puberty. We 
have shown that in children who start GH treatment in early puberty with an expected 
AH less than −2.5 SD score (SDS), additional treatment with a gonadotropin-releasing 
hormone analog (GnRHa) for 2 years from start of puberty, can increase AH (14). GnRHa 
treatment is, however, known to increase FM in children with precocious puberty (15-
17). On the other hand, a GH dose of 2 mg/m2/day (~0.067 mg/kg/day) during puberty 
results in a significant increase in AH compared with the standard dose of 1 mg/m2/day 
(~0.033 mg/kg/day) (14). Studies investigating combined treatment of GH and GnRHa 
(GH/GnRHa) in children born SGA have mainly focused on AH and short-term metabolic 
effects (14, 18), but the long-term effects of this combined treatment as well as the GH-
dose effect on metabolic health are unknown.
We present safety data of a longitudinal, randomized, dose-response GH trial involv-
ing short SGA children (≥8 years at start) who were treated with GH until AH, either with 
or without additional GnRHa for 2 years from start of puberty. First, metabolic param-
eters at AH were compared between children treated with combined GH/GnRHa and 
those treated with only GH. We expected that the effects of 2 years of additional GnRHa 
treatment on metabolic parameters would be temporary and would normalize after 
discontinuation of GnRHa treatment. We hypothesized that at AH, metabolic param-
eters would be similar between these two treatment groups. Secondly, we investigated 
the GH-dose effect (1 vs 2 mg/m2/day) on body composition, BP, and lipid profile in a 
subgroup of children who started GH treatment in early puberty (randomized to 1 or 2 
mg/m2/day) with 2 years of GnRHa treatment. We hypothesized that treatment with GH 
2 mg/m2/day from the onset of puberty until AH would result in a similar or even more 
favorable body composition, BP, and lipid profile than GH 1 mg/m2/day. 
MethoDS
Subjects
The Dutch SGA study included children when they met the following criteria: 1) birth 
length and/or birth weight SDS for gestational age less than −2.0 (19); 2) chronological 
age at least 8 years; 3) prepubertal stage (Tanner stage I) or early pubertal stage (breast 
stage II-III in girls and testicular volume <10 ml in boys) with a GnRHa-stimulating test 
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indicating central puberty (20, 21); 4) height less than −2.5 SDS and/or expected AH less 
than −2.5 SDS (height at start of puberty <140 cm), based on Dutch references (22); 5) 
well-documented growth data from birth to start of treatment; and 6) normal karyotype 
in all girls (14). Children were excluded in case of a complicated neonatal period with 
severe asphyxia (defined as Apgar score ≤3 after 5 minutes), long-term complications of 
respiratory ventilation (bronchopulmonary dysplasia), endocrine or metabolic disorders, 
growth failure caused by other disorders (celiac disease, emotional deprivation, severe 
chronic illness, or chondrodysplasia), chromosomal disorders, short stature homeobox 
haploinsufficiency or syndromes (except for Silver-Russell syndrome), and children who 
were using or had used medication interfering with growth or GH treatment. None of 
135 short SGA children were included in the Dutch SGA-study between December 2003 – December 2012
121 children continued treatment according to protocol
14 children did not yet reach adult height
9 children dropped-out due to
· lack of motivation (N=3)
· non-compliance (N=3)
· social problems (N=1)
· emigration (N=1)
· psychiatric disorder (N=1)
In 5 children GH dose was changed (patient care)
· increased dose due to limited growth (N=4)
· decreased dose due to high IGF-I levels (N=1)
50 children started GH before puberty
10 children started GH in puberty with an adult
height prediction >-2.5 SDS
Total group
Patients: 107 children at adult height
Treatment: GH treatment until adult height either with or without additional GnRHa for 2 years
Analysis: GH/GnRHa vs only GH
Subgroup
Patients: 47 children who started treatment in early puberty with an adult height prediction <-2.5 SDS
Treatment: GH (randomized to 1 or 2 mg/m2/day) until adult height with additional GnRHa for 2 years
Analysis: GH 1 vs 2 mg/m2/day
Figure 1. Flowchart of inclusion, dropout, and analyses.
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the children were GH deficient according to stimulation tests (GH peak >7.7 ng/ml) or 
overnight GH profiles.
The SGA study included 135 short SGA children (70 girls) (Figure 1). Nine children 
dropped out for the following reasons: lack of motivation despite ongoing catch-up 
growth (n=3), noncompliance (n=3), social problems (n=1), emigration (n=1), and 
psychiatric disorder (n=1). In four children, the GH dose was increased due to limited 
catch-up growth, and in one child decreased due to high IGF-I levels. Among the 121 
children who continued treatment according to protocol, 107 children reached AH 
(defined as height reached when growth velocity had decreased to <0.5 cm during the 
last 6 months, and bone age was ≥15 years for girls and ≥17 years for boys), or near AH 
(defined as height velocity between 0.5 and 2 cm during the last 6 months and adult 
pubertal stage). 
This study was performed according to the Helsinki Declaration and approved by the 
medical ethics committees of the participating centers. Written informed consent was 
obtained from parents or guardians and from children older than 12 years, and assent 
was obtained in children younger than 12 years of age. Due to ethical considerations, 
the medical ethics committees did not allow a randomized untreated short SGA group.
Design 
The Dutch SGA study is a longitudinal, randomized, dose-response GH trial involv-
ing short SGA children of at least 8 years of age. All children received somatropin sc 
daily (Genotropin; Pfizer, Inc.). Every 3 months, GH dose was adjusted to calculated 
body surface area. Prepubertal children received GH 1 mg/m2/day (Figure 2). When 
these children entered puberty or when children were in early puberty at the start of 
treatment, they were randomly assigned to treatment with either GH 1 or 2 mg/m2/day 
GH 1 mg/m2/day Puberty
Start treatment
before puberty
Start treatment in
early puberty
Height <140 cm
Height >140 cm
GnRHa +
GH 1 mg/m2/day
GnRHa +
GH 2 mg/m2/day
GH 1 mg/m2/day
GH 2 mg/m2/day
Randomization of GH dose
Figure 2. Flowchart of treatment regimen.
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after stratification for sex, pubertal stage, and parental height (one or two parents with 
a height <−2 SDS vs both parents with a height ≥−2 SDS). Because no model is known 
to predict AH accurately at the start of puberty, we used a pragmatic, arbitrary cutoff 
level. A height of less than 140 cm at the start of puberty was used to identify children 
with an AH expectation of less than −2.5 SDS, based on Dutch reference values (22, 23); 
these children received GnRHa (leuprolide acetate depots, 3.75 mg sc every 4 weeks) for 
2 years in addition to GH treatment. During GnRHa treatment, puberty was sufficiently 
suppressed in all children, both clinically and by GnRHa-stimulating tests or overnight 
gonadotropin profiles (24, 25).
Measurements 
Height, weight, and Tanner stage were determined at start and every 3 months by 
the same physicians. Height was measured to the nearest 0.1 cm using a Harpenden 
stadiometer (Holtain, Ltd). Weight was measured to the nearest 0.1 kg on a digital scale 
(Servo Balance KA-20-150S, Servo Berkel Prior). Height and weight were transformed 
into SDS for sex and chronological age according to Dutch references (22), using Growth 
Analyzer Research Calculation Tools (Growth Analyzer B.V.). AH SDS was calculated using 
references for Dutch adults (age 20 years) (22). As a component of metabolic syndrome, 
waist circumference was measured at baseline and subsequently every 6 months until 
AH in standing position by using a nonextensible tape at the midpoint between the iliac 
crest and the last rib. The mean of 2 measurements was used for analyses.
body composition 
In all children, body composition at start and at AH was measured by dual-energy X-
ray absorptiometry (DXA) scan (Lunar Prodigy; GE Healthcare). All scans were made on 
the same machine, and quality assurance was performed daily. For this type of DXA, 
the intra-assay coefficient of variation has been reported to be 0.41-0.88% for fat tis-
sue and 1.57-4.49% for lean body mass (LBM) (26). Total fat mass (FM) was measured 
including head and was expressed as percentage of total body weight (FM%). FM% SDS 
was calculated according to age- and sex-matched Dutch reference values (27). Because 
LBM is strongly related to height, LBM expressed as SDS for age and sex might result in 
an underestimation in case of short stature. Therefore, LBM was expressed as SDS for 
height and sex, according to Dutch reference values (27). In the subgroup of children 
who started GH treatment in early puberty (randomized to 1 or 2 mg/m2/day) with 2 
years of GnRHa treatment, DXA scans were performed at start and after 1, 2, 2.5, and 4 
years of treatment. The scans at AH were performed at the last visit or a visit in the last 
year before discontinuation of GH treatment. 
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blood pressure 
Systolic and diastolic BP were measured at start of treatment and 3-monthly thereafter, 
using an appropriately sized cuff while patients were in a sitting position. The mean of 
two measurements was used for analysis. Because height is an important determinant of 
BP in childhood, BP was expressed as SDS adjusted for height and sex (28). 
assays 
Fasting levels of total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDLc), 
apolipoprotein A-1 (ApoA-1), and apolipoprotein B (Apo-B) were measured at start of 
treatment and yearly thereafter. Low-density lipoprotein (LDLc) was calculated using 
the Friedewald formula: LDLc (mmol/l) = TC – HDLc – 0.45 x TG (29). 
TC and triglyceride were measured using an automated enzymatic method with the 
CHOD-PAP reagent kit and with the GPO-PAP reagent kit, respectively (Roche Diagnos-
tics). HDLc was measured using a homogeneous enzymatic colorimetric assay (Roche 
Diagnostics). ApoA-1 and Apo-B were determined by rate nephelometry on the Image 
Immunochemistry System, according to the manufacturer’s instructions (Beckman 
Coulter). The intra-assay variations of measurements of TC, triglyceride and HDLc were 
2.9, 3.3 and 3.9%. Between-run coefficients of variation for ApoA-1 and Apo-B were 4.2 
and 2.8% at levels of 0.94 and 0.53 g/l, respectively.
Metabolic syndrome
Revised criteria of the National Cholesterol Education Program (NCEP; Adult Treatment 
Panel III [ATP III]) were used to determine components of metabolic syndrome (30-32). 
Metabolic syndrome was defined as having three or more of the following risk factors: 
1) abdominal obesity: waist circumference in men greater than 102 cm, and in women 
greater than 88 cm; 2) triglyceride above 1.7 mmol/l; 3) HDLc in men below 1.03, in 
women below 1.3 mmol/l; 4) BP ≥130/ ≥85 mm Hg; 5) fasting glucose above 5.6 mmol/l.
Statistics 
Statistical analyses were performed using SPSS version 21 (IBM). Distribution of vari-
ables was determined by Kolmogorov-Smirnov test and normal Q-Q-plots. Clinical 
characteristics are presented as mean (SD). Differences at start between children treated 
with combined GH/GnRHa and those treated with only GH, were evaluated using an 
independent-sample t test for normally distributed variables. A one-sample t test was 
used to compare SDS results with zero (mean value for age- and sex-matched refer-
ences).
At AH, outcome measurements between children treated with combined GH/GnRHa 
and those treated with only GH, were evaluated using multiple regression analysis to 
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correct for variables such as GH dose, GH duration, age and sex. Correlations were deter-
mined using Pearson’s correlation test. 
Additional analyses were performed in a subgroup of children who started GH treat-
ment in early puberty (randomized to 1 or 2 mg/m2/day) with 2 years of GnRHa and 
subsequent GH until AH, to evaluate changes in body composition, BP and lipid levels, 
using repeated measurements analysis (linear mixed model) with an unstructured cova-
riance matrix with GH dose as the categorical independent variable. Lipid analyses were 
also adjusted for age and sex. Differences between the 1mg and 2mg groups at various 
time-points were evaluated using an independent-sample t test. P-values < 0.05 were 
considered statistically significant.
reSUltS 
clinical characteristics 
Table 1 shows the clinical characteristics of the total group of 107 short SGA children (58 
girls). At start of treatment, the mean (SD) age was 11.5 (1.5) years and height SDS -2.9 
(0.6). Sixty-four children were treated with combined GH/GnRHa and forty-three with 
only GH. Height SDS at start of puberty was significantly lower in the group treated with 
combined GH/GnRHa (P=0.001), but AH SDS was similar between groups (P=0.540). 
total group at adult height
The total group of 107 children was treated from start to AH (64 with combined GH/
GnRHa and 43 with only GH). At start, FM% SDS, systolic BP SDS and diastolic BP SDS 
were significantly higher and LBM SDS significantly lower than average. At AH, FM% 
SDS was significantly higher (0.4 SDS, P<0.001) and LBM SDS significantly lower (-0.3 
SDS, P=0.03) than average for healthy children, but FM% SDS and LBM SDS were similar 
between children treated with combined GH/GnRHa and those treated with only GH, 
corrected for GH dose and GH treatment duration (Table 2). At AH, a systolic BP SDS 
greater than 2 SDS was found in 6.5%, in contrast to 22.4% at start. The percentage of 
children with a diastolic BP SDS greater than 2 SDS increased over time, resulting in 4.7% 
at AH vs 0.9% at start. The change in diastolic BP SDS showed a positive correlation with 
age (P<0.001). The percentage of children with a diastolic BP SDS greater than 2 SDS 
was 6.3% in those treated with combined GH/GnRHa and 2.3% in those treated with 
only GH. At AH, systolic and diastolic BP SDS were similar between children treated with 
combined GH/GnRHa and those treated with only GH, corrected for GH dose and GH 
treatment duration (Table 2). Lipid levels remained within the normal range and were at 
AH similar between children with combined GH/GnRHa and those treated with only GH, 
corrected for GH dose, GH treatment duration, age and sex (Table 2). 
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At AH, the prevalence of metabolic syndrome was 3.7% (four of 107 adolescents), ac-
cording to the revised NCEP criteria. One girl was treated with combined GH/GnRHa and 
three boys were treated with only GH.
Subgroup of pubertal children randomized to gh 1 or 2 mg/m2/day and 2 years of 
gnrha
The GH-dose effects on body composition, BP, and lipid profile were analyzed in detail 
in a subgroup of 47 pubertal children. All these children were early pubertal at the start 
of GH treatment with a poor AH expectation. They received GnRHa for the first 2 years in 
addition to GH (randomized to 1 or 2 mg/m2/day) until AH. At start, 24 children (15 girls) 
were randomized to receive GH 1 mg/m2/day (1mg group) and 23 children (15 girls) to 
GH 2 mg/m2/day (2mg group). Age at discontinuation of GH treatment was 17.6 years in 
the 1mg group and 17.3 years in the 2mg group (P<0.001). GH treatment duration was 
similar between the GH-dose groups.
Table 1. Clinical characteristics of the total group
Characteristic Total Group GH/GnRHa GH P-value
N 107 64 43
Boys/girls 49/58 23/41 26/17 0.013
Gestational age, weeks 37.5 (3.1) 37.6 (3.2) 37.3 (3.1) 0.633
Birth weight SDS -2.0 (1.0) b -2.0 (0.9) b -2.0 (1.0) b 0.899
Birth length SDS -2.6 (1.2) b -2.7 (1.2) b -2.6 (1.2) b 0.677
TH SDS -0.7 (0.7) b -0.7 (0.7) b -0.7 (0.7) b 0.916
Start of study
Age, years 11.5 (1.5) 11.8 (1.3) 11.0 (1.8) 0.014
Height SDS -2.9 (0.6) b -2.9 (0.6) b -2.9 (0.6) b 0.547
Prepubertal / pubertal at start 50/57 17/47 33/10 <0.001
Start of puberty
Age, years 12.3 (1.0) 11.9 (0.9) 12.8 (0.9) <0.001
Height SDS -2.6 (0.7) b -2.7 (0.6) b -2.3 (0.6) b 0.001
GH dose 1 vs 2 mg/m2/day 53/54 31/33 22/21 0.782
Adult height
Age, years 17.4 (1.2) 17.4 (1.0) 17.4 (1.3) 0.977
Height SDS a -1.7 (0.8) b -1.7 (0.9) b -1.6 (0.8) b 0.540
Duration treatment, years 5.9 (1.4) 5.6 (1.2) 6.4 (1.5) 0.003
Abbreviations: TH, target height.
Data are expressed as mean (SDS), unless otherwise specified. Bold text indicates a significant P-value.
a AH SDS was calculated using Dutch references for Dutch adults (age 20 years).
b Variables in SDS compared with zero SDS, P<0.001.
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Table 2. Safety parameters at start and at AH in the total group
Total group GH/GnRHa GH P-value
N 107 64 43
Boys / girls 49/58 23/41 26/17 0.013
Start 
Body composition
FM% SDS 0.2 (0.7) d 0.2 (0.7) d 0.2 (0.8) 0.788
LBM SDS -1.6 (1.1) c -1.5 (1.0) c -1.7 (1.2) c 0.204
Blood pressure
Systolic BP SDS 1.3 (1.0) c 1.4 (1.0) c 1.2 (1.0) c 0.415
Diastolic BP SDS 0.2 (0.7) e 0.1 (0.8) 0.3 (0.7) e 0.288
Lipid levels a
TC, mmol/l 4.42 (0.7) 4.24 (0.5) 4.69 (0.8) 0.001
LDLc, mmol/l 2.38 (0.6) 2.32 (0.5) 2.47 (0.7) 0.185
HDLc, mmol/l 1.48 (0.3) 1.44 (0.3) 1.54 (0.3) 0.223
TG, mmol/l 0.79 (0.3) 0.76 (0.3) 0.83 (0.3) 0.076
ApoA-I, g/l 1.46 (0.2) 1.40 (0.2) 1.55 (0.2) 0.005
Apo-B, g/l 0.74 (0.2) 0.71 (0.1) 0.77 (0.2) 0.075
At adult height b
GH dose 1 vs 2 mg/m2/day 53/54 31/33 22/21 0.782
Body composition
FM% SDS 0.4 (0.8) c 0.4 (0.7) c 0.4 (0.9) d 0.545
LBM SDS -0.3 (1.3) e -0.4 (1.3) e -0.03 (1.3) 0.423
Blood pressure
Systolic BP SDS 0.5 (1.0) c 0.4 (0.9) c 0.6 (1.1) c 0.553
Diastolic BP SDS 0.7 (0.7) c 0.7 (0.7) c 0.8 (0.7) c 0.379
Lipid levels a
TC, mmol/l 3.95 (0.7) 3.93 (0.6) 3.98 (0.7) 0.437
LDLc, mmol/l 2.23 (0.6) 2.24 (0.6) 2.22 (0.6) 0.841
HDLc, mmol/l 1.40 (0.3) 1.41 (0.3) 1.40 (0.3) 0.841
TG, mmol/l 1.01 (0.4) 0.97 (0.4) 1.07 (0.4) 0.164
ApoA-I, g/l 1.37 (0.2) 1.36 (0.2) 1.38 (0.2) 0.752
Apo-B, g/l 0.70 (0.2) 0.70 (0.2) 0.70 (0.2) 0.847
Data are expressed as mean (SDS), unless otherwise specified. Bold text indicates a significant P-value.
a Lipid levels at start and at adult height were additionally adjusted for age and sex.
b At adult height, all comparisons between children treated with combined GH/GnRHa and only GH were 
corrected for GH-dose and GH duration. 
c, d, e Variables in SDS compared with zero SDS: c P≤0.001; d P<0.01; e P<0.04.
Metabolic health during GH and GH/GnRHa 47
Chapter
2
Body composition
There was a GH dose-dependent effect on FM% SDS during the entire treatment period 
with a higher FM% SDS in the 1mg group (P=0.035). At start, FM% SDS was similar be-
tween the GH-dose groups (P=0.171). During 2 years of combined GH/GnRHa treatment, 
FM% SDS increased significantly in the 1mg group (0.2 SDS, P=0.030) but remained simi-
lar in the 2mg group, resulting in a higher FM% SDS in the 1mg group at discontinuation 
of GnRHa (P=0.038) (Figure 3A). Because FM% SDS remained stable in both GH-dose 
groups in the years after discontinuation of GnRHa, this resulted in a higher FM% SDS at 
AH in the 1mg group (0.7 vs 0.2 SDS, P=0.022). 
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Figure 3. Body composition and BP levels in a subgroup of children who started GH treatment in early 
puberty with 2 years of GnRHa and subsequent GH until AH. 
Data are expressed as estimated marginal means with 95% confidence intervals. 
FM% SDS was calculated according to age- and sex-matched Dutch reference values. LBM and BP were 
expressed as SDS adjusted for height and sex (27, 28). 
* P-values between GH-dose groups <0.05. 
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LBM SDS showed no GH dose-dependent effect during the entire treatment period 
(P=0.691). At start, LBM SDS was -1.4 SDS in both GH-dose groups (P=0.955). During 
2 years of combined GH/GnRHa treatment, GH 2 mg/m2/day tended to induce an in-
crease in LBM SDS compared with start, but this did not reach statistical significance 
(P=0.074) (Figure 3B). At discontinuation of GnRHa, LBM SDS was similar between the 
GH-dose groups (P=0.518). From discontinuation of GnRHa to AH, LBM SDS increased 
significantly in both GH-dose groups (P<0.001), leading to a significantly higher LBM 
SDS at AH compared with start. At AH, LBM SDS was similar between GH-dose groups 
(P=0.669). 
Blood pressure
There was no GH dose-dependent effect on BP SDS during the entire treatment period. 
At start, systolic and diastolic BP SDS were similar between the GH-dose groups. During 
2 years of combined GH/GnRHa treatment, systolic BP SDS started to decline in both 
groups, which continued after discontinuation of GnRHa, resulting in a significantly 
lower systolic BP SDS at AH compared with start (P≤0.001), which was similar between 
groups (Figure 3C). 
Diastolic BP SDS tended to increase in both GH-dose groups during 2 years of combined 
GH/GnRHa treatment, resulting in a diastolic BP SDS of 0.5 in the 1mg group and 0.7 in 
the 2mg group at discontinuation of GnRHa treatment (between dose groups P=0.439) 
(Figure 3D). After discontinuation of GnRHa treatment, diastolic BP SDS remained stable 
in both GH-dose groups resulting in a similar diastolic BP SDS between the GH-dose 
groups at AH (P=0.974). 
Lipid profiles
There was no GH dose-dependent effect on any lipid level during the entire treatment 
period after adjustment for age and sex. Results are therefore shown for the GH-dose 
groups together (Table 3). At start, all lipid levels were similar between the GH-dose 
groups. During 2 years of combined GH/GnRHa treatment, HDLc and TG tended to in-
crease but this was only significant for HDLc (P=0.015). At discontinuation of GnRHa, all 
lipid levels were similar between the GH-dose groups. At AH, all lipid levels were similar 
to start and only one patient had elevated TC and LDLc and three patients had elevated 
TG, but there was no difference in lipid levels between the 1mg and 2mg groups. 
DiScUSSioN
Our study shows long-term data on metabolic health in short children born SGA treated 
with GH until AH, and randomized to GH 1 or 2 mg/m2/day from start of puberty, either 
with or without additional GnRHa for 2 years. At AH, after 5.9 years of GH treatment, 
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body composition, BP, and lipid levels were similar between children treated with 
combined GH/GnRHa and those treated with only GH. In the subgroup of children who 
started GH treatment in early puberty (randomized to 1 or 2 mg/m2/day) with 2 years 
of GnRHa treatment, the 1mg group showed an increase in FM% during 2 years of GH/
GnRHa treatment, which remained stable after discontinuation of GnRHa. This resulted 
in a significantly higher FM% in the 1mg group than the 2mg group at AH. LBM, BP, 
and lipid levels were similar between the GH-dose groups during the entire treatment 
period until AH.
Our findings show that 2 years of GnRHa treatment in addition to GH treatment 
compared with only GH treatment has no adverse effect on metabolic health at AH. 
In particular, there was no difference in FM% at AH between children treated with 
combined GH/GnRHa and those treated with only GH, also after correction for GH dose 
and duration. Studies in children with precocious puberty showed that GnRHa treat-
ment leads to an increase in FM% (15-17). Our study shows that at AH, when GnRHa 
treatment has been discontinued for many years, there is no indication that 2 years of 
GnRHa treatment had a long-term enhancing effect on FM%. From start to AH, we found 
a significant decline in systolic BP in both treatment groups. This resulted in much fewer 
children with a systolic BP greater than 2 SDS at AH (6.5% vs 21.5% at start). GH treat-
ment is known to cause a decline in systolic BP in children born SGA (12, 13, 33, 34). Our 
data showed that systolic BP declined similarly in children treated with GH/GnRHa and 
only GH, leading to a similar systolic BP at AH. It indicates that the addition of 2 years 
of GnRHa treatment in early puberty does not influence systolic BP in the long-term. 
Diastolic BP increased from start to AH, which is in contrast with previous studies (13, 
34). The increase in our study was, however, small with only five out of 107 subjects 
having a diastolic BP greater than 2 SDS at AH. Because diastolic BP SDS increased in 
both the GH/GnRHa-treated and GH-only-treated children, this increase was not caused 
by the additional GnRHa treatment. The increase in diastolic BP might be explained by 
the fact that BP was adjusted for height and sex and not for age, while diastolic BP tends 
to increase during puberty. Indeed, a positive correlation was found between diastolic 
BP SDS and age in our study population. From start to AH, we found favorable changes 
in lipid levels, which is consistent with previous studies in which a beneficial effect of 
GH treatment on lipid metabolism in children born SGA was shown (12, 13, 34). At AH, 
lipid levels were not higher in children treated with GH/GnRHa, indicating no long-term 
adverse effect of 2 years of additional GnRHa treatment on lipid levels. Metabolic syn-
drome was defined according to the revised NCEP criteria. At AH, it was present in 3.7% 
of all participants, which was lower compared with untreated, short SGA adolescents in 
whom a prevalence of 8.0% was found (34). 
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In addition, we analyzed body composition, BP, and lipid profile in detail in a subgroup 
of 47 children who started GH treatment in early puberty (randomized to 1 or 2 mg/m2/
day) with 2 years of GnRHa and subsequent GH until AH. 
During 2 years of combined GH/GnRHa treatment, we found an increase in FM% in 
the 1mg group, whereas FM% remained similar in the 2mg group. This supports our 
hypothesis that a higher GH dose of 2 mg/m2/day results in a more favorable body 
composition by counteracting the FM-enhancing effect of GnRHa treatment, whereas 
treatment with GH 1 mg/m2/day might be insufficient to prevent children from gaining 
FM during GnRHa treatment. Because FM% in children treated with GH 1 mg/m2/day 
remained less than 1SDS, the effect might not be clinically relevant in the long-term. 
The clinical relevance of a higher FM% also depends on the distribution of visceral and 
subcutaneous fat given that it is the former that is likely more related to a worse meta-
bolic health. DXA scan is the gold standard to measure body fat and lean body mass, but 
it cannot separate visceral fat from subcutaneous fat. An abdominal ultrasonography 
would be needed to distinguish between visceral and subcutaneous fat, but was not 
available in our study. 
We expected a temporary increase in systolic and diastolic BP during 2 years of ad-
ditional GnRHa treatment as found in a previous study (18), but systolic BP remained 
stable during combined GH/GnRHa treatment in both GH-dose groups. In contrast, 
diastolic BP tended to increase in both GH-dose groups during 2 years of combined 
GH/GnRHa treatment. However, the increase was very small and diastolic BP remained 
well within the normal range. At AH, there was no difference in systolic and diastolic BP 
between the GH-dose groups, which is in line with another study (12).
During the entire treatment period, all lipid levels were similar in both GH-dose 
groups, which is consistent with a previous report (12). HDLc and triglycerides tended to 
temporarily increase during 2 years of additional GnRHa treatment, which is consistent 
with a study in children with precocious puberty and GnRHa treatment (35), but the 
actual increase was very small and values returned to baseline after discontinuation of 
GnRHa. 
Overall, there seem to be no long-term adverse effects on metabolic health of 2 ad-
ditional years of GnRHa treatment and a higher GH dose from pubertal onset until AH. 
Possible psychosocial effects of suppressing on-time puberty have been studied in this 
cohort showing that additional GnRHa treatment had no adverse effect on the gain in 
quality of life (QOL) during 2 years (36). Long-term data on QOL are, however, needed 
before definite conclusions can be drawn. In addition, a cost-benefit analysis should be 
carried out when the long-term data on QOL come available in the next years, to deter-
mine the cost/benefit ratio of combined GH/GnRHa treatment and a higher GH dose. 
Although short stature should be evaluated as early as possible, in clinical practice 
some SGA children present with short stature around pubertal age. Previously we showed 
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that pubertal SGA children with a poor AH expectation can benefit from treatment with 
GH 1 mg/m2/day in combination with 2 years of GnRHa and benefit even more so with a 
double GH dose (14). Our current data show that combined GH/GnRHa has no long-term 
negative effects on metabolic health compared with only GH. Started in early puberty, a 
GH dose of 2 mg/m2/day results in a similar metabolic health at AH and a more favorable 
FM% than the standard 1 mg/m2/day and can therefore be considered in children who 
start GH treatment in early puberty with a poor AH expectation. 
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Context Pubertal children born small for gestational age with a poor adult height (AH) 
expectation can benefit from treatment with growth hormone (GH) 1 mg/m2/day (~0.033 
mg/kg/day) in combination with 2 years of GnRH analog (GnRHa) and even more so with 
GH 2 mg/m2/day. Because both GH and GnRHa can negatively influence insulin sensitiv-
ity, combining these treatments has raised concerns. The long-term GH-dose effects on 
insulin sensitivity in children treated with combined GH/GnRHa are unknown. 
Objective The purpose of this study was to investigate insulin sensitivity and β-cell 
function by a very precise method during long-term GH treatment, either with or with-
out 2 years of additional GnRHa and to study differences in insulin sensitivity during 
treatment until AH between GH at 1 or 2 mg/m2/day.
Methods This was a randomized, dose-response GH trial involving 110 short small for 
gestational age children (59 girls) treated with GH until AH (GH randomized to 1 or 2 
mg/m2/day). Sixty-seven children received additional GnRHa treatment. Frequently 
sampled intravenous glucose tolerance tests were performed and insulin sensitivity (Si), 
acute insulin response (AIR), and disposition index (DI) were calculated using Bergman’s 
MINMOD. The GH-dose effect was evaluated in a subgroup of 48 children who started 
GH treatment in early puberty (random to 1 or 2 mg/m2/day) combined with 2 years of 
GnRHa. 
Results At AH, after 5.9 years of GH treatment, Si, AIR, and DI were similar between chil-
dren treated with combined GH/GnRHa and those treated with GH only. In the subgroup 
of children who started GH treatment in early puberty (randomized to 1 or 2 mg/m2/day) 
together with 2 years of GnRHa treatment, there were no significant differences in Si, 
AIR, or DI between the GH-dose groups during the treatment. 
Conclusions Combined GH/GnRHa treatment has no long-term negative effects on 
insulin sensitivity and β-cell function compared with GH only. Started in early puberty, 
a GH dose of 2 mg/m2/day results in a similar insulin sensitivity at AH as a GH dose of 1 
mg/m2/day.
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iNtroDUctioN
Being born small for gestational age (SGA) has been associated with a higher prevalence 
of diabetes mellitus type 2 at a relative young adult age (1). We have shown that ad-
ditional treatment with a gonadotropin-releasing hormone analog (GnRHa) for 2 years 
at start of puberty can improve adult height (AH) in children who start growth hormone 
(GH) treatment in early puberty with an expected AH of < −2.5 standard deviation score 
(SDS) (2). Additional GnRHa treatment for 2 years has no long-term negative effects on 
body composition, blood pressure, and lipids (3). The long-term effects of combined 
GH/GnRHa treatment on insulin sensitivity and β-cell function in SGA-born children are 
unknown (4). Some studies in children with central precocious puberty (CPP) showed a 
deterioration of insulin sensitivity during GnRHa treatment (5, 6). Because GH treatment 
is also known to reduce insulin sensitivity (7-9), the combination of GH with GnRHa 
treatment has raised concern. The changes in insulin sensitivity during GH treatment 
seem to be independent of the GH dose, at least within the dose range studied (8, 10, 
11). 
We present metabolic data for a longitudinal, randomized, dose-response GH trial in-
volving short SGA children (≥8 years at start) who were treated with GH until AH, either 
with or without additional GnRHa for 2 years from start of puberty. First, insulin sensitiv-
ity and β-cell function at AH were compared between children treated with combined 
GH/GnRHa and those treated with GH only. We expected that the effects of 2 years of 
additional GnRHa treatment would be temporary and would normalize after discontinu-
ation of GnRHa treatment, resulting in similar insulin sensitivity and β-cell function at 
AH between these 2 treatment groups. Second, we investigated the GH dose effect (1 
vs 2 mg/m2/day) on insulin sensitivity and β-cell function in a subgroup of children who 
started GH treatment (randomized to 1 or 2 mg/m2/day) and 2 years of GnRHa treatment 
in early puberty. We hypothesized that treatment with GH 2 mg/m2/day (~0.067 mg/kg/
day) from the onset of puberty until AH would result in similar insulin sensitivity and 
β-cell function during treatment until AH compared with GH 1 mg/m2/day (~0.033 mg/
kg/day). 
MethoDS 
Subjects
The Dutch SGA study included children when they met the following criteria: 1) birth 
length and/or birth weight SDS for gestational age less than −2.0 (12); 2) chronological 
age of ≥8 years; 3) prepubertal stage (Tanner stage I) or early pubertal stage (breast 
stage II-III in girls and testicular volume of <10 ml in boys) with a GnRHa-stimulating 
test indicating central puberty (13, 14); 4) height at inclusion of less than −2.5 SDS in 
prepubertal children or when included in early puberty a height at the start of puberty 
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of <140 cm, which would result in an expected AH less than −2.5 SDS, based on Dutch 
references (15); 5) well-documented growth data from birth to the start of treatment; 
and 6) normal karyotype in all girls (2). Children were excluded in cases of a complicated 
neonatal period with severe asphyxia (defined as Apgar score ≤3 after 5 minutes), long-
term complications of respiratory ventilation (bronchopulmonary dysplasia), endocrine 
or metabolic disorders, growth failure caused by other disorders (celiac disease, emo-
tional deprivation, severe chronic illness, or chondrodysplasia), chromosomal disorders, 
short stature homeobox haploinsufficiency or syndromes (except for Silver-Russell 
syndrome), and use of medication interfering with growth or GH treatment. None of the 
children were GH deficient according to stimulation tests (GH peak >7.7 ng/ml) (16) or 
overnight GH profiles (17, 18).
The SGA study included 135 short SGA children (70 girls) (Figure 1). Nine children 
dropped out for the following reasons: lack of motivation despite ongoing catch-up 
growth (n=3), non-compliance (n=3), social problems (n=1), emigration (n=1), and 
psychiatric disorder (n=1). In 4 children, the GH dose was increased because of limited 
catch-up growth and in 1 child was decreased because of high serum IGF-I levels. Among 
the 121 children who continued treatment according to protocol, 110 children reached 
AH (defined as height reached when growth velocity had decreased to <0.5 cm during 
the last 6 months and bone age was ≥15 years for girls and ≥17 years for boys) or near 
AH (defined as height velocity between 0.5 and 2 cm during the last 6 months and adult 
pubertal stage). In the 110 children who were eligible for analyses at AH, a frequently 
sampled intravenous glucose tolerance (FSIGT) test at AH was performed in 76 children. 
Reasons for no FSIGT test at AH were patient fear for the intravenous catheters or stop-
ping of GH treatment >24 hours before the FSIGT test.
This study was performed according to the Declaration of Helsinki and approved by 
the medical ethics committees of the participating centers. Written informed consent 
was obtained from the parents or guardians of each child and from children who were 
12 years or older. Due to ethical considerations, the medical ethics committees did not 
allow a randomized untreated short SGA group.
Design 
The Dutch SGA study is a longitudinal, randomized, dose-response GH trial involving 
short SGA children of at least 8 years of age. All children received somatropin sc daily 
(Genotropin; Pfizer Inc). Every 3 months, the GH dose was adjusted to calculated body 
surface area. Prepubertal children received GH 1 mg/m2/day (Figure 2). When these 
children entered puberty or when children were in early puberty at start of treatment, 
they were randomly assigned to treatment with either GH 1 or 2 mg/m2/day after stratifi-
cation for sex, pubertal stage, and parental height (1 or 2 parents with a height less than 
−2 SDS vs both parents with a height of at least −2 SDS). Because no model is known 
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to predict AH accurately at the start of puberty, we used a pragmatic, arbitrary cutoff 
level. A height of <140 cm at the start of puberty was used to identify children with an 
AH expectation of less than −2.5 SDS, based on Dutch reference values (15, 19); these 
children received GnRHa (leuprolide acetate depots, 3.75 mg sc every 4 weeks) for 2 
years in addition to GH treatment. During GnRHa treatment, puberty was sufficiently 
suppressed in all children, both clinically and by GnRHa-stimulating tests or overnight 
gonadotropin profiles (18, 20).
135 short SGA children were included in the Dutch SGA-study between December 2003 – December 2012
121 children continued treatment according to protocol
11 children did not yet reach adult height
9 children dropped-out due to
· lack of motivation (N=3)
· non-compliance (N=3)
· social problems (N=1)
· emigration (N=1)
· psychiatric disorder (N=1)
In 5 children GH dose was changed (patient care)
· increased dose due to limited growth (N=4)
· decreased dose due to high IGF-I levels (N=1)
52 children started GH before puberty
10 children started GH in puberty with an adult
height prediction >-2.5 SDS
Total group
Patients: 110 children at adult height
Treatment: GH treatment until adult height either with or without additional GnRHa for 2 years
Analysis: GH/GnRHa vs only GH
Subgroup
Patients: 48 children who started treatment in early puberty with an adult height prediction <-2.5 SDS
Treatment: GH (randomized to 1 or 2 mg/m2/day) until adult height with additional GnRHa for 2 years
Analysis: GH 1 vs 2 mg/m2/day
Figure 1. Flowchart of inclusion, dropout, and analyses.
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Measurements 
Height, weight, and Tanner stage were determined at start and every 3 months. Height 
was measured to the nearest 0.1 cm using a Harpenden stadiometer (Holtain, Ltd). 
Weight was measured to the nearest 0.1 kg on a digital scale (Servo Balance KA-20-
150S, Servo Berkel Prior). Height and weight were transformed into SDS for sex and 
chronological age according to Dutch references (15), using Growth Analyzer Research 
Calculation Tools (https://growthanalyser.org). 
assays 
At the start of treatment and yearly until AH, blood samples were taken after an 
overnight fast. After centrifugation, all samples were kept frozen until assayed (-80°C). 
Serum fasting glucose levels were determined on an Architect ci8200 system (Abbott), 
and serum fasting insulin levels were measured by IRMA (Medgenix, Biosource Europe). 
The intra-assay coefficient of variation was 2.1% to 1.5% (6.6-53.3 milligram equivalents 
[mE]/l) and the interassay coefficient of variation was 6.5% to 6.1% (14.4-100.4 mE/l). 
Homeostasis model assessment of insulin resistance (HOMA-IR) was performed using 
the model HOMA-IR = (fasting glucose [millimoles per liter] x fasting insulin [milliunits 
per liter])/22.5 (21). 
insulin sensitivity and β-cell function
To assess glucose homeostasis, a modified FSIGT test with Tolbutamide was performed 
at AH after an overnight fast (22). Insulin sensitivity (Si), acute insulin response (AIR), and 
disposition index (DI) were calculated using Bergman’s MINMOD Millennium software 
(23). Si quantifies the capacity of insulin to stimulate glucose disposal, and AIR is an 
estimate of insulin secretory capacity, measured as the area under the curve from 0 to 
GH 1 mg/m2/day Puberty
Start treatment
before puberty
Start treatment in
early puberty
Height <140 cm
Height >140 cm
GnRHa +
GH 1 mg/m2/day
GnRHa +
GH 2 mg/m2/day
GH 1 mg/m2/day
GH 2 mg/m2/day
Randomization of GH dose
Figure 2. Flowchart of treatment regimen.
Insulin sensitivity during GH and GH/GnRHa 63
Chapter
3
10 minutes, corrected for baseline insulin levels. The DI equals AIR * Si and indicates the 
β-cell function.
In the subgroup of children who started GH treatment (randomized to 1 or 2 mg/
m2/day) in early puberty with additional 2 years of GnRHa treatment, an FSIGT was 
performed at baseline, after 1 year of combined GH/GnRHa treatment, and at AH at-
tainment. After approval of a protocol amendment, the last 15 children included in the 
SGA study underwent an additional FSIGT test 3 months after GnRHa treatment only, to 
determine the independent effects of GnRHa treatment on insulin sensitivity. 
body composition 
In all children, body composition at the start and at AH was measured by dual-energy 
X-ray absorptiometry (DXA) scan (Lunar Prodigy; GE Healthcare, Chalfont St. Giles, UK). 
All scans of the study group and reference population were performed on the same 
machine, and tests for quality assurance were performed daily. For measuring total body 
fat and lean body mass, this type of DXA machine has an intra-assay coefficient of 0.41% 
to 0.88% for fat tissue and 1.57% to 4.49% for lean body mass (LBM) (24). Total fat mass 
was measured and fat mass SDS was calculated according to age- and sex-matched 
Dutch reference values (25). 
In the subgroup of children who started GH treatment (randomized to 1 or 2 mg/
m2/day) in early puberty combined with 2 years of GnRHa treatment, DXA scans were 
performed according to the following schedule: at start and after 1, 2, 2.5, and 4 years 
of treatment. The scans at AH were performed at the last visit or at a visit in the last year 
before discontinuation of GH treatment. 
Statistics 
Statistical analyses were performed using SPSS version 21. Distribution of variables was 
determined by Kolmogorov-Smirnov test and normal Q-Q plots. Clinical characteristics 
are presented as mean (SD). A one-sample t test was used to compare SDS results with 
0 (mean value for age- and sex-matched references). Because of a skewed distribution, 
fasting insulin and HOMA-IR were square root-transformed, whereas Si, AIR, and DI were 
log-transformed for analyses. Sample size calculation was based on FSIGT test results in 
a previous Dutch study in short SGA children (26). The estimated sample size was based 
on an expected difference in mean Si between 2 groups of 10x10-4/min-1 (µU/ml), SD of 
10, testing at a significance level of 5%. Seventeen children in each group were sufficient 
to detect this difference with 80% power.
Total group analyses: differences at AH between children treated with combined GH/
GnRHa and those treated with GH only, were evaluated using an independent-sample 
t test. 
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Subgroup analyses: to evaluate GH dose-dependent effects and changes in insulin 
sensitivity and β-cell function from start to AH, additional analyses were performed in 
a subgroup of children who started GH treatment (randomized to 1 or 2 mg/m2/day) in 
early puberty combined with 2 years of GnRHa and subsequently continued GH treat-
ment until AH. We used repeated-measurements analysis (linear mixed model) with an 
unstructured covariance matrix with GH dose as the categorical independent variable 
and fat mass percentage (FM%) SDS as a covariate. Differences between the 1mg and 
2mg group at various time points were evaluated using an independent-sample t test. A 
paired-sample t test was used to compare insulin sensitivity and β-cell function at start 
of treatment and after 3 months of GnRHa treatment only. We assessed linear correla-
tions using Pearson correlation coefficient. P-values < 0.05 were considered statistically 
significant. 
reSUltS 
clinical characteristics 
Table 1 shows the baseline clinical characteristics of the total group of 110 short SGA 
children (59 girls) who were treated until AH. At start of treatment, mean (SD) age was 
11.4 (1.5) years and height SDS was -2.9 (0.6). Sixty-seven children were treated with 
combined GH/GnRHa and 43 with GH only. The combined GH/GnRHa group consisted 
of more girls (P=0.018) and more children that started treatment in early puberty with a 
more progressed Tanner stage (P<0.001). 
insulin sensitivity and β-cell function measured by fSigt tests
Total group at adult height 
Table 2 shows the insulin sensitivity and β-cell function at AH measured by FSIGT tests 
with Tolbutamide. The average GH treatment duration was 5.9 years of GH treatment. At 
AH, FM% SDS was similar between children treated with GH/GnRHa and those treated 
with GH only (P=0.832) (Table 2). 
FSIGT tests at AH were performed in 76 patients (48 after combined GH/GnRHa and 
28 after GH treatment only) at a mean age of 17.4 (1.2) years. Fasting glucose, fasting 
insulin, Si, and AIR were similar in children treated with combined GH/GnRHa and those 
treated with GH only (Table 2). DI, a measure of β-cell function, tended to be slightly 
higher in the combined GH/GnRHa group, but this did not reach statistical significance 
(P=0.066). All children were randomized to GH 1 or 2 mg/m2/day from pubertal onset 
until AH. In both the combined GH/GnRHa and GH groups, Si, AIR, and DI at AH were 
similar between children treated with GH 1 mg/m2/day and those treated with GH 2 
mg/m2/day. During the 5.9 (1.4) years of study, none of the patients developed diabetes 
mellitus type 2.
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Subgroup of early pubertal children randomized to GH 1 or 2 mg/m2/day and 2 years of 
GnRHa
In a subgroup of 48 children who started combined GH/GnRHa treatment in early pu-
berty, the GH-dose effects on insulin sensitivity and β-cell function were analyzed in 
detail. All children received GnRHa for the first 2 years in addition to GH (randomized to 
1 or 2 mg/m2/day). Twenty-five children (16 girls) were randomized to treatment with GH 
1 mg/m2/day (1mg group) and 23 (15 girls) to GH 2 mg/m2/day (2mg group). The boy/girl 
ratio and age at start were similar between the 1mg and 2mg groups. Because FM% SDS 
was significantly lower in the 2mg group during the entire treatment period (P=0.030), 
all analyses were adjusted for FM% SDS. 
In this subgroup, FSIGT tests were performed at start of treatment, after 1 year of 
combined GH/GnRHa treatment and at AH. At all these time points, Si, AIR, and DI were 
similar in children treated with GH 1 mg/m2/day and those treated with GH 2 mg/m2/
day. In both GH-dose groups, Si decreased during the first year of combined GH/GnRHa 
treatment after which Si remained similar until AH, resulting in significantly lower Si 
Table 1. Baseline clinical characteristics 
Total group GH/GnRHa GH P-value
N 110 67 43
Boys/girls 51/59 25/42 26/17 0.018
Gestational age, weeks 37.4 (3.3) 37.4 (3.6) 37.5 (3.0) 0.886
Birth weight SDS -2.0 (1.0) a -2.0 (0.9) a -2.0 (1.0) a 0.888
Birth length SDS -2.7 (1.3) a -2.8 (1.3) a -2.6 (1.2) a 0.513
Target height SDS -0.7 (0.7) a -0.7 (0.7) a -0.7 (0.7) a 0.849
Age, years 11.4 (1.5) 11.6 (1.2) 11.0 (1.8) 0.065
Height SDS -2.9 (0.6) a -2.9 (0.7) a -2.9 (0.6) a 0.591
Body Mass Index SDS -1.0 (1.0) -0.9 (1.0) -1.2 (1.0) 0.202
IGF-I SDS -1.17 (1.2) -1.08 (1.1) -1.30 (1.5) 0.374
Prepubertal / pubertal 52/58 19/48 33/10 <0.001
Pubertal stage (14)
Tanner I 52 19 33
Tanner II 41 36 5
Tanner III 17 12 5
Fasting glucose, mmol/l 5.0 (0.5) 5.0 (0.5) 4.9 (0.5) 0.605
Fasting insulin, mU/l 5.3 (4.8) 6.3 (5.5) 3.8 (3.0) 0.406
HOMA-IR 1.2 (1.2) 1.5 (1.4) 0.9 (0.8) 0.471
Data are expressed as mean (SDS), unless written otherwise. Fasting insulin and HOMA-IR were square-root 
transformed before analyses and adjusted for Tanner stage at baseline. Bold text indicates a significant 
P-value (P<0.05).
a Variables in SDS compared with zero SDS, P<0.01.
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values at AH than at start (Figure 3A). A compensatory increase in AIR was found during 
the first year of combined GH/GnRHa treatment in both GH-dose groups after which 
it decreased until AH. At AH, AIR was similar to start in both GH-dose groups (Figure 
3B). During the first year of combined GH/GnRHa treatment, DI remained similar in both 
GH-dose groups. In both GH-dose groups, DI was lower at AH than at start, but this did 
not reach statistical significance (P=0.12 and P=0.05) (Figure 3C). The 2mg group had a 
higher IGF-I SDS at AH than the 1mg group (1.3 vs 0.8 SDS, P=0.042), but Si, AIR, and DI 
were not significantly different between the GH-dose groups. 
Insulin sensitivity during 3 months of only GnRHa treatment
To investigate whether the changes during the first year of combined GH/GnRHa 
treatment were due to the effect of GH or could also be caused by a negative effect 
of GnRHa on insulin sensitivity, we performed an additional FSIGT test after 3 months 
of GnRHa treatment without GH in the last 15 children (9 girls) included in this study. 
After 3 months of GnRHa treatment, there were no significant changes in Si, AIR, or DI 
compared with baseline values (P=0.377, P=0.615, and P=0.181, respectively).
Table 2. Insulin sensitivity and β-cell function by FSIGT 
Total group GH/GnRHa GH P-value
N 110 67 43
GH dose 1 vs 2 mg/m2/day 55/55 33/34 22/21 0.845
At onset of puberty
Height SDS -2.6 (0.7) -2.7 (0.6) -2.3 (0.7) 0.002
At adult height
Age, years 17.4 (1.2) 17.4 (1.1) 17.4 (1.3) 0.853
Adult height SDS a -1.8 (0.8) -1.8 (0.9) -1.7 (0.8) 0.526
FM% SDS 0.4 (0.8) 0.4 (0.7) 0.4 (0.9) 0.832
Body Mass Index SDS -0.2 (1.1) -0.3 (1.0) -0.05 (1.1) 0.297
FSIGT (N=76) 48 28
Si x 10-4/min, mU/l 6.1 (5.2) 6.8 (5.8) 5.0 (3.9) 0.176
AIR, mU/l 706.9 (564.4) 726.3 (616.7) 673.8 (470.2) 0.881
DI (Si x AIR) 2929.3 (1762.9) 3159.4 (1871.4) 2534.7(1510.2) 0.066
Fasting glucose, mmol/l 5.0 (0.5) 5.0 (0.5) 5.1 (0.6) 0.506
Fasting insulin, mU/l 13.6 (6.6) 13.6 (7.3) 13.7 (5.2) 0.752
Data are expressed as mean (SDS), unless written otherwise. Fasting insulin and HOMA-IR were square-root 
transformed and Si, AIR, and DI were log-transformed before analyses. Bold text indicates a significant P-
value (P<0.05).
a Adult height SDS was calculated using references for Dutch adults (21 years).
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A Insulin sensitivity
B Insulin secretion
C Disposition index
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Figure 3. FSIGT results in a subgroup of children who started GH treatment in early puberty with 2 years of 
GnRHa and subsequent GH until adult height (AH). 
Data are expressed as estimated marginal means with 95% confidence intervals. 
There were no significant differences between the 2 GH-dose groups at any time point during the study. 
68 Insulin sensitivity during GH and GH/GnRHa
insulin sensitivity and β-cell function at adult height by hoMa-ir
The FSIGT test is not easily applied in large populations because of its complexity, costs, 
and invasiveness; thus, we tested in the total group how the FSIGT test results correlated 
with data obtained by HOMA-IR, which is a more practical, cheaper, and less invasive 
measure. At start, fasting insulin levels and HOMA-IR were higher in the combined GH/
GnRHa group (P=0.004 and P=0.005, respectively). However, after adjustment for the 
difference in Tanner stage at baseline, fasting insulin levels and HOMA-IR were similar 
between the combined GH/GnRHa group and GH group (Table 1). In all 110 children 
who reached AH, fasting glucose, fasting insulin, and HOMA-IR at AH were similar be-
tween children treated with GH/GnRHa and those treated with GH only. The correlation 
between HOMA-IR and Si measured by the FSIGT test was significant but not strong 
enough for HOMA-IR to serve as a proxy for Si measured by the FSIGT test in individual 
patients (r=-0.396, P<0.001). 
DiScUSSioN
This is the first study describing the long-term changes in insulin sensitivity and β-cell 
function determined by the FSIGT test with Tolbutamide in short children born SGA who 
started GH treatment at ages older than 8 years. They were randomized to GH 1 or 2 mg/
m2/day from start of puberty, either with or without additional GnRHa for 2 years. At 
AH, after an average of 5.9 years of GH treatment, Si, AIR, DI, fasting glucose, and fast-
ing insulin were similar between children treated with combined GH/GnRHa and those 
treated with GH only. In the subgroup of children who started GH treatment in early 
puberty (randomized to 1 or 2 mg/m2/day) together with 2 years of GnRHa treatment, 
there were no significant differences in Si, AIR, or DI between the GH-dose groups during 
the entire treatment. 
Our study shows that 2 years of GnRHa in addition to GH treatment results in a similar 
insulin sensitivity at AH compared with GH treatment only. Short-term studies in girls 
with CPP compared combined GH/GnRHa treatment with GH only or placebo and 
showed no negative metabolic side effects (27, 28). A long-term study until AH about 
the effects of GnRHa treatment in girls with CPP showed a lower insulin sensitivity at AH 
in treated girls than in untreated girls (5). In that study, however, insulin sensitivity was 
determined by HOMA-IR, which is not comparable with the gold standard FSIGT test 
with Tolbutamide that we used. Furthermore, the difference in insulin sensitivity, could 
be explained by the higher body mass index in the girls with CPP treated with GnRHa as 
there is a strong negative correlation between total body fat mass and insulin sensitivity 
(29). At AH, we found neither a higher fat mass in the SGA children treated with com-
bined GH/GnRHa nor a lower insulin sensitivity. Combined GH/GnRHa treatment tended 
Insulin sensitivity during GH and GH/GnRHa 69
Chapter
3
to cause a slightly higher DI, a measure of β-cell function, than GH treatment only, but 
the difference was not significant.
In the subgroup of 48 children who all started GH treatment (randomized to 1 or 2 mg/
m2/day) in early puberty with additional GnRHa treatment for 2 years, we found similar 
FSIGT test results during the entire treatment period in children treated with GH 1 mg/
m2/day and those treated with 2 mg/m2/day, reassuringly confirming our hypothesis 
that treatment with GH 2 mg/m2/day from start of puberty until AH does not result in 
a more impaired insulin sensitivity. These findings are in line with studies using oral 
glucose tolerance tests in SGA children treated with GH only (8, 10, 11, 30). The 2mg 
group had a higher IGF-I SDS at AH than the 1mg group (1.3 vs 0.8 SDS, P=0.042), but Si, 
AIR, and DI were not significantly different between the GH-dose groups.
In our subgroup, the decline in Si during the first year of combined GH/GnRHa treat-
ment was counterbalanced by a compensatory increase in AIR. This demonstrates that 
the β-cells can compensate for the decline in insulin sensitivity by increasing their insu-
lin secretion, indicating normal β-cell function. Indeed, β-cell function did not change 
throughout treatment. At AH, insulin sensitivity was significantly lower than at start, 
which is in line with previous findings in SGA children treated with GH until AH (8, 30). 
From start to AH, our patients transitioned through puberty, and it is well known that 
healthy children show a decrease in insulin sensitivity, an increase in insulin secretion, 
and a decrease in glucose disposition index during puberty (31), which leads to a lower 
insulin sensitivity in healthy postpubertal adolescents than in prepubertal children 
(22, 32, 33). Thus, the lower insulin sensitivity than baseline in our patients might be 
explained by the fact that they are postpubertal. 
Because both GH and GnRHa treatment can independently reduce Si (5-9), we also 
determined the effects on glucose homeostasis of GnRHa treatment without GH. After 
3 months of GnRHa treatment, insulin sensitivity and β-cell function were similar to 
baseline, indicating that short-term GnRHa treatment does not affect insulin sensitivity. 
This is in contrast to findings with oral glucose tolerance tests in girls with CPP after 1 
year of GnRHa treatment (6) but is supported by our finding that at AH, insulin sensitivity 
and β-cell function in children treated with GH/GnRHa were similar to those in children 
treated with GH only, suggesting that additional GnRHa for 2 years does not impair 
insulin sensitivity. 
Our data are unique because the method we used, the FSIGT test with Tolbutamide, is 
a gold standard for measuring insulin sensitivity and β-cell function like the euglycemic-
hyperinsulinemic clamp (34). The addition of Tolbutamide increases the reliability of the 
measurement of Si by providing a second surge of insulin instead of merely the initial 
fall in blood glucose which is, to some extent, due to glucose equilibrating into its full 
distribution volume and not to the action of insulin. The FSIGT test is more invasive, 
labor-intensive, and costly than other measurements of insulin sensitivity, for instance, 
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the oral glucose tolerance test and HOMA-IR, but the results are more accurate. A limita-
tion of this study is the absence of FSIGT tests at start of treatment in all children. This 
would have given us the opportunity to study the development of insulin sensitivity and 
β-cell function from start of treatment until AH. Furthermore, it will be interesting for 
future studies to measure insulin sensitivity also at discontinuation of 2 years of GnRHa 
treatment. Because of the invasiveness of FSIGT tests, we decided not to perform an 
FSIGT test at that time point.
Our research group previously published AH results for this cohort. Height SDS at 
start of puberty was significantly lower in children treated with GH/GnRHa, but AH was 
similar (Table 2). This finding indicates that children who are shorter at start of puberty 
(<140 cm) with a poor AH expectation benefit from additional GnRHa treatment. The 
double GH dose of 2 mg/m2/day during puberty resulted in a significantly better height 
gain SDS in boys (2).
In conclusion, our study is the first report showing that 2 years of GnRHa treatment in 
addition to GH treatment results in a similar insulin sensitivity and β-cell function at AH 
compared with GH treatment only in children born SGA, indicating that combined GH/
GnRHa treatment does not have long-term negative effects on glucose homeostasis in 
early adulthood. When started in early puberty, a GH dose of 2 mg/m2/day results in a 
similar insulin sensitivity from childhood into early adulthood as a GH dose of 1 mg/m2/
day. 
Acknowledgments We express our gratitude to all children and their parents for 
their participation in this study. We thank J. Bontenbal-van de Wege, J. van Houten, J. 
C. Bruinings-Vroombout, B. Kerkhof, and J. van de Puttelaar, research nurses, for their 
contribution to the study. We also greatly acknowledge W. Hackeng for performing labo-
ratory analyses. We thank all collaborating physicians and pediatricians who referred 
patients for participation in our study.
Insulin sensitivity during GH and GH/GnRHa 71
Chapter
3
refereNceS
1. Barker DJ, Hales CN, Fall CH, Osmond C, Phipps K, Clark PM 1993 Type 2 (non-insulin-depen-
dent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal 
growth. Diabetologia 36:62-67
2. Lem AJ, van der Kaay DC, de Ridder MA, Bakker-van Waarde WM, van der Hulst FJ, Mulder 
JC, Noordam C, Odink RJ, Oostdijk W, Schroor EJ, Sulkers EJ, Westerlaken C, Hokken-Koelega 
AC 2012 Adult height in short children born SGA treated with growth hormone and gonadotropin 
releasing hormone analog: results of a randomized, dose-response GH trial. The Journal of clinical 
endocrinology and metabolism 97:4096-4105
3. van der Steen M, Lem AJ, van der Kaay DC, Bakker-van Waarde WM, van der Hulst FJ, Neijens 
FS, Noordam C, Odink RJ, Oostdijk W, Schroor EJ, Westerlaken C, Hokken-Koelega AC 2015 
Metabolic Health in Short Children Born Small for Gestational Age Treated With Growth Hormone 
and Gonadotropin-Releasing Hormone Analog: Results of a Randomized, Dose-Response Trial. The 
Journal of clinical endocrinology and metabolism 100:3725-3734
4. van der Kaay D, Bakker B, van der Hulst F, Mul D, Mulder J, Schroor E, van Elswijk D, Rowaan 
I, Willeboer M, de Ridder M, Hokken-Koelega A 2010 Randomized GH trial with two different 
dosages in combination with a GnRH analogue in short small for gestational age children: effects 
on metabolic profile and serum GH, IGF1, and IGFBP3 levels. European journal of endocrinology / 
European Federation of Endocrine Societies 162:887-895
5. Chiavaroli V, Liberati M, D’Antonio F, Masuccio F, Capanna R, Verrotti A, Chiarelli F, Mohn 
A 2010 GNRH analog therapy in girls with early puberty is associated with the achievement of 
predicted final height but also with increased risk of polycystic ovary syndrome. European journal 
of endocrinology / European Federation of Endocrine Societies 163:55-62
6. Sorensen K, Mouritsen A, Mogensen SS, Aksglaede L, Juul A 2010 Insulin sensitivity and lipid 
profiles in girls with central precocious puberty before and during gonadal suppression. The Jour-
nal of clinical endocrinology and metabolism 95:3736-3744
7. Veening MA, Van Weissenbruch MM, Delemarre-Van De Waal HA 2002 Glucose tolerance, 
insulin sensitivity, and insulin secretion in children born small for gestational age. The Journal of 
clinical endocrinology and metabolism 87:4657-4661
8. Sas T, Mulder P, Aanstoot HJ, Houdijk M, Jansen M, Reeser M, Hokken-Koelega A 2001 Carbo-
hydrate metabolism during long-term growth hormone treatment in children with short stature 
born small for gestational age. Clinical endocrinology 54:243-251
9. de Zegher F, Ong K, van Helvoirt M, Mohn A, Woods K, Dunger D 2002 High-dose growth hor-
mone (GH) treatment in non-GH-deficient children born small for gestational age induces growth 
responses related to pretreatment GH secretion and associated with a reversible decrease in insulin 
sensitivity. The Journal of clinical endocrinology and metabolism 87:148-151
10. Chatelain P, Job JC, Blanchard J, Ducret JP, Oliver M, Sagnard L, Vanderschueren-Lodeweyckx 
M 1994 Dose-dependent catch-up growth after 2 years of growth hormone treatment in intrauter-
ine growth-retarded children. Belgian and French Pediatric Clinics and Sanofi-Choay (France). The 
Journal of clinical endocrinology and metabolism 78:1454-1460
11. Albanese A, Stanhope R 1993 Growth and metabolic data following growth hormone treatment 
of children with intrauterine growth retardation. Hormone research 39:8-12
12. Usher R, McLean F 1969 Intrauterine growth of live-born Caucasian infants at sea level: standards 
obtained from measurements in 7 dimensions of infants born between 25 and 44 weeks of gesta-
tion. The Journal of pediatrics 74:901-910
72 Insulin sensitivity during GH and GH/GnRHa
13. Cavallo A, Zhou XH 1994 LHRH test in the assessment of puberty in normal children. Hormone 
research 41:10-15
14. Tanner JM, Whitehouse RH 1976 Clinical longitudinal standards for height, weight, height veloc-
ity, weight velocity, and stages of puberty. Archives of disease in childhood 51:170-179
15. Fredriks AM, van Buuren S, Burgmeijer RJ, Meulmeester JF, Beuker RJ, Brugman E, Roede MJ, 
Verloove-Vanhorick SP, Wit JM 2000 Continuing positive secular growth change in The Nether-
lands 1955-1997. Pediatric research 47:316-323
16. Saggese G, Ranke MB, Saenger P, Rosenfeld RG, Tanaka T, Chaussain JL, Savage MO 1998 
Diagnosis and treatment of growth hormone deficiency in children and adolescents: towards a 
consensus. Ten years after the Availability of Recombinant Human Growth Hormone Workshop 
held in Pisa, Italy, 27-28 March 1998. Hormone research 50:320-340
17. van der Kaay DC, Rose SR, van Dijk M, Noordam C, van Rheenen E, Hokken-Koelega AC 2009 
Reduced levels of GH during GnRH analogue treatment in pubertal short girls born small for gesta-
tional age (SGA). Clinical endocrinology 70:914-919
18. van der Kaay DC, de Jong FH, Rose SR, Odink RJ, Bakker-van Waarde WM, Sulkers EJ, Hokken-
Koelega AC 2009 Overnight levels of luteinizing hormone, follicle-stimulating hormone and 
growth hormone before and during gonadotropin-releasing hormone analogue treatment in short 
boys born small for gestational age. Hormone research 71:260-267
19. Mul D, Fredriks AM, van Buuren S, Oostdijk W, Verloove-Vanhorick SP, Wit JM 2001 Pubertal 
development in The Netherlands 1965-1997. Pediatric research 50:479-486
20. van der Kaay DC, de Jong FH, Laven JS, Hokken-Koelega AC 2009 Overnight luteinizing and fol-
licle stimulating hormone profiles during GnRHa treatment in short girls born small for gestational 
age. Journal of pediatric endocrinology & metabolism : JPEM 22:161-169
21. Wallace TM, Levy JC, Matthews DR 2004 Use and abuse of HOMA modeling. Diabetes care 
27:1487-1495
22. Cutfield WS, Bergman RN, Menon RK, Sperling MA 1990 The modified minimal model: applica-
tion to measurement of insulin sensitivity in children. The Journal of clinical endocrinology and 
metabolism 70:1644-1650
23. Boston RC, Stefanovski D, Moate PJ, Sumner AE, Watanabe RM, Bergman RN 2003 MINMOD 
Millennium: a computer program to calculate glucose effectiveness and insulin sensitivity from the 
frequently sampled intravenous glucose tolerance test. Diabetes Technol Ther 5:1003-1015
24. Guo Y, Franks PW, Brookshire T, Antonio Tataranni P 2004 The intra- and inter-instrument reli-
ability of DXA based on ex vivo soft tissue measurements. Obesity research 12:1925-1929
25. Boot AM, Bouquet J, de Ridder MA, Krenning EP, de Muinck Keizer-Schrama SM 1997 Determi-
nants of body composition measured by dual-energy X-ray absorptiometry in Dutch children and 
adolescents. The American journal of clinical nutrition 66:232-238
26. Arends NJ, Boonstra VH, Duivenvoorden HJ, Hofman PL, Cutfield WS, Hokken-Koelega AC 
2005 Reduced insulin sensitivity and the presence of cardiovascular risk factors in short prepuber-
tal children born small for gestational age (SGA). Clinical endocrinology 62:44-50
27. Kamp GA, Mul D, Waelkens JJ, Jansen M, Delemarre-van de Waal HA, Verhoeven-Wind L, Frol-
ich M, Oostdijk W, Wit JM 2001 A randomized controlled trial of three years growth hormone and 
gonadotropin-releasing hormone agonist treatment in children with idiopathic short stature and 
intrauterine growth retardation. The Journal of clinical endocrinology and metabolism 86:2969-
2975
Insulin sensitivity during GH and GH/GnRHa 73
Chapter
3
28. Pasquino AM, Pucarelli I, Roggini M, Segni M 2000 Adult height in short normal girls treated 
with gonadotropin-releasing hormone analogs and growth hormone. The Journal of clinical endo-
crinology and metabolism 85:619-622
29. Leunissen RW, Oosterbeek P, Hol LK, Hellingman AA, Stijnen T, Hokken-Koelega AC 2008 Fat 
mass accumulation during childhood determines insulin sensitivity in early adulthood. The Journal 
of clinical endocrinology and metabolism 93:445-451
30. van Pareren Y, Mulder P, Houdijk M, Jansen M, Reeser M, Hokken-Koelega A 2003 Effect 
of discontinuation of growth hormone treatment on risk factors for cardiovascular disease in 
adolescents born small for gestational age. The Journal of clinical endocrinology and metabolism 
88:347-353
31. Goran MI, Gower BA 2001 Longitudinal study on pubertal insulin resistance. Diabetes 50:2444-
2450
32. Potau N, Ibanez L, Rique S, Carrascosa A 1997 Pubertal changes in insulin secretion and periph-
eral insulin sensitivity. Hormone research 48:219-226
33. Bloch CA, Clemons P, Sperling MA 1987 Puberty decreases insulin sensitivity. The Journal of 
pediatrics 110:481-487
34. Bergman RN, Prager R, Volund A, Olefsky JM 1987 Equivalence of the insulin sensitivity index 
in man derived by the minimal model method and the euglycemic glucose clamp. The Journal of 
clinical investigation 79:790-800

 CHAPTER 4
Puberty and pubertal growth in GH-treated 
SGA children: Eﬀ ects of 2 years of GnRHa 
versus no GnRHa
Manouk van der Steen, Annemieke J. Lem, Daniëlle C.M. van der Kaay,
Anita C.S. Hokken-Koelega
Journal of Clinical Endocrinology and Metabolism 2016;101:2005-2012
76 Puberty and growth in GH-treated SGA after GnRHa
abStract 
Context Most studies on puberty in children born small for gestational age (SGA) report 
height and age at onset of puberty. Growth hormone (GH) treated SGA children with an 
adult height (AH) expectation below -2.5 SDS at onset of puberty can benefit from an 
additional 2 years of GnRH analog (GnRHa) treatment. There are no data on puberty and 
growth after discontinuation of GnRHa treatment in GH-treated SGA children.
Objective This study aimed to investigate the effects on puberty and pubertal growth 
of 2 years GnRHa vs no GnRHa in GH-treated SGA children. 
Methods This was a GH trial involving 76 prepubertal short SGA children (36 girls) 
treated with GH. Thirty-two children received additional GnRHa for 2 years. Pubertal 
stages were 3-monthly assessed according to Tanner.
Results Age, bone age, and median height at pubertal onset were lower in girls and boys 
in the GH/GnRHa group compared with the GH group. In girls and boys treated with GH/
GnRHa, pubertal duration after stop of GnRHa treatment was shorter than pubertal du-
ration in those with GH only (40.9 vs 46.7 months, P=0.044; 50.8 vs 57.5 months, P=0.006; 
respectively). Height gain from onset of puberty until AH, including height gain during 
2 years of GnRHa treatment, was 25.4 cm in girls and 33.0 cm in boys, which was 6.6 cm 
more than girls and boys treated with GH only. AH was similar in children treated with 
GH/GnRHa compared with those with GH only.
Conclusions GH-treated SGA children who start puberty with an AH expectation below 
-2.5 SDS and are treated with 2 years of GnRHa have a shorter pubertal duration after 
discontinuation of GnRHa compared with pubertal duration in children treated with GH 
only. Height gain from onset of puberty until AH is, however, more due to adequate 
growth during 2 years of GnRHa treatment resulting in a similar AH as children treated 
with GH only. 
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iNtroDUctioN
Height and age at onset of puberty, as well as the magnitude and duration of pubertal 
growth are important determinants of adult height, explaining 15-20% of adult height 
(1). Most studies on puberty in children born small for gestational age (SGA) report 
height and age at onset of puberty but not pubertal duration. Study results are difficult 
to compare due to the use of various definitions for the milestones of puberty, but most 
authors seem to agree that puberty in short SGA children starts within the normal range 
but relatively early for their short stature (2-6). 
In children born SGA with persistent short stature, growth hormone (GH) is an ap-
proved therapy for increasing adult height (7-9). GH-treated SGA children with an 
expected adult height (AH) <−2.5 SDS at onset of puberty benefit from additional treat-
ment with a gonadotropin-releasing hormone analog (GnRHa) for 2 years from onset 
of puberty to increase AH (10). There are, however, no data on puberty and pubertal 
growth after discontinuation of GnRHa treatment in GH-treated SGA children. 
Based on our clinical experience, we expected that GH-treated SGA children treated 
with an additional 2 years of GnRHa from onset of puberty would show an accelerated 
pubertal progression after discontinuation of GnRHa resulting in less pubertal growth 
than children treated with GH only. However, due to the additional height gain during 
postponement of puberty by 2 years of GnRHa treatment, we expected AH and AH SDS 
to be similar in children treated with combined GH/GnRHa compared with those treated 
with GH only.
MethoDS
Subjects
In the Dutch SGA study, children could start GH treatment from the age of 8 years, either 
being prepubertal or in early puberty. The present study group consisted of 76 short 
SGA children (36 girls), a subgroup of the total Dutch SGA study, who were prepubertal 
at start of GH treatment and were followed until AH. Body composition, glucose ho-
meostasis, blood pressure, lipid levels, and AH have been reported for the total Dutch 
SGA study (10-12). Pubertal development in the present study group has never been 
published. Children were included when they met the following criteria; 1) birth length 
and/or birth weight SDS for gestational age less than −2.0 (13); 2) current height less 
than −2.5 SDS; 3) prepubertal stage at start of GH treatment (Tanner stage I); 4) well-
documented growth data from birth to start of treatment; and 5) normal karyotype in 
all girls. None of the children were GH deficient according to normal serum IGF-I levels 
(IGF-I level >-2 SDS) and stimulation tests (GH peak >7.7 ng/ml) or overnight GH profiles. 
Children started with daily sc somatropin treatment when prepubertal and were 
treated until AH. A height of less than 140 cm at onset of puberty was used to identify 
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children with an AH expectation of less than −2.5 SDS, based on Dutch reference values 
(14, 15). These children received 2 years of GnRHa treatment (leuprolide acetate depots, 
3.75 mg sc every 4 weeks) from onset of puberty in addition to GH treatment (GH/GnRHa 
group). During GnRHa treatment, puberty was sufficiently suppressed in all children, 
both clinically and by GnRHa-stimulating tests or overnight gonadotropin profiles (16, 
17). Children who started puberty with a height above 140 cm were treated with GH 
only (GH group). Children were treated with GH 1 mg/m2/day (~0.033 mg/kg/day) until 
onset of puberty. At onset of puberty, they were randomly assigned to treatment with 
either GH 1 or 2 mg/m2/day after stratification for sex, pubertal stage, and parental 
height (one or two parents with a height <−2 SDS vs both parents with a height >−2 
SDS). Every 3 months, the GH dose was adjusted to calculated body surface area. Figure 
1 shows the treatment regimen during the study. Seventy-one children reached AH 
(defined as height reached when growth velocity had decreased to <0.5 cm during the 
last 6 months, and bone age [BA] was ≥15 years in girls and ≥17 years in boys), or near 
AH (defined as height velocity between 0.5 and 2 cm during the last 6 months and adult 
pubertal stage). Five children did not reach adult height; one boy was still growing and 
four children dropped out for the following reasons: lack of motivation despite ongo-
ing catch-up growth (n=2), social problems (n=1), emigration (n=1). Data of these five 
children were used until the highest pubertal stage attainment during the study. 
The study was performed according to the Helsinki Declaration and approved by the 
medical ethics committees of the participating centers. Written informed consent was 
obtained from parents or guardians of each child and from children who were 12 years 
or older. Due to ethical considerations, the medical ethics committees did not allow a 
randomized untreated short SGA group.
Start treatment
before puberty
Height <140 cm
Height >140 cm
GnRHa +
GH 1 mg/m2/day
GnRHa +
GH 2 mg/m2/day
GH 1 mg/m2/day
GH 2 mg/m2/day
Randomization of GH dose
GH/GnRHa
GH
GH 1 mg/m2/day
Puberty
Figure 1. Flowchart of treatment regimen of prepubertal children of the Dutch SGA study.
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Measurements 
Height and weight were determined at start and every 3 months by the same physicians. 
Height was measured to the nearest 0.1 cm using a Harpenden stadiometer (Holtain, 
Ltd.). Weight was measured to the nearest 0.1 kg on a digital scale (Servo Balance KA-20-
150S, Servo Berkel Prior). Body mass index (BMI) was calculated (kilograms per square 
meter, rounded to the nearest tenth). Height, weight, and BMI were transformed into 
SDS for sex and chronological age according to Dutch references (14), using Growth 
Analyzer Research Calculation Tools (https://growthanalyser.org). Radiographs of the 
left hand and wrist were taken annually. BA was determined at start of GH treatment 
and yearly thereafter by one investigator (M.v.d.S.) according to Greulich and Pyle (18). 
Pubertal development
Pubertal stages were assessed according to the method of Tanner and Whitehouse (19) 
at each 3-monthly visit, allowing quite precise determination of pubertal onset, which 
was defined as breast development stage II for girls according to Tanner (19) and a 
testicular volume equal or more than 4 ml for boys as determined by means of a Prader 
orchidometer. End of GnRHa treatment, and thus restart of puberty, was defined as 4 
weeks after the last GnRHa injection. At each 3-monthly visit, girls were asked whether 
and when they had their menarche.
We defined several periods during pubertal development to compare pubertal dura-
tion between children treated with GH/GnRHa and those treated with GH only. In girls, 
Period 1 was defined as the period between onset of puberty (M2) and menarche. In 
boys, Period 1 was defined as the period between onset of puberty (a testicular volume 
of 4 ml) and a testicular volume of 16 ml. Because we wanted to be certain that there 
was central puberty, we performed a GnRH-analog test after the appearance of the first 
clinical signs (M2 in girls and a testicular volume of 4 ml in boys). This resulted in a delay 
between onset of puberty and start of GH/GnRHa treatment during which pubertal de-
velopment progressed. Period 1 in girls and boys treated with GH/GnRHa was therefore 
divided in two separate periods; onset of puberty until start of GnRHa treatment (period 
1A) and restart of puberty after stop of GnRHa until menarche in girls or until a testicular 
volume of 16 ml in boys (period 1B). In girls, Period 2 was defined as the period between 
menarche and AH. In boys, Period 2 was defined as the period between a testicular 
volume of 16 ml and AH.
Statistical analyses
We used the same definitions for pubertal milestones as the Fourth Dutch National 
Growth Study (1997), which served as reference for age and height at onset of puberty 
and age at menarche of normal-statured children born appropriate for gestational age 
(controls) (14). Statistical analyses were performed with SPSS version 21. Distribution 
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of variables was determined by Kolmogorov-Smirnov test and normal Q-Q-plots. Data 
are expressed as median (interquartile range). Differences between the groups were 
calculated using Mann–Whitney U tests. P-values < 0.05 were considered statistically 
significant. 
reSUltS
onset of puberty 
Table 1 lists the clinical data of all 76 prepubertal children compared with Dutch refer-
ences. All children started GH treatment 1 mg/m2/day when prepubertal. Median GH 
treatment duration until onset of puberty was 2.1 years (1.0-2.8) in girls and 2.7 years 
(1.6-3.9) in boys. 
Girls in the GH/GnRHa group started puberty at a similar age compared with Dutch 
references, whereas girls in the GH group started puberty significantly older compared 
with references. Age and BA at pubertal onset were significantly younger in girls in the 
GH/GnRHa group compared with girls in the GH group. As expected, median height in 
centimeters at pubertal onset was significantly lower in girls in the GH/GnRHa group 
(134.6 cm) than in the GH group (143.1 cm; P<0.001), but their height SDS at onset of 
puberty was similar. BMI SDS at pubertal onset was similar between groups.
Boys in the GH/GnRHa group started puberty at a similar age compared with Dutch 
references, whereas boys in the GH group started puberty significantly older compared 
with references. Age and BA at pubertal onset were significantly younger in boys in the 
GH/GnRHa group compared with boys in the GH group. As expected, median height in 
centimeters at pubertal onset was significantly lower in boys in the GH/GnRHa group 
(137.0 cm) than in the GH group (143.4 cm; P<0.001), but their height SDS at onset of 
puberty was similar. BMI SDS at pubertal onset was similar between groups.
bone maturation
At onset of puberty, BA was significantly younger in girls and boys treated with GH/
GnRHa than those treated with GH only (Table 1). BA at onset of puberty was similar in 
children who were randomly assigned to receive either 1 or 2 mg/m2/day. In the GH/
GnRHa group, the ratio ΔBA/ΔCA during 1 year of GnRHa treatment with sufficient sup-
pression of puberty was 0.3 years in girls and 0.5 years in boys. In the GH group, the ratio 
ΔBA/ΔCA during 1 year after onset of puberty was 1.0 year in girls and 0.75 years in boys. 
For girls, the ratio ΔBA/ΔCA was significantly lower in the GH/GnRHa group compared 
with the GH group (P=0.003), whereas in boys the ratio ΔBA/ΔCA was not significantly 
different (P=0.119).
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Table 1. Clinical characteristics of 76 prepubertal GH-treated SGA children versus Dutch references
Characteristic GH/GnRHa GH P-value b GH/GnRHa Dutch 
references c
Start of GH
Girls 
Age, years 10.1 (6.9 to 11.1) 9.9 (9.7 to 10.7) 0.837
Height, cm 123.4 (109.0 to 128.0) 124.9 (120.1 to 127.1) 0.334
Height, SDS -3.0 (-3.4 to -2.9) -3.0 (-3.5 to -2.7) 0.219
Boys
Age, years 9.0 (6.7 to 11.0) 10.1 (9.1 to 11.3) 0.065
Height, cm 116.0 (108.5 to 128.6) 122.9 (117.4 to 131.2) 0.039
Height, SDS -3.3 (-3.7 to -2.7) -2.9 (-3.2 to -2.6) 0.151
Onset of Puberty Restart Puberty
Girls 19 17 19 2266
GH dose 
(1 vs 2 mg/m2/day)
8 / 11 10 / 7 0.317 8 / 11
Age, years 11.5 (10.3 to 12.0) 12.4 (12.0 to 12.8) a 0.001 13.9 (12.8 to 14.5) 10.7
BA, years 10.8 (10.5 to 11.0) 11.3 (11.0 to 12.0) 0.003 12.0 (11.5 to 12.3)
BA delay, years -0.8 (-1.3 to 0.1) -0.8 (-1.7 to -0.6) 0.248 -1.6 (-2.5 to -1.0)
Height, cm 134.6 (130.3 to 136.1) 143.1 (140.3 to 145.5) <0.001 148.9 (144.4 to 153.8)
Height, SDS -2.6 (-3.0 to -1.9) -2.1 (-2.8 to -1.7) 0.257
BMI, SDS -0.6 (-1.3 to -0.3) -1.0 (-1.6 to -0.3) 0.496 -0.6 (-1.0 to 0.1)
Boys 13 27 12 2524
GH dose 
(1 vs 2 mg/m2/day)
8 / 5 12 / 15 0.311 7 / 5
Age, years 11.4 (10.9 to 12.8) 13.0 (12.6 to 13.5) a <0.001 13.6 (13.2 to 14.8) 11.5
BA, years 10.5 (10.0 to 11.4) 12.3 (11.4 to 12.8) 0.001 12.6 (12.3 to 13.4)
BA, years -0.7 (-2.4 to 0.03) -1.0 (-1.3 to -0.2) 0.919 -1.1 (-1.7 to -0.4)
Height, cm 137.0 (134.7 to 138.2) 143.4 (141.2 to 146.7) <0.001 152.2 (149.5 to 153.3)
Height, SDS -2.2 (-2.8 to -1.7) -2.2 (-2.5 to -1.7) 0.955
BMI, SDS -1.3 (-2.1 to -0.2) -0.8 (-1.7 to -0.3) 0.718 -1.0 (-2.3 to -0.1)
Data are expressed as median (IQR), unless written otherwise. Bold text indicates a significant P-value.
a P<0.001 compared with Dutch references. 
b P-value: comparison between GH/GnRHa group and GH group. 
c Data of 4th Dutch National Growth study (14).
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Pubertal duration
Because we wanted to be certain that there was central puberty, we performed a GnRH-
analog test after the appearance of the first clinical signs of puberty (M2 in girls and a 
testicular volume of 4 ml in boys). In girls and boys treated with GH/GnRHa, this resulted 
in a delay between onset of puberty and start of GnRHa treatment during which puber-
tal development progressed. The median delay was 3.4 months (1.6-4.8) in girls and 3.6 
months (1.5-5.0) in boys. During these months, puberty progressed and for that reason 
this period (1A) was added to the pubertal duration after stop of GnRHa treatment (1B) 
(see Figure 2, A and B; period 1 [A+B]).
Figure 2A shows the pubertal duration in girls. In girls treated with GH/GnRHa, period 
1A+1B lasted 21.3 months (15.0-26.2), which was not significantly different from period 
1 in girls treated with GH only, which lasted 17.8 months (10.4-27.6) (P=0.466). Period 2, 
menarche until AH, was 21.6 months (16.3-29.0) in girls treated with GH/GnRHa, which 
was shorter than the 27.8 months (20.3-31.8) in those treated with GH only (P=0.047). 
Time from onset of puberty until AH, period 1(A and B)+2, was 40.9 months (33.7-48.5) 
in girls treated with GH/GnRHa, which was shorter than the 46.7 months (41.1-58.6) in 
girls treated with GH only (P=0.044). Median age at menarche was significantly older in 
GH-group
GH/GnRHa-group
10.9 12.2 14.0 14.6 16.3 16.9
Median age
(years)
1
1A
1B
2
2
A Pubertal duration in girls
M2 to start GnRHa treatment
2 years of GnRHa
M2 to menarche
Menarche to adult height
Prepuberty
Restart puberty to menarche
2
1A
1B
1
GH/GnRHa-group
GH-group
11.4 13.0 15.2 15.7 17.517.8
Median age
(years)
TV 4 ml to start GnRHa treatment
2 years of GnRHa
TV 4 ml to TV 16 ml
TV 16 ml to adult height
Prepuberty
Restart puberty to TV 16 ml
2
1A
1B
1
B Pubertal duration in boys
1 2
21B
1A
Figure 2. Pubertal duration.
Abbreviations: M2, breast development stage II according to Tanner; TV, testicular volume.
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girls treated with GH/GnRHa compared with those treated with GH only (14.6 vs 14.0 
years, P=0.001). Girls in both groups had their menarche at an older age compared 
with the median age of 13.15 years in healthy Dutch references (P<0.001 and P=0.004, 
respectively). There was no significant difference in pubertal duration between the two 
GH-dose groups.
Figure 2B shows the pubertal duration in boys. In boys treated with GH/GnRHa, period 
1A+1B until a testicular volume of 16 ml, lasted 24.4 months (16.7-29.2) which was not 
significantly different from period 1 in boys treated with GH only which lasted 27.1 
months (21.6-39.8) (P=0.111). Period 2, from a testicular volume of 16 ml to AH, was 23.9 
months (19.3-33.9) in boys treated with GH/GnRHa and 27.3 months (21.3-33.1) in those 
treated with GH only (P=0.887). Time from onset of puberty until AH, period 1(A and 
B)+2, was 50.8 months (47.4-53.6) in boys treated with GH/GnRHa, which was shorter 
than the 57.5 months (50.9-62.1) in boys treated with GH only (P=0.006). There was no 
significant difference in pubertal duration between the two GH-dose groups. 
growth from onset of puberty to ah 
Figure 3A shows the growth from onset of puberty to AH in girls. At onset of puberty, 
the median height of girls in the GH/GnRHa group was 134.6 cm (130.3-136.1), which 
was significantly lower than the median height of girls in the GH group, which was 143.1 
cm (140.3-145.5) (P<0.001). During 2 years of GnRHa treatment, the median height gain 
in girls was 12.7 cm (11.1-13.7). At restart of puberty, 4 weeks after discontinuation of 
GnRHa treatment, median height was 148.9 cm (144.4-153.8) in girls treated with GH/
GnRHa and their median height gain during period 1A+1B until menarche was 9.0 cm 
(7.9-11.1), which was not significantly different from the median height gain of 9.7 cm 
(7.2-17.6) in period 1 in girls treated with GH only (P=0.398). Median height gain in period 
2 from menarche until AH was 3.9 cm (3.2-4.4) in girls treated with GH/GnRHa, which was 
significantly less than the 5.6 cm (4.4-8.5) gain in girls in the GH group (P=0.002). Median 
height gain during period 1(A+B)+2 until AH was 13.3 cm (11.1-14.3) in girls treated with 
GH/GnRHa and 18.8 cm (13.8-23.6) in girls treated with GH only (P=0.003). The median 
total height gain from onset of puberty until AH, including the height gain during GnRHa 
treatment, was 25.4 cm (24.4-26.4) in girls treated with GH/GnRHa, which was 6.6 cm 
more than in girls treated with GH only who gained 18.8 cm (13.8-23.6) (P=0.001). Girls 
with GH/GnRHa treatment were shorter at pubertal onset than those treated with GH 
only but they reached a similar median AH (160.4 vs 162.7 cm; P=0.217) and AH SDS (-1.6 
vs -1.2; P=0.217). In girls treated with GH/GnRHa and those treated with GH only, there 
was no significant difference in pubertal growth between the two GH-dose groups. 
Figure 3B shows the growth from onset of puberty to AH in boys. At onset of puberty, 
the median height of boys in the GH/GnRHa group was 137.0 cm (134.7-138.2), which 
was significantly lower than the median height of boys in the GH group, which was 143.4 
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cm (141.2-146.7) (P<0.001). During 2 years of GnRHa treatment, the median height gain 
in boys was 13.1 cm (11.1-14.4). At restart of puberty, 4 weeks after discontinuation of 
GnRHa treatment, median height was 152.2 cm (149.5-153.3) in boys treated with GH/
GnRHa and their median height gain during period 1A+1B until a testicular volume 
of 16 ml was 13.5 cm (11.1-17.7), which was significantly less than the median height 
gain in period 1 in boys treated with GH only who gained 18.8 cm (16.5-21.8) (P=0.020). 
Median height gain in period 2 from a testicular volume of 16 ml until AH was 6.1 cm 
(2.8-7.9) in boys treated with GH/GnRHa, which was not significantly different from the 
median height gain of 7.7 cm (4.0-9.4) in period 2 in boys treated with GH only (P=0.354). 
Median height gain during period 1(A+B)+2 until AH, was 21.0 cm (19.4-22.9) in boys 
treated with GH/GnRHa and 26.4 cm (22.6-29.6) in boys treated with GH only (P=0.001). 
The median total height gain from onset of puberty until AH, including the height gain 
during GnRHa treatment, was 33.0 cm (29.9-37.4) in boys treated with GH/GnRHa, which 
was 6.6 cm more than in boys treated with GH only who gained 26.4 cm (22.6-29.6) 
(P=0.001). Boys with GH/GnRHa treatment were shorter at pubertal onset than those 
treated with GH only but they reached a similar median AH (170.8 vs 169.6 cm; P=0.884) 
Height (cm) Height (cm)
GH/GnRHa GH
GH/GnRHa GH
A Pubertal height gain in girls
160.4
155.8
148.9
134.6
162.7
153.8
143.1
M2 to start GnRHa treatment
2 years of GnRHa
M2 to menarche
Menarche to adult height
Prepuberty
Restart puberty to menarche
2
1A
1B
1
1B
1A
1
22
22
1
1B
1A
B Pubertal height gain in boys
Height (cm)Height (cm)
170.8
164.1
152.2
137.0
169.6
162.6
143.4
TV 4 ml to start GnRHa treatment
2 years of GnRHa
TV 4 ml to TV 16 ml
TV 16 ml to adult height
Prepuberty
Restart puberty to TV 16 ml
2
1A
1B
1
Figure 3. Pubertal height gain. 
Abbreviations: M2, breast development stage II according to Tanner; TV, testicular volume.
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and AH SDS (-1.9 vs -2.0; P=0.960). In boys treated with GH/GnRHa and those treated 
with GH only, there was no significant difference in pubertal growth between the two 
GH-dose groups.
DiScUSSioN
This study presents the long-term effects of 2 years of additional GnRHa treatment on 
puberty and pubertal growth in GH-treated children born SGA with an AH expectation 
below -2.5 SDS at onset of puberty. Although children treated with combined GH/
GnRHa were shorter at onset of puberty and had a shorter pubertal duration after 
discontinuation of GnRHa, their total height gain from onset of puberty until AH was 
greater compared with those treated with GH only due to an adequate growth during 2 
years of GnRHa. This resulted in a similar AH as those treated with GH only.
When the option of additional GnRHa treatment is discussed with parents, they often 
have questions on how much height their child will gain during GnRHa treatment and 
what to expect after discontinuation of GnRHa treatment; when to expect menarche 
and how much height gain will occur after menarche. Data to answer these questions 
were lacking. Our study presents data on puberty and pubertal growth when 2 years of 
GnRHa treatment is added to GH treatment in SGA children with an AH expectation be-
low -2.5 SDS at onset of puberty. We show that girls and boys grew approximately 13 cm 
during 2 years of GnRHa treatment. Girls treated with 2 years of additional GnRHa had 
their menarche approximately 1.5 years after restart of puberty, with a range from 1-2 
years, which is in line with findings in girls with central precocious puberty treated with 
GnRHa (20-22). They grew nearly 10 cm from restart of puberty until AH and reached 
their AH approximately 3 years after restart of puberty. From menarche until AH, girls 
treated with GH/GnRHa grew approximately 4 cm compared with nearly 5.5 cm in girls 
treated with GH only. Boys grew approximately 20 cm from restart of puberty until AH 
and reached their AH nearly 4 years after restart of puberty. Total growth from onset of 
puberty until AH was 6.6 cm more in girls and boys treated with GH/GnRHa than in those 
treated with GH only, which resulted in a similar AH in those treated with GH/GnRHa 
and GH only. In children treated with GH/GnRHa, total duration from onset of puberty 
until AH was longer because of the additional GnRHa treatment, which delayed puberty 
for 2 years. Without the 2 years of GnRHa treatment, pubertal duration was, however, 
shorter compared with children treated with GH only. The shorter pubertal duration 
after GnRHa treatment was not due to more progression in bone maturation according 
to Greulich and Pyle (18), as BA at onset of puberty was significantly younger and BA 
development during GnRHa treatment was slower in the GH/GnRHa group compared 
with the GH group. 
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A possible explanation for the shorter pubertal duration after GnRHa treatment in 
children treated with GH/GnRHa could be continuing senescence of the growth plate, 
the progressive loss of function and structural involution of the growth plate, which 
is growth dependent (23), during GnRHa treatment. When growth plates are more 
senescent, and have expended more of their growth potential, a shorter exposure to 
estrogen is sufficient to complete growth plate fusion (24). There are no other studies 
reporting pubertal duration after discontinuation of GnRHa treatment in SGA children 
and therefore comparing our results to other studies was not possible.  
Adult height in GH-treated children is influenced by pubertal timing and early on-
set can result in a loss of prepubertal gain in height SDS. Although our study was not 
designed to evaluate onset of puberty, our findings show that the total group of GH-
treated children born SGA did not start puberty at a younger age compared to normal-
statured Dutch children born appropriate for gestational age. Children in the GH/GnRHa 
group started puberty at a similar age as Dutch references, but relatively early for their 
actual height which is in line with previous studies (2-6). Age at onset of puberty and 
at menarche was significantly older in the GH group, although within the normal age 
range for Dutch references (14), which is in line with previous studies in SGA children 
(25-27). Given that pubertal development in the GH/GnRHa group was delayed for 2 
years by additional GnRHa treatment, comparing age at menarche in the GH/GnRHa 
group to Dutch references would be inappropriate. 
This present study was not designed to investigate pubertal postponement by GnRHa 
vs no postponement in a randomized design. GnRHa treatment in addition to GH de-
pended on absolute height at start of puberty and adult height prediction. Despite this 
limitation, our study provides pragmatic data on expectations for GH-treated children 
born SGA in whom additional GnRHa treatment is contemplated and shows a beneficial 
effect of GnRHa treatment on height which is consisted with previous studies in other 
populations (28-30). 
GnRHa treatment was well tolerated in all children and no adverse effects were re-
ported. Metabolic health, insulin sensitivity, and β-cell function at AH showed similar 
results in children treated with combined GH/GnRHa and those treated with GH only 
(11, 12). In the current study, all girls treated with GnRHa reported regular cycles at AH 
and one pregnancy after AH with normal offspring was reported. Long-term follow-up 
in girls with central precocious puberty treated with GnRHa also showed that the inter-
ruption of the GnRH axis in childhood did not impair reproductive function in adulthood 
(21). Definitive conclusions on long-term reproductive function in young women born 
SGA treated with GnRHa can, however, not be made because long-term follow-up data 
are not yet available. 
In conclusion, when GH-treated SGA children with an AH expectation below -2.5 SDS 
at onset of puberty are treated with 2 years of additional GnRHa treatment, their pu-
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bertal duration after discontinuation of GnRHa treatment is shorter compared with the 
pubertal duration in children with an AH expectation above -2.5 SDS treated with GH 
only. Although they are shorter at onset of puberty, adequate growth during 2 years of 
GnRHa treatment leads to a better total growth from onset of puberty until AH resulting 
in a similar AH as those treated with GH only.
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Context Growth hormone (GH) treatment results in a reduction in fat mass (FM) and 
insulin sensitivity (Si), and an increase in lean body mass (LBM). Only short-term longitu-
dinal changes after cessation of GH treatment in subjects born SGA are available. 
Methods 199 previously GH-treated SGA young adults (SGA-GH) were longitudinally 
followed for 5 years after attainment of adult height: at GH-cessation, and at 6 months, 
2 and 5 years thereafter. Data at 5 years after GH-cessation were compared to untreated 
age-matched controls: 51 untreated short SGA adults (SGA-S), 92 SGA adults with spon-
taneous catch-up growth (SGA-CU), and 142 adults born appropriate for gestational age 
(AGA). Body composition was determined by DXA scans. Frequently sampled intrave-
nous glucose tolerance (FSIGT) tests were used to assess Si, acute insulin response (AIR), 
and β-cell function (DI).
Results FM, trunk and limb fat increased during 5 years after GH-cessation whereas LBM 
decreased. At 5 years after GH-cessation, FM was higher and LBM lower compared to 
data at GH-cessation. Si and DI increased and AIR decreased after GH-cessation, but only 
during the first 6 months. At 5 years after GH-cessation, Si was higher, AIR lower and DI 
similar to results at GH-cessation. At 5 years after GH-cessation, SGA-GH adults had a 
similar FM, Si, AIR, and DI, and a lower LBM than untreated SGA-S adults. LBM was lower 
and FSIGT results similar compared to SGA-CU and AGA adults.
Conclusions This longitudinal study during 5 years after GH treatment shows significant 
changes in body composition, insulin sensitivity, and β-cell function after GH-cessation, 
reflecting the loss of GH properties. At 5 years after GH-cessation, FM, insulin sensitiv-
ity, and β-cell function of previously GH-treated SGA adults were similar to untreated 
short SGA adults, indicating that long-term GH treatment in children born SGA has no 
unfavorable effect on metabolic health in early adulthood.
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iNtroDUctioN 
Approximately 10% of children born small for gestational age (SGA) show insufficient 
catch-up growth and remain short with a height below -2 SDS (1, 2). Growth hormone 
(GH) treatment effectively induces catch-up growth and improves adult height (AH) in 
most short children born SGA (3-6). GH treatment results in a decline in fat mass (FM), an 
increase in lean body mass (LBM), and a lower insulin sensitivity (7, 8). 
Children born SGA have a higher risk to develop diabetes mellitus type 2 in adulthood 
(9-11) and since GH treatment causes GH-induced insulin resistance (12, 13), concern 
has been expressed regarding the long-term consequences of GH treatment in children 
born SGA. French data of the Safety and Appropriateness of Growth hormone treatments 
in Europe (SAGhE) project suggested that there might be an increased cardiovascular 
mortality in adults born SGA who were treated with GH during childhood (14). The main 
limitation of the SAGhE project is, however, the absence of an appropriate control group 
of untreated SGA patients. To study the effect of GH treatment on the risk of diabetes 
mellitus type 2, it is important to address the already known increased risk in children 
born SGA, and compare previously GH-treated subjects born SGA with untreated sub-
jects born SGA. 
The primary aim of our study was to investigate the longitudinal changes in body 
composition and insulin sensitivity after cessation of GH treatment. We, therefore, 
evaluated body composition and frequently sampled intravenous glucose tolerance 
test results (FSIGT results) during 5 years after cessation of GH treatment in young adults 
born SGA. We hypothesized that after cessation of GH treatment, body composition 
would change in line with the loss of GH properties, i.e. an increase in FM and a decrease 
in LBM, and that GH-induced insulin resistance would be reversible. We compared the 
data at 5 years after cessation of GH treatment, to young adults born SGA with persistent 
short stature who were never treated with GH (SGA-S subjects) to assess the effect of 
GH treatment during childhood on body composition and insulin sensitivity in early 
adulthood. We hypothesized that body composition and FSIGT results of previously 
GH-treated SGA adults would return to levels of untreated SGA-S adults. To evaluate 
whether GH-induced catch-up growth had a similar effect on adult body composition 
as spontaneous catch-up growth, we additionally compared the data at 5 years after 
cessation of GH treatment to young adults born SGA with spontaneous catch-up to a 
normal stature (SGA-CU subjects).
MethoDS
Subjects
The total study group comprised 484 young adults (265 females, 54.8%) of which 199 
young adults born SGA (birth weight and/or birth length <-2 SDS) had participated in 
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a GH trial (103 females, 51.8%). These children started GH treatment when prepubertal, 
aged 5 to 8 years, with a height SDS below -2.5 and no growth failure caused by other 
disorders. Children with GH-deficiency (defined as a maximum serum GH <20 mU/l 
during a GH stimulation test) were excluded. GH 1 mg/m2/day (~0.033 mg/kg/day) was 
given daily sc at bedtime (r-hGH Norditropin; Novo Nordisk A/S, Bagsværd, Denmark). 
Every 3 months, the GH dose was adjusted to the calculated body surface area. GH treat-
ment was discontinued at attainment of AH, defined as height reached when growth 
velocity had decreased to <0.5 cm during the last 6 months and bone age was ≥15 years 
for girls and ≥16.5 years for boys, or near AH, defined as height velocity between 0.5 and 
2 cm during the last 6 months and adult pubertal stage. 
At GH-cessation, GH-treated young adults were invited to participate in the current 
follow-up study evaluating metabolic health at AH while still on GH treatment, and at 
6 months, 2 and 5 years after cessation of GH treatment. Some SGA-GH subjects did 
not participate at every study moment, due to the time-consuming aspect, and some 
participants had not yet discontinued GH treatment for 2 or 5 years. Data at 5 years after 
GH-cessation were compared with those of 285 participants of an age-matched healthy 
young adult study cohort, aged 18 to 24 years: 51 untreated young adults born SGA 
(birth length <-2 SDS) with persistent short stature (<-2 SDS) (SGA-S), 92 young adults 
born SGA (birth length <-2 SDS) with catch-up growth and a normal stature (>-1 SDS) 
(SGA-CU), and 142 young adults born appropriate for gestational age (birth length >-1 
SDS) with a normal stature (>-1 SDS) (AGA) (15, 16). SGA-S and SGA-CU young adults 
were randomly recruited from several hospitals in the Netherlands, where they had been 
registered because of their small birth size (birth length <-2 SDS) with or without short 
stature (<-2 SDS). In addition, healthy young adults from schools of different educational 
levels were randomly asked to participate as AGA controls. 
The medical ethics committee of the Erasmus University Medical Centre Rotterdam 
approved the studies. Written informed consent was obtained from all subjects and, if 
they were younger than 18 years at cessation of GH treatment, also from their parents 
or custodians. 
Measurements
Standing height was measured to the nearest 0.1 cm using a Harpenden stadiometer 
(Holtain, Ltd) and weight to the nearest 0.1 kg on a digital scale (Servo Balance KA-20-
150S, Servo Berkel Prior). Height and weight were expressed as SDS adjusted for chrono-
logical age and gender according to Dutch references (17), using Growth Analyzer Re-
search Calculation Tools (https://growthanalyser.org). AH SDS at 5 years after cessation 
of GH treatment was calculated using references for Dutch adults (21 years) (17).
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body composition
Body composition was measured by one dual-energy X-ray absorptiometry (DXA) scan 
(Lunar Prodigy, GE Healthcare). Quality assurance was performed daily. For this type 
of DXA, the intra-assay coefficient of variation has been reported as 0.41-0.88% for fat 
tissue and 1.57-4.49% for lean body mass (LBM) (18). Total fat mass (FM), LBM, trunk fat, 
and limb fat were determined. 
insulin sensitivity and β-cell function
Glucose homeostasis was assessed by FSIGT tests with Tolbutamide after an overnight 
fast (19). Insulin sensitivity (Si), glucose effectiveness (Sg), acute insulin response (AIR), 
and disposition index (DI) were calculated using Bergman’s MINMOD Millennium 
software (20). Si quantifies the capacity of insulin to stimulate glucose disposal and Sg 
reflects the capacity of glucose to mediate its own disposal. AIR is an estimate of insulin 
secretory capacity, measured as the area under the curve from 0 to 10 minutes corrected 
for baseline insulin levels. The DI equals AIR x Si and indicates the β-cell function. 
assays
Fasting glucose levels were determined on an Architect ci8200 system (Abbott). Fasting 
insulin levels were measured by IRMA (Medgenix, Biosource Europe) with an intra-assay 
coefficient of variation of 2.1% to 1.5% (6.6–53.3 milligram equivalents [mE]/l) and 
interassay coefficient of variation 6.5% to 6.1% (14.4–100.4 mE/l). Serum levels of total 
insulin-like growth factor-I (IGF-I) was expressed as SDS adjusting for age and gender, 
using reference values for healthy children with normal stature determined in the same 
laboratory (21).
Statistics
Statistical analyses were performed using SPSS version 23. Distribution of variables was 
determined by Kolmogorov-Smirnov test and normal Q-Q-plots. Clinical characteris-
tics are presented as mean (SD). ANOVA was used to determine differences between 
subgroups. Because of a skewed distribution, Si, Sg, AIR, and DI were log-transformed. 
Longitudinal changes in body composition and FSIGT results were analyzed using 
repeated measurements analysis with an unstructured covariance type. Correlations 
between IGF-I SDS and FM were determined using Pearson’s correlation test. ANCOVA 
was used for adjusted comparisons between the groups at the age of 21 years. Results 
were regarded as statistically significant at P<0.05.
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clinical characteristics
Table 1 shows the clinical characteristics of the previously GH-treated SGA (SGA-GH) 
adults at various time points. Mean age at start of GH treatment had been 6.4 (2.0) years 
and mean GH treatment duration 10.0 (2.3) years. At 5 years after cessation of GH treat-
ment, mean age was 21.3 (1.5) years which was similar to untreated SGA-S, SGA-CU, and 
AGA adults. AH SDS was -1.6 (0.9) SDS, which was significantly higher in SGA-GH adults 
compared to SGA-S adults (P<0.001) but significantly lower than in SGA-CU (P<0.001) 
and AGA adults (P<0.001). 
Table 1. Clinical characteristics
SGA-GH SGA-S SGA-CU AGA
N 199 51 92 142
Sex (male/female) 96 / 103 18 / 33 38 / 54 67 / 75
Gestational age, weeks 36.0 (3.8) 38.1 (3.1) a 36.0 (3.4) 36.3 (4.1)
Birth length SDS -3.2 (1.6) -3.0 (0.9) -3.0 (0.8) 0.2 (0.8) b
Birth weight SDS -2.3 (1.2) -2.1 (0.9) -2.3 (0.8) 0.3 (1.2) b
At start of GH treatment
Age, years 6.4 (2.0) N/A N/A N/A
Height SDS -3.0 (0.6) N/A N/A N/A
Weight for Height SDS -1.5 (1.2) N/A N/A N/A
At adult height
Age, years 16.4 (1.3) N/A N/A N/A
Height SDS -1.2 (0.8) N/A N/A N/A
Weight for Height SDS -0.7 (1.1) N/A N/A N/A
GH duration, years 10.0 (2.3) N/A N/A N/A
At age 21 years (5 years after GH)
Sex (male/female) 36 / 52 18 / 33 38 / 54 67 / 75
Age, years 21.3 (1.5) 20.9 (1.8) 20.7 (1.7) 20.9 (1.7)
Adult height SDS (21 years) -1.6 (0.9) b -2.6 (0.5) b -0.2 (0.7) c 0.1 (0.8) 
Weight for Height SDS -0.2 (1.4) c 0.2 (1.4) 0.2 (1.2) 0.3 (1.0)
Abbreviations: SGA-GH, previously GH-treated adults born SGA; SGA-S, untreated adults born SGA with 
short stature; SGA-CU, adults born SGA with spontaneous catch-up growth; AGA, adults born appropriate 
for gestational age; N/A, not applicable.
Data are expressed as mean (SD).   a P<0.02 compared with the other groups.
b P<0.001 compared with the other groups.  c P≤0.01 compared with AGA.
longitudinal changes after gh-cessation in Sga-gh adults
Longitudinal changes in body composition 
Figure 1 shows the longitudinal changes in body composition after cessation of GH in 
the SGA-GH adults, expressed as estimated marginal means. During 6 months after GH-
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cessation, FM, trunk fat, and limb fat increased significantly (all P<0.001). From 6 months 
until 2 years and from 2 years until 5 years after GH-cessation, FM, trunk fat, and limb 
fat showed a constant increase (all P<0.001). At 5 years after GH-cessation, FM, trunk 
fat, and limb fat were significantly higher than at GH-cessation (all P<0.001). Additional 
adjustment for age did not change these results. 
During 6 months after GH-cessation, LBM declined (P<0.001) and remained similar 
thereafter, resulting in a lower LBM at 5 years after GH-cessation compared to LBM at 
GH-cessation. After additional adjustment for age, LBM steadily declined during 5 years 
after GH-cessation and was lower at 5 years after GH-cessation compared to LBM at GH-
cessation (P<0.001). 
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Figure 1. Longitudinal changes of body composition parameters.
Data are expressed as estimated marginal means with the upper limit of the 95% confidence interval.
* P<0.001.
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Longitudinal changes in serum IGF-I levels
During 6 months after cessation of GH treatment, IGF-I SDS decreased from 1.2 SDS 
to -0.1 SDS (P<0.001) and remained similar thereafter. No significant correlations were 
found between serum IGF-I SDS and the amount of FM at GH-cessation, and at 6 months 
and 2 and 5 years after GH-cessation. 
Longitudinal changes in insulin sensitivity and β-cell function measured by FSIGT
Figure 2 shows the longitudinal changes in Si, Sg, AIR, and DI measured by FSIGT after 
GH-cessation in the SGA-GH adults, expressed as estimated marginal means. During 
6 months after GH-cessation, Si, Sg, and DI increased significantly (P<0.001, P=0.002 
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Figure 2. Longitudinal changes of FSIGT results.
Data are expressed as estimated marginal means with the upper limit of the 95% confidence interval. 
NS; not statistically significant. * P<0.005, # P<0.05.
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and P<0.001, respectively). From 6 months until 2 years and from 2 years until 5 years 
after GH-cessation, Si, Sg, and DI did not significantly change. AIR decreased during 
6 months after GH-cessation (P<0.001), remained similar from 6 months until 2 years 
and decreased again from 2 years until 5 years after GH-cessation (P=0.033). At 5 years 
after GH-cessation, Si and Sg were significantly higher (both P<0.001) and AIR was sig-
nificantly lower (P<0.001) than levels at GH-cessation, whereas DI, the proxy for β-cell 
function, was similar to DI at GH-cessation. Additional adjustment for FM and age did 
not change these results.
comparison between Sga-gh adults and untreated Sga-S, Sga-cU, and aga adults
Body composition
Since the SGA-GH, SGA-S, SGA-CU, and AGA groups differed in male/female ratio and 
height, which are important factors for body composition, the comparisons of body 
composition between groups were adjusted for these factors (Figure 3). At 5 years after 
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Figure 3. Comparison of body composition between groups.
Data are expressed as estimated marginal means with the upper limit of the 95% confidence interval, ad-
justed for height and gender. Data of SGA-GH adults are data at 5 years after GH-cessation.
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GH-cessation, FM and fat distribution (trunk FM and limb FM) were similar in SGA-GH, 
SGA-S, SGA-CU, and AGA adults. SGA-GH adults had the lowest LBM (P=0.007 compared 
to SGA-S, P<0.001 compared to SGA-CU and AGA).
Insulin sensitivity and β-cell function
Because the SGA-GH, SGA-S, SGA-CU, and AGA groups differed in male/female ratio, 
comparisons in FSIGT results were adjusted for gender. At 5 years after GH-cessation, 
SGA-GH adults had a similar Si, Sg, AIR, and DI as untreated SGA-S adults (Figure 4). 
SGA-GH adults had a similar Si, AIR, and DI as SGA-CU and AGA adults, but a higher Sg 
than SGA-CU and AGA adults (P=0.003 and P=0.018, respectively). SGA-CU adults had 
the lowest Si and Sg levels with Si being lower compared to AGA (P=0.006) and Sg being 
lower compared to SGA-GH (P=0.003).
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Figure 4. Comparison of FSIGT results between groups.
Data are expressed as estimated marginal means with the upper limit of the 95% confidence interval, ad-
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DiScUSSioN
Our longitudinal study during 5 years after cessation of GH treatment is currently the 
longest and largest follow-up study in 199 GH-treated young adults born SGA. It has 
been reported that adults treated with GH during childhood for isolated short stature 
have an increased cardiovascular mortality, raising concerns about the long-term safety 
of GH treatment (14). We now show that cessation of GH treatment has significant ef-
fects on body composition, insulin sensitivity, and β-cell function, reflecting the loss of 
GH properties. The GH-induced insulin resistance was reversible after cessation of GH 
treatment, despite the persistent increase in FM. At 5 years after GH-cessation, body 
composition, insulin sensitivity, and β-cell function of previously GH-treated young 
adults born SGA were similar to untreated age-matched adults born SGA, with or with-
out catch-up growth, and to those born AGA, except for LBM which was lower in the 
previously GH-treated SGA adults. 
After cessation of GH treatment, FM increased and LBM decreased, which is contrary 
to the changes that occur during GH treatment. The increase in FM was neither due to 
increasing age over time nor to lower serum IGF-I levels, indicating that changes reflect 
the loss of the lipolytic characteristics of GH. Despite the significant increase in FM after 
cessation of GH, FM at 5 years after GH-cessation, adjusted for gender and height, was 
similar in previously GH-treated SGA adults and untreated SGA-S, SGA-CU, and AGA 
adults of similar age. We, therefore, anticipate that the future development of body 
composition in previously GH-treated SGA adults will be similar to that of untreated 
short adults born SGA. 
During 6 months after cessation of GH treatment, Si, Sg, AIR, and DI (ß-cell function) 
improved and sustained thereafter, despite the increase in FM. Since Si has a strong cor-
relation with FM, this indicates that the beneficial effect of GH-cessation on Si is greater 
than the opposite effect of gaining more FM. At 5 years after GH-cessation, Si was higher 
and AIR was lower compared to levels at GH-cessation, suggesting that GH-induced 
insulin resistance and increased insulin secretion were fully reversed. Beta-cell function 
at 5 years after GH-cessation was similar to β-cell function at GH-cessation, which is 
reassuring since particularly a reduction in ß-cell function relates to an increased risk 
for diabetes mellitus type 2. We used the FSIGT test with Tolbutamide which is a gold 
standard for measuring Si and β-cell function like the euglycemic-hyperinsulinemic 
clamp (22). Because the FSIGT test is more invasive, labor-intensive, and costly than 
other measurements of Si, such as the oral glucose tolerance test and HOMA-IR, no 
other studies have performed FSIGT tests in such high numbers of SGA subjects after 
cessation of GH treatment, making our data unique. 
There are no longitudinal data on body composition and insulin sensitivity after cessation 
of GH treatment, besides our preliminary results in 48 adolescents born SGA during only 6 
months after GH-cessation, which showed similar changes (23). We now show that during 
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the subsequent 5 years after GH-cessation, FM steadily increases and AIR further declines. 
At 5 years after GH-cessation, FM, Si, Sg, AIR, and DI are similar in previously GH-treated SGA 
adults and untreated SGA-S adults, indicating that GH treatment does not impair insulin 
sensitivity on the long-term. We previously showed in another, considerably smaller group 
of GH-treated SGA subjects, that Si and β-cell function at 6.5 years after GH treatment were 
similar to untreated SGA-S subjects but there was no comparison with SGA-CU and AGA 
subjects (24). In the present study, FM, LBM, Si, Sg, AIR, and DI of previously GH-treated SGA 
adults were also compared to untreated SGA-CU adults to evaluate whether GH-induced 
catch-up growth had a similar effect as spontaneous catch-up growth. FM was similar but 
SGA-CU adults had the lowest Si and Sg levels which is consistent with previous findings 
that accelerated catch-up in weight for length in early life is associated with a higher risk for 
an unfavorable health profile in adulthood (16, 25-28).
A previous study reported that adults treated with GH during childhood for isolated 
short stature have an increased cardiovascular mortality but it is unknown whether se-
verely GH-deficient adults in that study were treated with GH into adulthood or stopped 
GH treatment at AH (14). Other studies reported no deaths due to cardiovascular disease 
or cancer and indicated that patients without risk factors for cardiovascular disease and 
malignancies can expect an uneventful course after treatment (29, 30). A limitation of 
these previous studies was that data of previously GH-treated SGA adults were compared 
with national reference values and not with a control group of untreated SGA patients. To 
study the effect of GH treatment on the risk of diabetes mellitus type 2 and cardiovascular 
diseases, it is important to address the already known increased risk for these diseases in 
children born SGA, and compare GH-treated adults born SGA with untreated subjects born 
SGA instead of only with subjects born AGA. Our study now provides these important and 
long-awaited data which are of interest to healthcare practitioners worldwide. 
In conclusion, our follow-up study during 5 years after cessation of GH treatment 
shows significant longitudinal changes in body composition, insulin sensitivity, and 
β-cell function reflecting the loss of GH properties. The steady increase in FM during 
5 years after GH treatment indicates the loss of GH properties. Reassuringly, the GH-
induced changes in insulin sensitivity and β-cell function were fully reversed within 
6 months after cessation of GH treatment, despite the increase in FM. At 5 years after 
GH-cessation, FM, insulin sensitivity, and β-cell function of previously GH-treated SGA 
adults were comparable to untreated short SGA adults, indicating that long-term GH 
treatment of SGA children with short stature does not have an unfavorable effect on 
body composition, insulin sensitivity, and β-cell function in young adulthood.
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Context Growth hormone (GH) treatment results in a decline in blood pressure and lipid 
levels. Five year longitudinal changes in cardiovascular risk factors and carotid Intima 
Media Thickness (cIMT) after cessation of GH treatment in subjects born small for gesta-
tional age (SGA) are unknown. 
Objective To assess longitudinal changes in systolic and diastolic blood pressure (SBP 
and DBP), fasting lipid levels and cIMT in previously GH-treated young adults born SGA 
(SGA-GH). To compare SGA-GH subjects at 5 years after GH-cessation to untreated age-
matched controls.
Methods 199 SGA-GH adults were longitudinally followed for 5 years after attainment of 
adult height: at GH-cessation, and at 6 months, 2 and 5 years thereafter. Data at 5 years 
after GH-cessation were compared to: 51 untreated short SGA adults (SGA-S), 92 SGA 
adults with spontaneous catch-up growth (SGA-CU), and 142 adults born appropriate 
for gestational age (AGA). 
Results GH-cessation resulted in an increase in SBP and DBP, but only during the first 6 
months. SBP and DBP recovered thereafter and were similar at 5 years after GH-cessation 
compared to levels at GH-cessation. At 5 years after GH-cessation, SGA-GH adults had a 
similar SBP and DBP as untreated SGA-S adults. Lipid levels increased after GH-cessation 
in parallel to the increase in fat mass, but remained lower than levels in SGA-S adults. 
GH-cessation had no effects on cIMT levels and at 5 years after GH-cessation, SGA-GH 
adults had a similar cIMT as SGA-S adults. SBP, DBP, lipid levels, and cIMT of SGA-GH 
adults were similar to SGA-CU and AGA adults. 
Conclusion This longitudinal study during 5 years after GH-cessation shows that long-
term GH treatment in children born SGA does not only improve adult height but has 
also no unfavorable effects on cardiovascular health in early adulthood and might be 
beneficial with regard to the lipid profile.
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iNtroDUctioN 
Approximately 10% of children born small for gestational age (SGA) show insufficient 
catch-up growth and remain short with a height below -2 SDS (1, 2). Growth hormone 
(GH) treatment effectively induces catch-up growth and increases adult height (AH) in 
short children born SGA (3-6). 
Low birth weight is associated with an increased risk for cardiovascular diseases (CVD) 
(7). Preliminary data of the Safety and Appropriateness of Growth hormone treatments 
in Europe (SAGhE) project showed that adults who were treated with GH during child-
hood for isolated short stature have an increased mortality rate due to cardiovascular 
disorders(8). Other studies reported no deaths due to CVD (9). A limitation of these 
studies is the lack of longitudinal data after cessation of GH treatment, and a comparison 
with an appropriate control group of untreated SGA patients. 
The primary aim of the present study was, therefore, to investigate longitudinal 
changes of cardiovascular risk factors in young adults born SGA during 5 years after 
cessation of GH treatment. We investigated changes in blood pressure, lipid levels, 
and carotid intima-media thickness (cIMT) since these are accurate determinants of 
cardiovascular events in later life (10-14). We hypothesized that after cessation of GH 
treatment, blood pressure and lipid levels would increase during 6 months, in line with 
the loss of GH properties, but would remain unchanged during the following years. Our 
secondary aim was to assess the effect of GH treatment during childhood on blood 
pressure, lipid levels, and cIMT in early adulthood and we, therefore, compared data 
of previously GH-treated young adults born SGA (SGA-GH) at 5 years after cessation 
of GH treatment to age-matched young adults born SGA with persistent short stature 
who were never treated with GH (SGA-S subjects). We hypothesized that cardiovascular 
risk factors of previously GH-treated SGA adults would be similar to levels of untreated 
SGA-S adults. To evaluate whether GH-induced catch-up growth has a similar effect on 
cardiovascular risk factors as spontaneous catch-up growth, we additionally compared 
the data at 5 years after cessation of GH treatment to untreated young adults born SGA 
with spontaneous catch-up to a normal stature (SGA-CU subjects) and with healthy 
controls born appropriate for gestational age (AGA subjects). 
MethoDS
Subjects
The total study group comprised 484 young adults (265 females, 54.8%) of which 199 
young adults born SGA (birth weight and/or birth length <-2 SDS) had participated in a 
GH trial (103 females, 51.8%). At start of GH treatment, children were prepubertal, aged 
5-8 years, with a height SDS below -2.5 and no growth failure caused by other disorders. 
Children with GH-deficiency (defined as a maximum serum GH <20 mU/l during a GH 
112 Cardiovascular health after GH-cessation
stimulation test) were excluded. GH 1 mg/m2/day (~0.033 mg/kg/day) was given daily sc 
at bedtime (r-hGH Norditropin; Novo Nordisk A/S, Bagsværd, Denmark). Every 3 months, 
the GH dose was adjusted to the calculated body surface area. GH treatment was dis-
continued at attainment of AH, defined as height reached when growth velocity had 
decreased to <0.5 cm during the last 6 months and bone age was ≥15 years for girls and 
≥16.5 years for boys, or near AH, defined as height velocity between 0.5 and 2 cm during 
the last 6 months and adult pubertal stage. 
At GH-cessation, GH-treated young adults were invited to participate in the current 
follow-up study evaluating cardiovascular risk factors at AH while still on GH treatment, 
and at 6 months, 2 and 5 years after cessation of GH treatment. Some SGA-GH subjects 
did not participate at every study moment, due to the time-consuming aspect, and 
some participants had not yet discontinued GH treatment for 2 or 5 years. cIMT mea-
surements were added to the follow-up protocol for SGA-GH participants at a later stage 
and therefore numbers for cIMT measurements were lower than for blood pressure and 
lipid levels (N=70 at GH-cessation, N=60 at 6 months, N=67 at 2 years, and N=57 at 5 
years after GH-cessation). 
At 5 years after cessation of GH treatment, data of 88 SGA-GH young adults were 
compared with those of 285 participants of an age-matched healthy young adult study 
cohort (15, 16): 51 untreated young adults born SGA (birth length <-2 SDS) with persis-
tent short stature (<-2 SDS) (SGA-S), 92 young adults born SGA (birth length <-2 SDS) 
with catch-up growth and a normal stature (>-1 SDS) (SGA-CU), and 142 young adults 
born appropriate for gestational age (birth length >-1 SDS) with a normal stature (>-1 
SDS) (AGA) (17). SGA-S and SGA-CU young adults were randomly recruited from several 
hospitals in the Netherlands, where they had been registered because of their small 
birth size (birth length <-2 SDS) with or without short stature (<-2 SDS). In addition, 
healthy young adults from schools of different educational levels were randomly asked 
to participate as AGA controls. 
The medical ethics committee of the Erasmus University Medical Centre Rotterdam 
approved the studies. Written informed consent was obtained from all subjects and, if 
they were younger than 18 years at cessation of GH treatment, also from their parents 
or custodians. 
Measurements
All participants fasted for 12 hours and abstained from smoking and alcohol for 16 hours. 
Height was measured to the nearest 0.1 cm using a Harpenden stadiometer (Holtain, 
Ltd) and weight to the nearest 0.1 kg on a digital scale (Servo Balance KA-20-150S, Servo 
Berkel Prior). Height and weight were expressed as SDS adjusted for chronological age 
and gender according to Dutch references (18), using Growth Analyzer Research Calcu-
lation Tools (https://growthanalyser.org). Waist circumference was measured in standing 
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position by using a nonextensible tape at the midpoint between the iliac crest and the 
last rib. The mean of two measurements was used for analyses. All participants filled out 
a questionnaire on alcohol use and smoking.
blood pressure 
Brachial diastolic blood pressure (DBP) and systolic blood pressure (SBP) were measured 
in the supine position after 10 minutes of rest using the non-dominant arm with an 
automatic device (Accutorr Plus, Datascope Corp.) every 5 minutes for 1 hour and the 
mean of these 13 measurements was taken to reflect resting blood pressure. Blood pres-
sure was expressed in SDS using sex- and age-matched reference values (19).
carotid intima Media thickness (ciMt)
Carotid ultrasonography of both the left and right carotid artery was performed in 
participants in the supine position with the head tilted slightly to the contralateral side, 
using the same 7.5 MHz linear array transducer. A longitudinal 1 cm segment of the 
common carotid artery, proximal to the bifurcation, was identified for measurements 
and images were transferred to a computer. We used the B-mode of Art Lab, a special 
intima-media thickness assessment program, to measure the intima media thickness. 
This measurement was repeated 6 times for each common carotid artery and the mean 
was calculated. Since cIMT is influenced by gender, height, and gestational age, cIMT 
analyses were adjusted for these characteristics when comparing SGA-GH adults to 
untreated control groups.
assays
Fasting levels of total cholesterol, triglyceride (TG) and high-density lipoprotein 
(HDLc) were measured. Total cholesterol and TG were determined using an automated 
enzymatic method with the CHOD-PAP reagent kit and with the GPO-PAP reagent kit, 
respectively (Roche Diagnostics). HDLc was measured using a homogeneous enzymatic 
colorimetric assay (Roche Diagnostics). The intra-assay variations of measurements of 
total cholesterol, TG and HDLc were 2.9, 3.3 and 3.9%. Low-density lipoprotein (LDLc) 
was calculated using the Friedewald formula: LDLc (mmol/l) = TC – HDLc – 0.45 * TG (20).
Metabolic syndrome
At 5 years after cessation of GH treatment, the various components of metabolic syn-
drome were assessed in all participants. Revised criteria of the National Cholesterol 
Education Program (NCEP, Adult Treatment Panel III (ATP III)) were used to determine the 
presence of metabolic syndrome, defined as having three or more of the following risk 
factors: 1) abdominal obesity: waist circumference in men >102 cm, in women >88 cm; 
2) raised TG levels: ≥1.7 mmol/l; 3) reduced HDLc levels: in men ≤1.03, in women ≤1.3 
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mmol/l; 4) high blood pressure: ≥130/ ≥85 mm Hg; 5) increased fasting glucose: ≥5.6 
mmol/l (21-23). 
Statistics
Statistical analyses were performed using SPSS version 23. Distribution of variables was 
determined by Kolmogorov-Smirnov test and normal Q-Q-plots. Clinical characteristics 
are presented as mean (SD). ANOVA was used to determine differences between sub-
groups. Because of a skewed distribution, cIMT and lipid levels were log-transformed. 
Longitudinal changes were analyzed using repeated measurements analysis with an 
unstructured repeated covariance type. Longitudinal changes were adjusted for age. 
ANCOVA was used for adjusted comparisons between the groups at the age of 21 years, 
i.e. 5 years after cessation of GH treatment in the SGA-GH young adults. Comparison of 
the components of metabolic syndrome was performed using Fisher’s exact test. Results 
were regarded as statistically significant at P<0.05.
reSUltS
clinical characteristics of Sga-gh subjects
Table 1 shows the clinical characteristics of 199 SGA-GH participants at start of GH treat-
ment and at attainment of AH when GH treatment was discontinued and the follow-up 
study started. Mean age at start of GH treatment had been 6.4 (2.1) years and mean GH 
treatment duration 10.0 (2.3) years. At 5 years after GH-cessation, mean age was 21.3 
(1.5) years. The percentage of participants who smoked increased after cessation of GH 
treatment; 17.1% at AH, 18.9% at 6 months after GH-cessation, 22.6% at 2 years after 
GH-cessation and 30.1% at 5 years after GH-cessation.
longitudinal changes after gh-cessation in Sga-gh adults
Blood pressure
Figure 1A shows the longitudinal changes in SBP and DBP after cessation of GH in the 
SGA-GH adults, adjusted for age. SBP and DBP increased during 6 months after GH-
cessation (both P<0.001) and decreased in the 18 months thereafter (both P<0.001). 
From 2 until 5 years after GH-cessation, SBP and DBP remained similar. At 5 years after 
GH-cessation, SBP and DBP were similar compared to SBP and DBP at GH-cessation. Ad-
ditional adjustment for percentage of smokers did not change these results. 
Mean SBP and DBP SDS remained within the normal range, being 0.17 (0.8) SDS and 
0.02 (0.6) SDS (respectively) at GH-cessation, and 0.32 (1.0) SDS and 0.24 (0.7) SDS (re-
spectively) at 5 years after GH-cessation.
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Lipid levels
Figure 1B shows the longitudinal changes in lipid levels after cessation of GH in the 
SGA-GH adults, adjusted for age. During 6 months after GH-cessation, total choles-
terol remained similar, LDLc increased (P=0.016), and TG decreased (P<0.001). In the 
subsequent 18 months, cholesterol, LDLc, and TG increased (P=0.028, P=0.007, and 
P=0.006, respectively). From 2 years until 5 years after GH-cessation, cholesterol and 
LDLc remained similar, and TG increased (P=0.022). HDLc did not significantly change 
after cessation of GH treatment. At 5 years after GH-cessation, all lipid levels were higher 
compared to levels at GH-cessation but not significantly (P-values between 0.09 and 
0.21). 
Pearson correlation test showed that fat mass was a positive determinant for levels 
of cholesterol, LDLc, and TG (all P<0.001). After additional adjustment for fat mass, the 
increase in cholesterol, LDLc, and TG from 6 months until 2 years after GH-cessation 
disappeared. 
Table 1. Clinical characteristics of SGA-GH participants
At start of GH treatment
At adult height, 
Start of follow-up study
N 199 199
Sex (male/female) 96 / 103 96 / 103
Age, years 6.4 (2.1) 16.4 (1.3)
GH treatment duration, years N/A 10.0 (2.3)
Height SDS -3.0 (0.6) a -1.2 (0.8) a,c
Weight for Height SDS -1.5 (1.2) a -0.7 (1.1) a
Body Mass Index 14.0 (1.3) 20.2 (2.4)
Body Mass Index SDS -1.4 (1.1) a -0.2 (1.0) b
Systolic blood pressure, mmHg 103.2 (12.1) 111.1 (9.4)
Diastolic blood pressure, mmHg 58.7 (9.0) 62.0 (6.1)
Systolic blood pressure SDS 0.7 (1.1) a 0.17 (0.8) b
Diastolic blood pressure SDS -0.04 (1.0) 0.02 (0.6)
Cholesterol, mmol/l 4.15 (1.2) 3.96 (1.2)
LDLc, mmol/l 2.29 (1.4) 2.02 (1.4)
HDLc, mmol/l 1.36 (1.3) 1.41 (1.3)
TG, mmol/l 0.85 (1.6) 0.92 (1.5)
IGF-I SDS -0.5 (1.2) a 1.2 (0.8) a
Abbreviations: N/A, not applicable. Data are expressed as mean (SD). Systolic and diastolic blood pressure 
were expressed in SDS, using sex- and age-matched reference values (19).
a P<0.001 compared with zero SDS.
b P<0.02 compared with zero SDS. 
c P<0.001 compared with -2.0 SDS.
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Figure 1. Longitudinal changes after cessation of GH treatment.
Data are expressed as estimated marginal means with the upper limit of the 95% confidence interval, ad-
justed for age. * P<0.010, # P<0.05.
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cIMT
Figure 1C shows the longitudinal changes in cIMT after cessation of GH in the SGA-GH 
adults, adjusted for age. During 6 months after GH-cessation, and from 6 months until 
2 years and 2 years until 5 years after GH, cIMT did not significantly change. cIMT at 5 
years after GH-cessation was similar to cIMT at GH-cessation. Additional adjustment for 
smoking did not change these results.
comparison between Sga-gh adults and untreated Sga-S, Sga-cU, and aga adults
At 5 years after cessation of GH, data of SGA-GH adults were compared to untreated 
controls. Mean age of the SGA-GH adults was 21.3 (1.5) years which was similar to un-
treated SGA-S, SGA-CU and AGA adults (Table 2). Adult height SDS of the SGA-GH adults 
was -1.6 (0.9) SDS which was significantly higher compared to SGA-S adults (P<0.001) 
but significantly lower than in SGA-CU (P<0.001) and AGA adults (P<0.001). The percent-
age of participants who smoked was similar between the groups. The SGA-CU adults 
smoked the most cigarettes per day (15 cigarettes), but this was only significantly differ-
ent compared to AGA adults (7 cigarettes per day, P=0.004).
Table 2. Clinical characteristics of the total study group
SGA-GH SGA-S SGA-CU AGA
N 88 51 92 142
Sex (male / female) 36 / 52 18 / 33 38 / 54 67 / 75
Gestational age, weeks 36.1 (3.7) 38.1 (3.1) a 35.9 (3.5) 36.3 (4.1)
Birth length SDS -3.3 (1.6) -3.0 (0.9) -2.9 (0.8) 0.2 (0.8) b
Birth weight SDS -2.4 (1.2) -2.1 (0.9) -2.3 (0.8) 0.3 (1.2) b
Smokers, % 30.1 25.5 28.3 23.9
Alcohol users, % 90.0 76.5 77.2 81.7
Age, years 21.3 (1.5) 20.9 (1.8) 20.7 (1.7) 20.9 (1.7)
Adult height SDS (21 years) -1.6 (0.9) b -2.6 (0.5) b -0.2 (0.7) c,d 0.1 (0.8)
Weight for Age SDS -1.4 (1.5) e -1.4 (1.5) e -0.02 (1.2) c 0.2 (0.9) c
Body Mass Index 21.4 (3.5) f 23.2 (4.4) 22.5 (4.2) 22.4 (3.1)
Body Mass Index SDS -0.5 (1.4) a 0.2 (1.4) -0.01 (1.3) 0.03 (1.1)
Waist circumference, cm 72.2 (9.0) e 75.1 (9.6) 79.2 (11.3) 78.9 (9.3)
Fasting glucose, mmol/l 4.7 (0.4) 4.9 (0.6) 4.7 (0.5) 5.0 (1.0)
Fasting insulin, mU/l 10.0 (5.2) 10.7 (4.8) 10.3 (3.9) 10.0 (5.3)
IGF-I SDS -0.4 (0.9) -0.4 (0.8) -0.3 (0.7) -0.4 (0.8)
Data are expressed as mean (SD). Abbreviations: SGA-GH, previously GH-treated adults born SGA; SGA-
S, untreated adults born SGA with short stature; SGA-CU, adults born SGA with spontaneous catch-up 
growth; AGA, adults born appropriate for gestational age. 
a P<0.04 compared with the other groups.  d P=0.010 compared with AGA.
b P<0.001 compared with the other groups.  e P<0.001 compared with SGA-CU and AGA.
c P<0.001 compared with SGA-GH and SGA-S. f P<0.05 compared with SGA-S.
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Blood pressure
Since the SGA-GH, SGA-S, SGA-CU, and AGA adults differed in male/female ratio and 
height, which are important factors for blood pressure, the SBP and DBP comparisons 
between groups were adjusted for these factors (Figure 2A). At the age of 21 years, i.e. 5 
years after cessation of GH treatment in the SGA-GH adults, SBP and DBP were similar in 
SGA-GH and SGA-S adults. SGA-GH adults had a similar SBP but a lower DBP compared 
to SGA-CU and AGA adults (P=0.002 and P=0.016, respectively). Adjustment for the 
number of cigarettes smoked per day, resulted in a similar DBP in all groups.
At 5 years after cessation of GH, mean SBP was 0.32 (1.0) SDS in SGA-GH, 0.22 (1.1) SDS 
in SGA-S, 0.36 (1.0) SDS in SGA-CU, and 0.24 (0.8) SDS in AGA adults. Mean DBP SDS was 
0.24 (0.7) SDS in SGA-GH, 0.49 (0.8) SDS in SGA-S, 0.53 (0.7) SDS in SGA-CU, and 0.42 (0.6) 
SDS in AGA adults.
Lipid levels
Because the SGA-GH, SGA-S, SGA-CU, and AGA adults differed in male/female ratio, the 
lipid comparisons between groups were adjusted for gender. At the age of 21 years, i.e. 
5 years after cessation of GH treatment, the SGA-GH adults had lower cholesterol and 
LDLc levels than the untreated SGA-S adults (P=0.003 and P<0.001, respectively) (Figure 
2B). SGA-GH adults tended to have higher HDLc levels than SGA-S adults (P=0.050), and 
TG levels were similar (data not shown). SGA-GH adults had similar cholesterol, LDLc, 
and TG levels as SGA-CU and AGA adults. SGA-GH had higher HDLc levels than SGA-CU 
adults (P=0.045, data not shown). Of the 4 groups, untreated SGA-S adults had the high-
est cholesterol and LDLc levels compared to SGA-GH, SGA-CU, and AGA adults (Figure 
2B). 
cIMT 
Without adjustments, cIMT was similar between SGA-GH, SGA-S, SGA-CU, and AGA 
adults. Adjustment for gender, height, and gestational age did not change these results 
(Figure 2C). Pearson correlation tests showed that SBP, cholesterol, and LDLc were 
positively related to cIMT (P=0.002, P=0.039, and P=0.006, respectively). After additional 
adjustment for SBP, cholesterol or LDLc, cIMT remained similar between SGA-GH, SGA-S, 
SGA-CU, and AGA adults.
Metabolic syndrome at the age of 21 years in Sga-gh adults, and untreated 
Sga-S, Sga-cU, and aga adults
The presence of metabolic syndrome according to the ATP III criteria could be inves-
tigated in 77 SGA-GH adults, 47 SGA-S adults, 85 SGA-CU adults, and 137 AGA adults 
(Table 3). The percentage of participants with abdominal obesity, high TG levels, low 
HDLc levels, high SBP or DBP, or high fasting glucose was not significantly different 
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between the groups. Of all participants, 46.0% (159/346) had one or more risk factors for 
metabolic syndrome. According to the ATP III criteria, 2 of 77 SGA-GH adults (2.6%) had 
three or more risk factors for metabolic syndrome compared with 3 of 47 untreated SGA-
S adults (6.4%), but this difference did not reach statistical significance. The percentage 
of adults having three or more risk factors for metabolic syndrome tended to be higher 
in SGA-S adults compared with AGA adults (6.4% vs 0.7%, P=0.053). 
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Figure 2. Comparison between groups.
A.  Comparison of SBP and DBP, data are expressed as estimated marginal means with the upper limit of 
the 95% confidence interval, adjusted for gender and height. 
B.  Comparison of lipid levels, data are expressed as estimated marginal means with the upper limit of the 
95% confidence interval, adjusted for gender. 
C.  Comparison of cIMT, data are expressed as estimated marginal means with the upper limit of the 95% 
confidence interval, adjusted for gender, height, and gestational age. 
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DiScUSSioN
Our longitudinal study during 5 years after cessation of GH treatment is currently the 
longest and largest follow-up study in 199 GH-treated young adults born SGA. We show 
that cessation of GH treatment has significant effects on blood pressure, but only during 
the first 6 months after GH-cessation. The changes in lipid levels after cessation of GH 
treatment were related to the increase in fat mass. Cessation of GH treatment had no 
effects on cIMT levels. At 5 years after cessation of GH, previously GH-treated SGA young 
adults had a similar blood pressure and cIMT, and a more beneficial lipid profile, com-
pared to untreated age-matched short SGA young adults who had higher cholesterol 
and LDLc levels. The percentage of participants with metabolic syndrome at the age 
of 21 years was not significantly different between previously GH-treated SGA young 
adults and untreated short SGA young adults.
Atherosclerosis, the main cause of CVD, is a chronic inflammatory condition with 
adverse remodeling of various arterial walls resulting in hypertension and a higher IMT. 
Before start of GH treatment, short children born SGA had a higher SBP compared to 
peers born AGA but SBP and DBP decreased during long-term GH treatment which is in 
line with previous studies (24). We show that SBP and DBP, adjusted for age, increased in 
the first 6 months after cessation of GH treatment, reflecting the loss of GH properties. 
Fortunately, this increase was followed by a decrease in the subsequent 18 months after 
which SBP and DBP remained similar until 5 years after GH treatment. At 5 years after 
GH-cessation, SBP and DBP were around zero SDS and not significantly different from 
levels at GH-cessation. Studies on changes in cIMT during GH treatment in children and 
adults with GH deficiency showed no change or even a decrease in cIMT (25-31). Only 
one study reported cIMT after 4 years of GH treatment in 31 children born SGA and 
found no association between GH treatment and changes in cIMT (32). To the best of our 
knowledge, our study is the first to report cIMT after cessation of GH treatment in previ-
Table 3. Metabolic syndrome components, according to ATP III criteria
Symptoms SGA-GH SGA-S SGA-CU AGA
Abdominal obesity 4/77 (5.2%) 2/47 (4.3%) 9/85 (10.6%) 13/137 (9.5%)
High TG levels 5/77 (6.5%) 6/47 (12.8%) 7/85 (8.2%) 11/137 (8.0%)
Low HDLc levels 21/77 (27.3%) 17/47 (36.2%) 30/85 (35.3%) 36/137 (26.3%)
High blood pressure 4/77 (5.2%) 6/47 (12.8%) 7/85 (8.2%) 6/137 (4.4%)
High fasting glucose 5/77 (6.5%) 5/47 (10.6%) 2/85 (2.4%) 9/137 (6.6%)
One or more symptoms 31/77 (40.3%) 23/47 (48.9%) 41/85 (48.2%) 64/137 (46.7%)
Three or more symptoms 2/77 (2.6%) 3/47 (6.4%) a 2/85 (2.4%) 1/137 (0.7%)
Abbreviations: SGA-GH, previously GH-treated adults born SGA; SGA-S, untreated adults born SGA with 
short stature; SGA-CU, adults born SGA with spontaneous catch-up growth; AGA, adults born appropriate 
for gestational age.
a P=0.053 compared with AGA adults. 
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ously GH-treated adults born SGA and shows that cIMT, adjusted for age, did not change 
after cessation of GH treatment. At 5 years after GH-cessation, previously GH-treated 
SGA adults had a similar SBP, DBP, and cIMT as untreated SGA-S adults. These findings 
indicate that long-term GH treatment has no long-lasting unfavorable effects on blood 
pressure and cIMT, thereby contradicting the hypothesis that there is a link between GH 
treatment and vascular diseases (8, 33). This is supported by the fact that levels of ma-
trix metalloproteinase-9, which play a role in the development of atherosclerosis (34), 
decrease during GH treatment, in parallel to the decrease in blood pressure (35). Since 
our participants were relatively young and CVD might not yet be clinically apparent, we 
cannot conclude on the long-term risk for CVD. Epidemiological data, however, indicate 
that a cIMT value above 1 mm at any age is associated with a significantly increased risk 
for myocardial infarction and/or cerebrovascular disease, and none of the previously 
GH-treated SGA adults and other participants in our study had a cIMT above 1 mm at any 
time point during the study (36). 
Previous reports showed that cholesterol and LDLc significantly decreased during 
GH treatment (24, 37, 38), indicating that GH treatment has a beneficial effect on lipid 
metabolism. Our data show that this beneficial effect on lipid metabolism sustains after 
cessation of GH treatment since previously GH-treated SGA adults had lower cholesterol 
and LDLc levels than untreated SGA-S adults, despite the increase in lipid levels after 
GH-cessation which was related to the increase in fat mass after GH-cessation. These 
findings are reassuring, since elevated lipid levels contribute to a higher risk for CVD (39). 
Evidence indicates that, on the long-term, adults with metabolic syndrome have an 
elevated risk for CVD-attributed mortality (39, 40). The previously GH-treated SGA adults 
showed no increased risk for metabolic syndrome. In our study, the percentage of adults 
with metabolic syndrome was highest in the untreated SGA-S adults, which was border-
line significant compared to AGA adults. Thus, GH treatment does not increase the risk 
for metabolic syndrome, at least until 5 years after cessation of treatment. 
To evaluate whether GH-induced catch-up versus spontaneous catch-up growth to a 
normal stature has a similar effect on blood pressure, lipid levels, and cIMT, we also com-
pared these outcomes in previously GH-treated SGA adults to those of SGA-CU adults 
of a similar age. DBP was significantly higher in SGA-CU adults, whereas SBP, lipid levels, 
and cIMT were similar. This might be due to the catch-up in weight for length in early life 
(15, 41) but can also be due to a higher number of cigarettes smoked per day in SGA-
CU adults compared to previously GH-treated SGA adults, since smoking is positively 
related to blood pressure. After adjustment for the number of cigarettes smoked per 
day, DBP was similar between previously GH-treated SGA and SGA-CU adults.
A limitation of previous studies on the long-term mortality after GH treatment such as 
the preliminary data of the Safety and Appropriateness of Growth hormone treatments 
in Europe (SAGhE) project (8, 9), is the lack of an appropriate control group of untreated 
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SGA patients. To study the effect of GH treatment on the risk for CVD, it is particularly 
important to determine the presence of risk factors for these diseases in GH-treated 
adults born SGA compared to untreated adults born SGA. Our study now provides such 
data. 
We previously reported the longitudinal changes in body composition, insulin sen-
sitivity, and β-cell function during 5 years after cessation of GH treatment in the same 
population and demonstrated that fat mass steadily increased after GH-cessation while 
the GH-induced changes in insulin sensitivity and β-cell function were fully reversed (42). 
Body composition, insulin sensitivity, and β-cell function at 5 years after GH treatment 
had reached the same values as in untreated short SGA young adults (42). Together with 
our present findings that blood pressure and cIMT were similar, and lipid levels lower 
in previously GH-treated SGA young adults compared to untreated short SGA young 
adults, we can now conclude that long-term GH treatment in children born SGA does 
not only improve adult height but has also no unfavorable effects on metabolic and 
cardiovascular health in early adulthood and might be beneficial with regard to the lipid 
profile. Longer-term follow-up is important to evaluate if these effects sustain over a 
longer period.
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abStract 
Background Some children born small for gestational age (SGA) show advanced bone 
age (BA) maturation during growth hormone (GH) treatment. ACAN gene mutations 
have been described in children with idiopathic short stature and advanced BA.
Objective To determine presence of ACAN gene mutations in short SGA children with 
advanced BA and to assess the response to GH treatment. 
Methods BA assessment in 290 GH-treated SGA children and ACAN-sequencing in 29 
children with an advanced BA of ≥0.5 year compared with calendar age.
Results ACAN gene mutations were found in 4/29 SGA children with advanced BA 
(13.8%). Mutations were related to the characteristics: midface hypoplasia (P=0.003), 
joint problems (P=0.010), and broad great toes (P=0.003). Children with advanced BA 
having none or only 1 of these characteristics had no ACAN gene mutation. Of children 
with advanced BA and 2 of these characteristics, 50% had an ACAN gene mutation. Of 
children with advanced BA and 3 of these characteristics, 100% had an ACAN gene mu-
tation. All GH-treated children with an ACAN gene mutation received additional GnRHa 
treatment for 2 years from onset of puberty. At adult height, 1 girl was 5 cm taller than 
her mother and 1 boy was 8 cm taller than his father with the same ACAN gene muta-
tion. In boys, bone maturation was delayed by aromatase inhibitor treatment.
Conclusion This study expands the differential diagnosis of genetic variants in children 
born SGA and proposes a clinical scoring system for identifying subjects most likely to 
have an ACAN gene mutation. ACAN-sequencing should be considered in children born 
SGA with persistent short stature, who show advanced bone age and midface hypopla-
sia, joint problems, or broad great toes. Our findings suggest that children with an ACAN 
gene mutation benefit from GH treatment with 2 years of GnRHa treatment. 
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iNtroDUctioN
Children born small for gestational age (SGA) comprise a heterogeneous group with 
a broad spectrum of clinical characteristics (1, 2). Although several factors have been 
identified in the etiology of children born SGA, the etiology remains unidentified in up 
to 40% of cases. Approximately 10% of children born SGA remain short and are therefore 
treated with growth hormone (GH) to increase adult height (3-7). Adult height (AH) is 
one of the most heritable human traits (8), but only a small number of genetic mutations 
(<1%), explaining short stature in children born SGA, has been found (9-11). Uncovering 
the genetic etiology of short stature is important for health prognosis, genetic counsel-
ing, and treatment options. 
Some children born SGA have an accelerated bone age (BA) maturation during child-
hood, resulting in early closure of the epiphyseal growth plates and cessation of growth 
at a young age with a disappointing short AH. Heterozygous mutations in the ACAN 
gene have been identified in children with idiopathic short stature and advanced BA (12, 
13). Various clinical characteristics have been described in affected individuals: advanced 
BA, early growth cessation, short stature (i.e. height below -2.5 SDS), midface hypopla-
sia, flat nasal bridge, prognathism, posteriorly rotated ears, broad forehead, broad great 
toes, short thumbs, brachydactyly, joint problems, exaggerated lumbar lordosis, and 
genu valgum (12-14). Due to the variance in clinical characteristics, the identification 
of appropriate patients for genetic testing remains a challenge. We, therefore, assessed 
BA in 290 GH-treated children born SGA, and performed genetic testing in 29 children 
suspected for mutations in the ACAN gene due to advanced BA. Phenotypic character-
istics of children with advanced BA were used to develop a scoring system to identify 
children most likely to test positive for mutations in the ACAN gene, and for distinguish-
ing these children from those not likely to test positive. In addition, the response to GH 
treatment with additional gonadotropin-releasing hormone analog (GnRHa) for 2 years, 
and aromatase inhibitor treatment in boys, was evaluated in children with a confirmed 
mutation in the ACAN gene. 
MethoDS
Subjects
The study population consisted of 290 children born SGA with persistent short stature, 
without known genetic abnormalities, who were participating in 2 prospective cohort 
trials evaluating the effects of GH treatment (15, 16). The inclusion criteria for these GH 
trials were: 1) birth length and/or birth weight SDS for gestational age less than -2.0 
(17); 2) height SDS or predicted AH at start of GH treatment less than -2.5 SDS, based 
on Dutch references (18); 3) well-documented growth data from birth to start of GH 
treatment; and 4) an uncomplicated neonatal period, without signs of severe asphyxia 
130 ACAN mutations in GH-treated SGA
(Apgar score >3 after 5 minutes) or long-term complications of respiratory ventilation 
such as bronchopulmonary dysplasia. 
Reported findings in patients with ACAN gene mutations showed that BA was persis-
tently advanced during childhood. In our study population of 290 children born SGA, 
radiographs of the left hand and wrist were taken at start of GH treatment and yearly 
thereafter. BA was assessed according to Greulich and Pyle (19). We selected children for 
ACAN-sequencing based on an advanced BA of at least 0.5 year at ≥ 2 radiographs prior 
to pubertal onset (Table 1, group 1). Some of the children in our study population came 
to medical attention in early puberty and started GH treatment with additional GnRHa 
for 2 years to postpone puberty and improve AH. Since GnRHa treatment influences 
bone maturation, and BA before start of combined GH/GnRHa treatment was not known 
in all children, only the first radiograph at start of treatment was reliable to assess BA in 
these children. Persistent advanced BA was therefore not a possible selection criteria 
and selection was based on an advanced BA of at least 0.5 year at start of GH/GnRHa 
treatment (Table 1, group 2). Based on these criteria, 42 children were selected for ACAN-
sequencing. In 13 children, ACAN-sequencing was not possible because they did not 
want to revisit the hospital after attainment of AH. In total, targeted ACAN-sequencing 
was performed in 29 children after written informed consent.
The following physical characteristics were assessed by one physician (M.v.d.S.), after 
instruction by a clinical geneticist, and recorded as present or absent; midface hypo-
plasia, prognathism, flat nasal bridge, broad forehead, microcephaly defined as head 
circumference below -2.0 SDS, posteriorly rotated ears, joint problems, broad great toes, 
brachydactyly, exaggerated lumbar lordosis, and genu valgum.
Sequencing
Amplicon sequencing of ACAN was performed in all 29 participants essentially as previ-
ously described (20, 21). The sequences of the primers that were used are available in 
Supplemental table 1.
Statistical analyses
Statistical analyses were performed using SPSS version 23 (IBM). Birth length and 
birth weight were transformed into SDS for sex and gestational age (17). Height was 
transformed into SDS for sex and chronological age according to Dutch references (18), 
using Growth Analyser Research Calculation Tools (https://growthanalyser.org). AH SDS 
was calculated using references for Dutch adults (age 21 years) (18). Mann-Whitney U 
test and Fisher’s exact test were used to assess the difference in clinical characteristics 
between children with and without mutations in the ACAN gene. P-values < 0.05 were 
considered statistically significant.
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reSUltS
ACAN-sequencing was performed in 29 children (13 males, 16 females) with advanced 
BA, originating from 26 nonrelated Dutch families. Clinical characteristics are summa-
rized in Table 1. Four children, 3 boys, including one dizygotic twin, had a mutation in 
the ACAN gene. 
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clinical presentation
Family A 
Figure 1A shows the pedigree. The proband (A.IV:1) is a girl, born SGA at 32 6/7 weeks 
of gestation. She had persistent short stature and was referred to our clinic at the age 
of 5.0 years with a BA equal to her calendar age (CA) (Table 2). She has midface hypo-
plasia, broad great toes, and short thumbs. A skeletal survey showed underdeveloped 
facial bones, no vertebral body deformities. Her twin brother (A.IV:2) was born SGA and 
referred to our clinic at the age of 11.9 years because of persistent short stature with a 
BA 0.6 year advanced relative to his CA (Table 2). He has midface hypoplasia, mild pos-
teriorly rotated ears, and broad great toes. Both children were referred to orthopedics 
because of persistent pain and dysfunction of their knees and elbows and osteoarthritis 
was diagnosed. Because of recurrent urinary tract infections, the boy was referred to a 
pediatric urologist and abdominal ultrasound showed an absent left kidney. 
Height of their mother (A.III:1) is 140.3 cm (-4.7 SDS) and she has midface hypoplasia, 
broad great toes, short thumbs, exaggerated lumbar lordosis, osteoarthritis, and partial 
adrenal insufficiency. The height of the children’s maternal grandfather (A.II:1) is 151.6 
cm (-4.6 SDS) and the maternal grandmother (A.II:2) is 158.0 cm (-2.0 SDS). The grand-
father has midface hypoplasia and had knee and hip replacement surgery at a young 
age due to osteoarthritis. ACAN-sequencing identified a pathogenic heterozygous 
nonsense mutation, c1608C>A, in the proband, her twin brother, mother, and maternal 
grandfather. The maternal uncle (A.III:2) has a height of 173 cm (-1.6 SDS) and no ACAN 
gene mutation. 
Family B
Figure 1B shows the pedigree. The proband (B.IV:1) is a boy, born SGA at 38 6/7 weeks 
of gestation. He had persistent short stature and was referred to our clinic at the age 
of 11.7 years with a BA 0.8 years advanced relative to his CA (Table 2). He has midface 
hypoplasia, mild prognathism, broad great toes, and exaggerated lumbar lordosis. At 
the age of 14 years, he was referred to orthopedics because of persistent pain in both 
knees and osteochondritis dissecans was diagnosed based on knee X-rays and magnetic 
resonance imaging.
Height of his father (B.III:1) is 169.5 cm (-2.1 SDS) and mother (B.III:2) 135.9 cm (-5.4 
SDS). His mother has midface hypoplasia, short thumbs, broad great toes, exaggerated 
lumbar lordosis, and osteoarthritis of her knees for which she had replacement surgery 
several times. The mother has no nails on most of her digits (hands and feet). The pro-
band has one sister with a height of 156.3 cm (-1.5 SDS) at the age of 14.5 years (B.IV:2). 
The proband’s maternal grandfather (B.II:1) is deceased, his height was 155.0 cm (-4.1 
SDS) and he had osteoarthritis of neck and vertebrae. The height of proband’s maternal 
grandmother (B.II:2) is 143.0 cm (-4.3 SDS) and she has midface hypoplasia, short thumbs, 
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and problems of both knees and neck. The height of proband’s maternal uncle (B.III:3) is 
158.0 cm (-3.7 SDS). ACAN-sequencing identified a pathogenic heterozygous nonsense 
mutation, c.7090C>T, in the proband, his mother, his maternal grandmother, and uncle. 
Besides, ACAN-sequencing identified 2 additional heterozygous missense mutations in 
the proband’s mother and his maternal uncle, c.1973A>G (p.(Asn658Ser)) and c.5419G>A 
(p.(Gly1807Arg)). The pathogenicity of the second mutation is uncertain. These 2 missense 
mutations could not be tested in the proband’s maternal grandfather since he is deceased. 
The unaffected father and sister of the proband had no ACAN gene mutation. 
Family C
Figure 1C shows the pedigree. The proband (C.III:1) is a boy, born SGA at 41 weeks of ges-
tation. He had persistent short stature and was referred to our clinic at the age of 12.3 
years with a BA 1.0 year advanced relative to his CA (Table 2). He has midface hypoplasia, 
broad great toes, and posteriorly rotated ears, but no joint problems. 
Height of his father (C.II:3) is 157.4 cm (-3.8 SDS) and mother (C.II:4) 174.6 cm (0.6 
SDS). The proband’s father has midface hypoplasia and joint problems of his hips. The 
proband has one brother (C.III:2) with an AH of 185.0 cm (0.2 SDS). One paternal aunt 
(C.II:1) has severe knee problems and a height of 153 cm (-2.7 SDS) and one parternal 
uncle (C.II:2) has a height of 160 cm (-3.4 SDS). ACAN-sequencing identified a patho-
genic heterozygous frameshift mutation, c.4762_4765del (p.(Gly1588fs), which leads to 
an early stopcodon, in the proband and his father. The proband’s mother and brother 
had no ACAN gene mutation. Siblings of the proband’s father were not tested for ACAN 
gene mutations.
Table 2. Clinical characteristics of the 4 children with an ACAN gene mutation
A.IV:1 A.IV:2 B.IV:1 C.III:1
Birth characteristics
Gestational age, weeks 32 6/7 32 6/7 38 6/7 41
Birth weight, SDS -2.1 -0.9 -0.1 -1.8
Birth length, SDS -4.4 -2.1 -3.0 -3.0
At referral to our clinic
Age, years 5.0 11.9 11.7 12.3
Bone age, years 5.0 12.5 12.5 13.3
Height, cm 94.5 135.6 131.7 135.4
Height, SDS -3.7 -2.4 -2.7 -2.7
Weight for Height, SDS -1.1 2.0 0.7 -0.4
Sitting height to height ratio, SDS 2.2 1.4 1.4 1.6
Head circumference, SDS -3.0 -1.3 -0.2 -1.6
A.IV:1, proband family A; A.IV:2, twin brother of proband family A; B.IV:1, proband family B; C.III:1, proband 
family C.
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Presence of mutations in the acaN gene and phenotypic characteristics
Overall, 13.8% of the children with advanced BA had an ACAN gene mutation (4 of 29). 
Supplemental table 2 provides additional phenotypic information of all 29 children. 
Children with an ACAN gene mutation differed significantly for presence of midface 
hypoplasia, joint problems, and broad great toes, from children without an ACAN gene 
mutation (Table 3; P=0.001). Figure 2 shows a flowchart on the probability of having an 
ACAN gene mutation. Children with advanced BA and none or only 1 of the additional 
characteristics midface hypoplasia, joint problems, or broad great toes, had no ACAN 
gene mutation. Of children with 2 additional characteristics, 50% had an ACAN gene 
mutation. When 2 additional characteristics were present and at least one parent had a 
height below -3.5 SDS, the occurrence rate of ACAN gene mutations increased to 100%. 
All children with advanced BA ≥0.5 year and all 3 additional characteristics had a muta-
tion in the ACAN gene (100%). 
In the families with confirmed mutations in the ACAN gene, all affected individuals 
had midface hypoplasia and broad great toes. Joint problems were present in all affected 
individuals except in the proband of family C (C.III:2). All affected individuals without GH 
treatment had a height below -3.5 SDS.
Table 3. Statistical comparison of the clinical characteristics of patients with and without an ACAN gene 
mutation
ACAN gene mutation No ACAN gene mutation P-value
N 4 25
Mean (SD) numbers of factors recorded ‘yes’ 5.25 (1.0) 1.92 (1.5) 0.001
Characteristics N % N %
Midface hypoplasia 4 100 4 16 0.003
Broad great toes 4 100 4 16 0.003
Joint problems 3 75 2 8 0.010
Posteriorly rotated ears 2 50 4 16 NS
Brachydactyly 1 25 4 16 NS
Prognathism 1 25 5 20 NS
Microcephaly 1 25 2 8 NS
Exaggerated lumbar lordosis 1 25 2 8 NS
Flat nasal bridge 0 0 6 24 NS
Broad forehead 0 0 5 20 NS
Genu valgum 0 0 4 16 NS
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growth response and bone maturation during gh treatment
The 4 children with an ACAN gene mutation were treated with GH based on persistent 
short stature after SGA birth. Timing of pubertal onset was normal in all 4 children, but 
relatively early for their short stature. Because of an AH expectation below -2.5 SDS at 
pubertal onset, they were all treated with 2 years of additional GnRHa treatment from 
onset of puberty to postpone puberty (leuprolide acetate depots, 3.75 mg sc every 4 
weeks). Figure 3 shows the growth charts of the children with an ACAN gene mutation.
The girl of family A started GH treatment at the age of 5 years with a dose of 1 mg/
m2/day (0.033 mg/kg/day) (Figure 3A). From the age of 7 years, her BA was 1.5-2.0 years 
advanced. She started puberty at the age of 10 years with a height of 132.3 cm (-1.8 
SDS) and was additionally treated with GnRHa. During GnRHa treatment, her bone 
maturation slowed compared with the years before, but her growth rate decreased and 
GnRHa treatment was therefore discontinued after 1.5 years, while GH treatment was 
Persistent short stature after SGA birth
290 cases
Advanced BA of at least 0.5 year at multiple
examinations prior to pubertal onset
42 cases
Clinical characteristics:
Midface hypoplasia, joint problems, broad great toes
3 characteristics present
3 cases
no characteristics present
16 cases
2 characteristics present
2 cases
Informed consent and ACAN sequencing performed
29 cases (26 families)
No informed consent
13 cases
1 characteristic present
8 cases
0% ACAN
gene mutations
Height of both parents
above -3.5 SDS
0% ACAN
gene mutations
100% ACAN
gene mutations
100% ACAN
gene mutations
50% ACAN
gene mutations
Height of at least one
parent below -3.5 SDS
Figure 2. Clinical scoring system for ACAN gene mutations.
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continued. At the age of 13.3 years, the GH dose was increased to 2 mg/m2/day because 
of a disappointing pubertal growth spurt. Her growth ceased at the age of 14 years, 
when BA was 17 years, with a height of 145.5 cm (AH -3.9 SDS) which was 5 cm taller than 
her mother (AH -4.7 SDS). 
The 3 boys all started GH treatment combined with 2 years of GnRHa in early puberty, 
age 11.5-12.0 years (Figure 3, B-D). Due to the GH trial design, they were randomly as-
signed to receive either GH 1 mg/m2/day (boy from family C) or GH 2 mg/m2/day (boys 
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Figure 3. Growth charts of patients with an ACAN gene mutation. 
A:  proband family A (A.IV:1). 
B:  brother of proband family A (A.IV:2). 
Abbreviations: AI, aromatase inhibitor. 
Growth charts according to Growth Analyser 4.0 (18). Triangles represent bone age.
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from family A and B). Bone maturation was advanced at start of GH treatment but 
stopped during GnRHa treatment. Because of rapid development of Tanner stage and 
bone maturation after discontinuation of GnRHa, the boys of family A and B were treated 
with an aromatase inhibitor (AI) from the age of 14 and 15 years, respectively (Letrozole, 
2.5 mg daily). Due to abnormalities in the knee joint, AI treatment was discontinued for 
4 months in the boy of family B, during which BA rapidly advanced. AI treatment was 
restarted after the diagnosis osteochondritis dissecans. Currently, BA is delayed in both 
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Figure 3. Growth charts of patients with an ACAN gene mutation. 
C:  proband family B (B.IV:1).
D:  proband family C (C.III:1).
Abbreviations: AI, aromatase inhibitor. 
Growth charts according to Growth Analyser 4.0 (18). Triangles represent bone age.
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boys (1-1.5 years) while treated with AI. They have not yet reached AH and have a current 
height of 164.7 cm and 161.3 cm, respectively. In the boy of family C, growth ceased at 
the age of 18.6 years with a height of 165.3 cm (AH -2.6 SDS) (Figure 3D), which is 8 cm 
taller than his father (-3.8 SDS). 
Treatment had no adverse effects and DXA scans of the total body and lower lumbar 
spine showed normal bone mineral density in all children. 
DiScUSSioN
In this study, we performed ACAN-sequencing in 29 short children born SGA with an ad-
vanced BA, who participated in prospective GH trials including 290 children born SGA. 
In 4 children (13.8%), one dizygotic twin, we identified heterozygous genetic mutations 
in the ACAN gene. Our data show that ACAN gene mutations are related to the presence 
of midface hypoplasia, joint problems, and broad great toes. ACAN gene mutations were 
present in 50-100% of the children with advanced BA and at least 2 of these charac-
teristics. We, therefore, suggest that ACAN-sequencing could be considered in children 
with a combination of advanced BA and at least 2 of these clinical characteristics. When 
BA is advanced in the absence of these characteristics, a mutation in the ACAN gene is 
less likely, regardless of parental height. GH treatment with 2 years of additional GnRHa 
followed by aromatase inhibitor treatment in boys, which successfully delayed bone 
maturation, was beneficial in all 4 patients with a confirmed mutation in the ACAN gene. 
Longitudinal bone growth occurs at the growth plate by forming and remodeling car-
tilage into bone tissue. The ACAN gene is located on chromosome 15q26 and consists 
of 19 exons ranging in size from 77-4224 base pairs (22). It encodes for the aggrecan 
protein, which is a member of the lectican (chondroitin sulfate proteoglycan) family. 
The encoded protein is a proteoglycan and a critical component of the extracellular 
matrix in both articular and growth plate cartilaginous tissue, explaining the effects 
on joints (articular cartilage) and growth (growth plate cartilage) in case of a mutation. 
Mutations in the ACAN gene result in a broad phenotypic spectrum of nonlethal skeletal 
dysplasias including spondyloepimetaphyseal dysplasia, spondyloepiphyseal dysplasia 
(Kimberley type), familial osteochondritis dissecans, and various idiopathic short stature 
phenotypes (12-14, 20, 23-25). The exact mechanism of how each distinct mutation in 
the ACAN gene leads to a range of phenotypes is unknown, but in all published studies, 
affected individuals had short stature and early growth cessation. It is unknown whether 
all previously reported individuals with ACAN gene mutations had an advanced BA and 
since we selected on advanced BA, there is a small chance that ACAN gene mutations 
were present in the children not tested. However, an antiangiogenic function of the 
aggrecan matrix has been proposed (26) and mutations in the ACAN gene might, there-
fore, lead to premature or increased invasion of the growth plate by blood vessels and 
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osteoblasts. This causes ossification of growth cartilage resulting in advanced BA, early 
epiphyseal fusion and premature growth cessation (27). Since all previously reported 
individuals with ACAN gene mutations had early growth cessation and short stature, 
advanced BA could be assumed in these subjects.
We show that having an advanced BA is insufficiently indicative for a mutation in the 
ACAN gene in children born SGA since only 13.8% of the children with advanced BA had 
an ACAN mutation. Patients should, therefore, have additional characteristics. Various 
different characteristics have been described in patients with ACAN gene mutations (12-
14, 20, 24, 25), but we only found an association with midface hypoplasia, joint problems, 
and broad great toes. These characteristics have also been described in other individuals 
with ACAN gene mutations (12-14). The occurrence of short thumbs was not indicative 
for ACAN gene mutations when analyzed in our 29 patients. However, all women with an 
ACAN gene mutation, and none of the men, had short thumbs. This might indicate that 
phenotypic characteristics of ACAN gene mutations differ in females and males, which is 
also true for SHOX deficiency in which Madelung deformity is more common in females 
(28). It could, therefore, be that there are more phenotypic characteristics indicative for 
mutations in the ACAN gene, which we did not find because of the small number of 
patients in our study. Nevertheless, this is the first study proposing a clinical scoring 
system for ACAN-sequencing (Figure 2), showing that advanced BA combined with the 
presence of midface hypoplasia, joint problems, or broad great toes, has a predictive 
value of 50-100% of identifying an ACAN gene mutation. 
GH treatment with additional 2 years of GnRHa, resulted in an AH of 145.5 cm (-3.9 
SDS) in the girl from family A, and an AH of 165.3 cm (-2.6 SDS) in the boy from family C. 
This is respectively 5 and 8 cm taller than their parent with the same sex and ACAN gene 
mutation. Another study reported combined GH/GnRHa treatment in a girl aged 11.5 
years with a heterozygous ACAN gene mutation in the C-type lectin domain (12). GnRHa 
treatment successfully blocked bone maturation but both GH and GnRHa treatment 
were discontinued at the age of 13.5 years, for unknown reasons, and growth ceased 
shortly thereafter at an AH of 135.8 cm (-4.2 SDS). A case report of GH treatment in a boy 
with a heterozygous missense mutation in the C-type lectin domain of the ACAN gene, 
showed that the treated boy was 11.5 cm taller than the mean height of the untreated 
males with ACAN gene mutations in his family (20, 25). These findings together, suggest 
that children born SGA who have a mutation in the ACAN gene, benefit from GH treat-
ment with 2 years of additional GnRHa treatment in early puberty. In our study, 2 boys 
received also aromatase inhibitor treatment. Since these 2 boys have not yet reached 
their AH, effectiveness of aromatase inhibitor treatment is still uncertain. However, since 
bone maturation was successfully stopped and bone mineral density remained normal 
during aromatase inhibitor treatment, this could be considered in boys with an ACAN 
gene mutation.
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Remarkably, accelerated bone maturation did not occur in early childhood but from 
the age of 7 years in the affected girl and the age of 11 years in the affected boys. This 
highlights the importance of regularly reevaluating the original diagnosis in children 
born SGA, who comprise a heterogeneous group with a broad spectrum of clinical char-
acteristics since SGA is a definition and not a diagnosis (1, 2). Being born SGA has been 
associated with an adverse health profile in young adulthood, and short stature during 
childhood and adolescence, resulting in a short AH, is associated with reduced quality of 
life (29). Therefore, identifying underlying causes of being born SGA remains important 
to alert physicians to potential comorbidities and to improve future treatment options. 
In most cases, however, no diagnosis is made since only a small number of genetic muta-
tions (<1%) explaining short stature after SGA birth, has been found (9-11). 
In conclusion, our study expands the differential diagnosis of genetic variants in short 
children born SGA and proposes a clinical scoring system for identifying subjects most 
likely to have an ACAN gene mutation and for distinguishing these subjects from those 
not likely to test positive. Although the full phenotypic spectrum of this disorder is yet 
to be elucidated, our findings show that children born SGA with persistent short stature, 
advanced BA, and at least 2 of the clinical characteristics midface hypoplasia, joint prob-
lems, or broad great toes, have a high likelihood of an ACAN gene mutation. Patients 
with advanced BA without additional characteristics are less likely to have a mutation in 
the ACAN gene. Our findings suggest that children with an ACAN gene mutation benefit 
from GH treatment with 2 years of additional GnRHa, and in boys this could be followed 
by treatment with an aromatase inhibitor, which might further increase adult height. 
Further research on treatment options is warranted to improve height in children with 
ACAN gene mutations.
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SUPPleMeNtal tableS
Supplemental table 1. Primer sequences
OliogID1 OliogID2 Fragment/Exon SeqOligoID1 SeqOligoID2
050-547 050-548 15 CTCCTCCATCCCCTCTGC TGAATGCATCTCTCTCCAGG
050-549 050-550 16 GATGATGAAGAGGCTCCACG AGAGCCTCACCTGTAGCTGG
050-551 050-552 17 CACAACCAGCATAGGTCATCC ACGGTGTAGGGTCCCCAG
050-553 050-554 18 GTAGTCTGGGGAGAGCCTGG GAGGACACCGTCTGGGTG
050-507 050-508 01 TGTGGGACTGAAGTTCTTGG CAACAGCCAAAAAGTTTGC
050-509 050-510 02 TGACTCTGCTTGACCTCACC GCACCAGGTTCAGTACCCAG
051-199 051-200 03 CTAACAGGTCTCTCTTCTACC AGTTAAGTAACTTGGCTGAGG
050-513 050-514 04 CAGCCAGTTCCCTAAGGTCC ACTAGCTGATGGGCTAGGGC
050-515 050-516 05 GGGAGGAGGATTCAAAGGC AGGTGTCAGTGGGGAGATGG
050-517 050-518 06 GAGAAGACCCTTACCCAGC TCCCCTCTTCCCTCTAGGAC
050-519 050-520 07 GAGCCATGCTCATCTCCAG CCACGTGCCAGGTTAAGTAG
050-521 050-522 08 CCAATATGTCAGGCAGCAGG TCATTCATTAACCCACAAGG
050-523 050-524 09 AGTAGCCTCTGGCCTCAGC TGTATCGCCCTGTCAGCTC
050-525 050-526 10 GAACTCTGTCCTGGGTGGG GATCCGGTGAACCCAGTG
050-527 050-528 11 TAAGCGAGAAGGCAAACAGC GGCACACTGTAGGAAGACAGG
050-529 050-530 12_01 ATTTGAGCTTAAAGTGGGGC CATCTCCACTGCCTGTGAAG
050-531 050-532 12_02 TCAGAGGAACCATCAGCCTC GAGGTCTCTAGAACTTCTCC
050-533 050-534 12_03 AGGTTGTAGAGACTTCTGCC AAGTCCAAGTCTCCAGAAGC
050-535 050-536 12_04 CTGGAAAAGAAGACTTGGTGG AAGGCTGCCCACTGAGATC
050-537 050-538 12_05 GCACTAGTCAACCCTTTGGC TCTAAAATGCCAGAAGGCCC
050-539 050-540 12_06 GAATCTGTAACCCAGGCTCC AGGGGACCCAGAATCTTCTC
050-541 050-542 12_07 TCAGTCCCAGAATCTAGCAG CCTTCTGTGCTGCAGTAGGC
050-543 050-544 13 TCTTGGAGGCCATGGTAG GGGGATGAAGAAGTCTGTCC
050-545 050-546 14 GCCATAAGACTGGCAGCATC CTGCCTTCTGAAAGGTGAGG
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geNeral DiScUSSioN 
Twenty-five years ago, in 1991, our research group initiated the first Dutch study on 
growth hormone (GH) treatment in children born small for gestational age (SGA) to 
improve knowledge and care for these children. Since then, several Dutch studies have 
been initiated to evaluate the effectiveness and safety of GH treatment in children 
born SGA. GH treatment is most effective when started at a young age (1-3), but some 
children come to medical attention at an older age, even when pubertal development 
has started. In 2003, the Dutch SGA study was initiated to investigate the effectiveness 
of GH treatment in children born SGA who start treatment at the age of 8 years or older. 
In addition, we evaluated the effectiveness and safety of additional GnRHa treatment 
for 2 years to improve adult height in children who start puberty with an expected adult 
height less than −2.5 SDS (height at start of puberty <140 cm), based on Dutch refer-
ences (4). Furthermore, the effect of GH 1 mg/m2/day vs 2 mg/m2/day (~0.033 vs 0.067 
mg/kg/day) from pubertal onset until adult height was compared. 
Low birth weight is associated with a higher risk of developing metabolic and car-
diovascular disease in later life (5-7). Since both GH and GnRHa treatment influence 
determinants of metabolic and cardiovascular health, evaluating the long-term con-
sequences of these treatments is essential. The effectiveness of GH treatment, with or 
without additional GnRHa treatment, has been described by previous PhD fellows of 
the Dutch SGA study (8-12). In the studies presented in this thesis, we investigated the 
effects of additional GnRHa treatment for 2 years on metabolic health, cardiovascular 
health, and pubertal development and growth (Chapters 2, 3, and 4). In addition, we 
assessed the longitudinal changes in metabolic and cardiovascular health during 5 years 
after cessation of GH treatment, and compared the data of previously GH-treated SGA 
adults to untreated adults born SGA and adults born appropriate for gestational age 
(AGA) (Chapters 5 and 6). Furthermore, ACAN gene mutations were investigated as an 
underlying cause of short stature after SGA birth which might have consequences for 
growth response and health prognosis (Chapter 7).
In this chapter, our results are discussed in view of current literature. Subsequently, 
clinical implications of our results are presented and recommendations for future re-
search are provided.
Metabolic aND carDiovaScUlar health DUriNg gh treatMeNt with or 
withoUt gNrha 
In 2012, our research group showed that pubertal children born SGA with a poor adult 
height expectation can benefit from treatment with GH 1 mg/m2/day combined with 
2 years of GnRHa and even more so with a double GH dose of 2 mg/m2/day (11). Since 
data on the metabolic effects of combined GH/GnRHa treatment were scarce (8), we 
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compared the metabolic effects of combined GH/GnRHa treatment with those of treat-
ment with GH only by evaluating longitudinal changes in body composition, blood pres-
sure, lipid levels, insulin sensitivity, and β-cell function until adult height was reached in 
children born SGA.
In chapters 2 and 3, we demonstrate that body composition, blood pressure, lipid 
profile, insulin sensitivity, and β-cell function at adult height (~ after 6 years of GH treat-
ment) were similar between children treated with combined GH/GnRHa and those 
treated with GH only. In children who started combined GH/GnRHa treatment in early 
puberty, a double GH dose of 2 mg/m2/day resulted in a lower fat mass and a similar lean 
body mass, blood pressure, lipid profile, insulin sensitivity, and β-cell function as the 
standard GH dose of 1 mg/m2/day.
The metabolic effects of GnRHa treatment were mainly known from studies in children 
with central precocious puberty (CPP). During GnRHa treatment, sex steroids and stimuli 
to gain lean body mass are suppressed, which could result in changes in body composi-
tion toward relatively more fat mass and less lean body mass. Studies evaluating the 
effects of GnRHa treatment on fat mass in children with CPP were, however, inconclusive 
with most studies finding no change in fat mass and some showing a modest decrease 
(13-20). Other studies reported an increase in fat mass during GnRHa treatment, which 
returned to baseline values after cessation of treatment (21, 22). In chapter 2, we show 
an increase in fat mass percentage SDS during 2 years of combined GH/GnRHa treatment 
in children treated with GH 1 mg/m2/day, but not in those treated with GH 2 mg/m2/
day. This could indicate that GnRHa treatment has indeed a fat mass enhancing effect 
which is counterbalanced by the lipolytic effects of GH treatment, particularly when GH 
is administered in a higher dose, whereas treatment with GH 1 mg/m2/day appears less 
sufficient to prevent children from gaining fat mass during GnRHa treatment. The clini-
cal relevance of gaining fat mass during GnRHa treatment depends on the proportion 
of visceral vs subcutaneous fat, since visceral fat is likely to be more related to a worse 
metabolic health as opposed to subcutaneous fat. Besides, the clinical relevance also 
depends on the persistence of the gain in fat mass after cessation of treatment. Since 
we used a DXA scan to assess fat mass and lean body mass, we could not distinguish be-
tween visceral and subcutaneous fat. However, visceral adipose tissue induces specific 
cytokine changes, such as an increase in proinflammatory cytokines (tumor necrosis 
factor-alpha (TNF-alpha) and interleukin-6 (IL-6)) and a decrease in adiponectin, which 
induces insulin resistance. In chapter 3, we show a decrease in insulin sensitivity during 
combined GH/GnRHa treatment, which might indicate an increase in visceral fat mass 
during combined GH/GnRHa treatment. Since the decline in insulin sensitivity during 
combined GH/GnRHa treatment could also be due to the GH treatment, we evaluated 
insulin sensitivity during 3 months of only GnRHa treatment and found that insulin 
sensitivity remained similar. Although 3 months of GnRHa treatment might have been 
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too short to detect significant changes in insulin sensitivity, these findings indicate that 
short-term GnRHa treatment does not affect insulin sensitivity and that the decline in 
insulin sensitivity during combined GH/GnRHa was, therefore, due to the GH treatment. 
At adult height, when GnRHa treatment had been discontinued for many years, fat 
mass and insulin sensitivity were similar in adolescents treated with combined GH/
GnRHa and those treated with GH only, despite the changes that occurred during 
combined GH/GnRHa treatment. This indicates that the fat mass enhancing effect of 
GnRHa treatment is temporarily and disappears after cessation of GnRHa treatment. This 
is in line with studies in women treated with GnRHa during childhood for CPP (23, 24). 
One study in girls with CCP showed lower insulin sensitivity at adult height in GnRHa-
treated compared to untreated girls (25). In that study, however, HOMA-IR was used 
to determine insulin sensitivity, which is not comparable with the frequently sampled 
intravenous glucose tolerance (FSIGT) tests we used. Besides, the girls with lower insulin 
sensitivity had also a higher body mass index, which could explain the difference in 
insulin sensitivity between the treatment groups. 
Despite the difference in fat mass percentage SDS, insulin sensitivity, acute insulin 
response, β-cell function, blood pressure and lipid levels were similar in children treated 
with GH 1 mg/m2/day and those treated with GH 2 mg/m2/day, which is in line with 
previous findings in SGA children who started GH treatment prepubertal (26-30).
Conclusions
In conclusion, our present findings show that there are no long-lasting unfavorable effects 
of combined GH/GnRHa treatment on metabolic and cardiovascular profile at adult height 
when compared to GH treatment only. A GH dose of 2 mg/m2/day started in early puberty, 
results in a similar metabolic and cardiovascular profile as the standard GH dose of 1 mg/
m2/day.
PUbertal DeveloPMeNt aND growth DUriNg gh treatMeNt with or 
withoUt gNrha 
Clinically, children treated with combined GH/GnRHa seem to have an accelerated 
pubertal progression after cessation of GnRHa treatment which might result in a shorter 
pubertal duration and less pubertal growth. There were, however, no data on pubertal 
development and growth after cessation of GnRHa treatment in GH-treated SGA chil-
dren. We, therefore, investigated pubertal development and growth in 76 children who 
started GH treatment prepubertal and were treated until adult height. Children with a 
poor adult height expectation at onset of puberty were treated with additional 2 years 
of GnRHa treatment from onset of puberty.
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In chapter 4, we show that pubertal duration after cessation of GnRHa treatment was 
shorter than pubertal duration in those treated with GH only (40.9 vs 46.7 months in 
girls; 50.8 vs 57.5 months in boys). Bone maturation diminished during GnRHa treat-
ment but was not completely stopped, which is in line with other studies (16, 19, 31-37). 
This indicates that senescence of the growth plate, the progressive loss of function and 
structural involution of the growth plate, which is growth dependent (38), continued 
during GnRHa treatment. When growth plates are more senescent and have expended 
more of their growth potential, a shorter exposure to estrogen is sufficient to complete 
growth plate fusion (39), leading to a shorter period of growth after cessation of GnRHa 
treatment. There are no other studies reporting pubertal duration after discontinuation 
of GnRHa treatment in SGA children and we, therefore, could not compare our results 
to other studies.
In children with CPP treated with GnRHa only, a decreased growth rate during GnRHa 
has been reported, which is lower than the growth rate of prepubertal children (13, 32, 
33, 40, 41). Reduced levels of insulin-like growth factor 1 (IGF-I) and GH during GnRHa 
treatment could explain the diminished growth rate during GnRHa treatment (42). In 
our study, girls and boys grew approximately 13 cm during 2 years of combined GH/
GnRHa treatment, i.e. 6.5 cm/year, which is in line with the annual growth of prepubertal 
children. This indicates that GH treatment can normalize growth during GnRHa treat-
ment. The average height gain from onset of puberty until adult height was 25.4 cm 
in girls and 33.0 cm in boys treated with combined GH/GnRHa, which is similar to the 
average pubertal height gain in healthy children born AGA (4). Adult height was similar 
in children treated with GH/GnRHa compared with those with GH only. This shows that 
additional GnRHa treatment has a beneficial effect on adult height in GH-treated SGA 
children who start their puberty when still short. 
In chapters 2 and 3, we show that additional 2 years of GnRHa treatment had no nega-
tive effects on metabolic health, insulin sensitivity, and β-cell function (43, 44). Besides, 
GnRHa treatment was well tolerated in all children and no adverse effects were reported. 
All girls treated with GnRHa reported regular cycles at adult height and one pregnancy 
after adult height with normal offspring was reported. Thus, the interruption of the 
GnRH axis in childhood did not impair reproductive function in adulthood, which is in 
line with findings in girls with CPP treated with GnRHa only (45). 
Conclusions
In conclusion, pubertal duration after cessation of GnRHa treatment is shorter in SGA chil-
dren with combined GH/GnRHa treatment compared to pubertal duration in children treated 
with GH only. Due to adequate growth during 2 years of additional GnRHa treatment, height 
gain from onset of puberty until adult height is more in children treated with combined GH/
GnRHa treatment than in children treated with GH only. Thus, although children with GH/
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GnRHa treatment started puberty with a shorter stature, they reached a similar adult height 
as children treated with GH only. 
Metabolic aND carDiovaScUlar riSK factorS DUriNg 5 yearS after 
ceSSatioN of gh treatMeNt
Low birth weight is associated with an increased risk of diabetes mellitus type 2 and 
cardiovascular diseases (CVD) (5-7, 46). Despite the fact that biosynthetic GH has been 
used for more than 25 years, there were no longitudinal data on the long-term effects 
after cessation of GH treatment in young adults born SGA. We, therefore, evaluated 
longitudinal changes in body composition, insulin sensitivity, β-cell function, blood 
pressure, lipid levels and carotid intima media thickness (cIMT), during 5 years after 
cessation of GH treatment and compared these data with age-matched control groups. 
In chapters 5 and 6, we demonstrate that fat mass increased continuously and lean 
body mass decreased. At 5 years after cessation of GH treatment, fat mass was higher 
and lean body mass lower compared to values at adult height when GH treatment was 
discontinued, indicating that the lipolytic and anabolic effects of GH treatment on body 
composition were lost after cessation of treatment. Insulin sensitivity and β-cell function 
improved during 6 months after cessation of GH treatment and sustained thereafter. 
The initial increase in blood pressure during the first 6 months after cessation of GH 
treatment recovered thereafter, and at 5 years after cessation of GH treatment, blood 
pressure was similar to levels at cessation of GH treatment. Lipid levels increased after 
GH-cessation in parallel to the increase in fat mass. cIMT levels did not change after 
cessation of GH treatment. 
Preliminary data of the Safety and Appropriateness of Growth hormone treatments 
in Europe (SAGhE) project showed that adults treated with GH during childhood for 
isolated short stature have an increased mortality rate due to cardiovascular disorders, 
whereas others reported no deaths due to CVD (47-49). A limitation of the SAGhE 
project is the lack of an appropriate control group of untreated SGA patients, which is 
necessary to study the effect of GH treatment on the risk of developing diabetes mellitus 
type 2 and CVD, knowing that subjects born SGA have an increased risk for develop-
ing these diseases. We now show that at the age of 21 years, 5 years after cessation of 
GH treatment, fat mass was similar and lean body mass lower in previously GH-treated 
young adults compared to untreated short SGA young adults. Since the GH-treated 
young adults born SGA were the smallest at birth, body composition might have been 
reprogrammed during fetal and early life, which could explain the lower lean body mass 
in early adulthood in these subjects. Insulin sensitivity and β-cell function were similar in 
the previously GH-treated young adults compared to untreated short SGA young adults, 
indicating that GH treatment during childhood does not impair insulin sensitivity on the 
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longer-term. Lipid levels increased after GH-cessation in parallel to the increase in fat 
mass, but remained lower than levels in untreated short SGA young adults, suggesting 
that the beneficial effect of GH treatment on lipid metabolism sustains after cessation 
of GH treatment. These findings are reassuring since elevated lipid levels contribute to 
a higher risk for CVD. Blood pressure and cIMT were similar in the previously GH-treated 
young adults compared to age-matched untreated short SGA young adults, contradict-
ing the hypothesis that there is a link between GH treatment and vascular diseases (47, 
50). We previously showed that levels of matrix metalloproteinase-9, which play a role 
in the development of atherosclerosis (51), decrease during GH treatment, in parallel to 
the decrease in blood pressure (52), which supports our current findings. On the other 
hand, our participants were relatively young and cardiovascular disease might not yet 
be clinically apparent. Epidemiological data, however, indicate that a cIMT value above 
1 mm at any age is associated with a significantly increased risk for myocardial infarc-
tion and/or cerebrovascular disease (53), and none of the previously GH-treated young 
adults born SGA and other participants in our study had a cIMT above 1 mm at any time 
point during the study. 
At 5 years after cessation of GH treatment, previously GH-treated SGA young adults 
had a similar body composition, insulin sensitivity, blood pressure, and cIMT, and a more 
beneficial lipid profile, than untreated short SGA young adults. This indicated that GH 
treatment during childhood has no long-term unfavorable effects on metabolic and car-
diovascular profile which is reassuring. However, metabolic and cardiovascular health in 
late adulthood in both GH-treated and untreated SGA adults remains unknown. Longer-
term follow-up of metabolic and cardiovascular risk factors is, therefore, indicated in 
these predisposed subjects.
Conclusions
Our study shows that the metabolic and cardiovascular risk factors significantly change 
after cessation of GH treatment due to the loss of GH properties. At 5 years after cessation of 
long-term GH treatment, however, the metabolic and cardiovascular profiles of previously 
GH-treated SGA young adults are similar or more beneficial than in untreated young adults 
born SGA, showing that long-term GH treatment in children born SGA has no unfavorable 
effects on metabolic and cardiovascular profile in early adulthood.
acaN geNe MUtatioNS iN Short chilDreN borN Sga
Some children born SGA show accelerated bone age maturation during childhood, 
resulting in early closure of the epiphyseal growth plates, cessation of growth at a 
young age, and extremely short adult stature. The cause of this accelerated bone age 
maturation was unknown. As heterozygous mutations in the ACAN gene were reported 
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in children with idiopathic short stature and advanced bone age (54, 55), we wanted to 
evaluate if ACAN gene mutations could explain the accelerated bone age maturation 
in some GH-treated children born SGA. Besides, we aimed to develop a clinical scoring 
system to identify subjects most likely to test positive for an ACAN gene mutation and 
to assess the effectiveness of GH treatment in children with an ACAN gene mutation.
In chapter 7, we demonstrate the presence of ACAN gene mutations in short SGA 
children, thereby expanding the differential diagnosis of genetic variants in children 
born SGA with persistent short stature. The variance in clinical characteristics in patients 
with confirmed ACAN gene mutations made it difficult to distinguish which children 
were likely to have an ACAN gene mutation (54-59). We did show that mutations are 
related to advanced bone maturation in combination with the characteristics midface 
hypoplasia, joint problems, and broad great toes. Based on advanced bone age and 
these characteristics, we developed a clinical scoring system which will help physicians 
identifying children who most likely have an ACAN gene mutation (Figure 1). Advanced 
bone age in combination with 3 characteristics had a predictive value of 100% on hav-
ing an ACAN gene mutation. Also, in case of advanced bone age in combination with 
Persistent short stature after SGA birth
Advanced BA of at least 0.5 year at multiple
examinations prior to pubertal onset
Clinical characteristics:
Midface hypoplasia, joint problems, broad great toes
3 characteristics presentno characteristics present 2 characteristics present1 characteristic present
0% ACAN
gene mutations
Height of both parents
above -3.5 SDS
0% ACAN
gene mutations
100% ACAN
gene mutations
100% ACAN
gene mutations
50% ACAN
gene mutations
Height of at least one
parent below -3.5 SDS
Figure 1. Clinical scoring system for ACAN gene mutations.
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2 of these characteristics and at least one extremely short (height <-3.5 SDS) parent, 
100% of the children had an ACAN gene mutation. Advanced bone age in combination 
with 2 characteristics but without short parents, still resulted in the identification of an 
ACAN gene mutation in 50% of the cases. Children with none or only 1 characteristic 
did not have an ACAN gene mutation. Our study is the first to describe a clinical scoring 
system which will likely improve awareness of ACAN gene mutations in short children 
born SGA. The identification of more children with an ACAN gene mutation will improve 
our knowledge of these mutations and might, therefore, result in better healthcare and 
treatment options for these children. 
Remarkably, accelerated bone maturation did not occur in early childhood but from 
the age of 7 years in the affected girl and the age of 11 years in the affected boys. This 
highlights the importance of regular reevaluations of the original diagnosis in children 
born SGA. 
Since being born SGA is an indication for GH treatment, children with an ACAN gene 
mutation who are born SGA can be treated with GH. However, one of the European 
requirements to start GH treatment in children born SGA is a distance to target height of 
at least 1 SDS (60). Children with an ACAN gene mutation who inherited this mutation 
from a parent, will most likely have a smaller distance to target height (<1 SDS) because 
that parent will be very short. They would, therefore, be excluded from GH treatment. A 
previous study from our research group has shown that this distance to target height cri-
terion is not justified (9). Since a mutation in the ACAN gene results in a skeletal disorder 
(61), the effectiveness of GH treatment in children with skeletal disorders is uncertain 
and for many thus questionable. There are no published data on the effectiveness of 
GH treatment in children with an ACAN gene mutation. Nonetheless, our study shows 
that the GH/GnRHa-treated SGA adolescents with an ACAN gene mutation had a better 
adult height SDS than their parent with the same ACAN gene mutation, suggesting that 
GH treatment with additional 2 years of GnRHa treatment is beneficial for short children 
born SGA with an ACAN gene mutation. The number of adolescents with an ACAN gene 
mutation and attainment of adult height was, however, small and therefore definite 
conclusions can not be drawn. 
Conclusions 
Our data show that the combination of persistent short stature after SGA birth, advanced 
bone age, midface hypoplasia, joint problems, and broad great toes, is highly suggestive 
for an ACAN gene mutation. Although ACAN gene mutations result in skeletal disorders, 
our data suggest that children born SGA with an ACAN gene mutation can benefit from GH 
treatment with additional 2 years of GnRHa treatment.
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geNeral coNclUSioNS aND cliNical iMPlicatioNS
GH treatment is an approved and frequently applied growth promoting therapy in chil-
dren born SGA, which is most effective when started at a young age (1-3). Our research 
group has shown that GH treatment can still be beneficial when started at an older age, 
even when pubertal development has started, and that additional 2 years of GnRHa 
treatment is beneficial in GH-treated SGA children who start puberty with an expected 
adult height less than -2.5 SDS (11). The studies in this thesis demonstrate that the ad-
dition of 2 years of GnRHa treatment in GH-treated SGA children has no unfavorable 
effects on metabolic and cardiovascular health when compared to GH treatment only. In 
addition, our research group has shown that the same treatment had no adverse effect 
on bone mineral density and health-related quality of life in GH-treated SGA children 
(10, 12). Thus, additional GnRHa treatment to GH treatment appears effective and safe 
and can, therefore, be considered in SGA children who start puberty with an expected 
adult height below -2.5 SDS. Based on the data of the Dutch SGA study, adjustment of 
the treatment guideline for short children born SGA should be considered.
When GH treatment is started in early puberty, a GH dose of 2 mg/m2/day results in 
a better adult height in boys and a similar metabolic and cardiovascular profile as the 
standard GH dose of 1 mg/m2/day. We do, however, not recommend high GH dosing 
in all children since concerns have been expressed regarding the possible detrimental 
effects of persistently relatively high serum IGF-I levels. Nonetheless, our data show that 
a GH dose of 2 mg/m2/day could be considered in a small group of short, pubertal SGA 
children who come to medical attention at such an old age that only a few years of 
growth remain. 
The metabolic and cardiovascular profile of previously GH-treated young adults born 
SGA is similar to that of untreated young adults born SGA, indicating that long-term 
GH treatment during childhood does not only improve adult height but has also no 
unfavorable effects on health. Cessation of GH treatment, however, leads to the loss of 
GH properties which is disadvantageous. The significant changes in body composition 
highlight the importance to inform patients to keep a healthy lifestyle and diet when 
long-term GH treatment is discontinued. 
Children born SGA comprise a heterogeneous group with a broad spectrum of under-
lying causes, including syndromes like Noonan, 3M, Turner, and Bloom, and mutations in 
the IGF1R gene and the ALS gene. Our study shows that ACAN gene mutations can also 
be an underlying cause in short children born SGA. We recommend that children with 
persistent short stature after SGA birth, advanced bone age, midface hypoplasia, joint 
problems, and broad great toes are tested for ACAN gene mutations. Although ACAN 
gene mutations result in a skeletal disorder, combined GH/GnRHa treatment improves 
adult height in those born SGA. Since clinical characteristics tend to change over time, it 
is important to regularly reevaluate the original diagnosis in children born SGA.
160 General discussion
DirectioNS for fUtUre reSearch 
Follow-up into adulthood after attainment of adult height is required to investigate 
the long-term effects of additional GnRHa treatment on metabolic and cardiovascular 
profile, fertility, bone mineral density, and health-related quality of life, in young adults 
born SGA. Besides, studies with a follow-up duration beyond 5 years after cessation of 
GH treatment are needed to finally conclude on the lifetime risk of metabolic and car-
diovascular diseases in previously GH-treated adults born SGA, since the development 
of these diseases might occur later in life. 
Up until now, genetic mutations underlying persistent short stature in children born 
SGA have only been found in a small percentage of patients. Further research into the 
genetic basis of human stature will increase our knowledge and might explain the 
variability of the SGA phenotype. This might lead to a more precise prediction of the re-
sponse to GH treatment, which will ultimately lead to individualized treatment options.
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chaPter 1
This chapter gives an overview of definitions, prevalence, and possible causes of small 
for gestational age (SGA) birth. It provides a general introduction on growth, the growth 
hormone (GH) axis, the pituitary hormone axis, and puberty. Treatment options and the 
reported effects of these treatments in short children born SGA, who come to medical 
attention around onset of puberty, are discussed. Furthermore, the association between 
low birth weight and a higher risk of metabolic and cardiovascular disease in later life 
are described. Finally, the aims of the studies performed and the outline of this thesis 
are presented.
chaPter 2
Pubertal children born SGA with a poor adult height expectation can benefit from treat-
ment with GH 1 mg/m2/day in combination with 2 years of GnRH analog (GnRHa) and 
even more so with a double GH dose. We evaluated the long-term effects of combined 
GH/GnRHa and 2 different GH doses on metabolic health in children born SGA.
At adult height, fat mass percentage SDS, lean body mass SDS, blood pressure SDS, 
and lipid levels were similar in 64 children treated with combined GH/GnRHa and 43 
children treated with GH only. The GH-dose effect on metabolic health was evaluated 
in a subgroup of 47 children who started GH treatment in early puberty (randomized 
to 1 or 2 mg/m2/day ~ 0.033 or 0.067 mg/kg/day) with additional GnRHa for 2 years. Fat 
mass percentage SDS was lower during treatment with GH 2 mg/m2/day. There was no 
GH dose-dependent effect on lean body mass SDS, blood pressure SDS, and lipid profile.
In conclusion, combined GH/GnRHa treatment has no long-term negative effects on 
metabolic health compared with GH only. Started in early puberty, a GH dose of 2 mg/
m2/day results in a similar metabolic health at adult height and a more favorable fat 
mass percentage SDS than GH 1 mg/m2/day.
chaPter 3
Pubertal children born SGA with a poor adult height expectation can benefit from treat-
ment with GH 1 mg/m2/day in combination with 2 years of GnRHa and even more so 
with a double GH dose. We evaluated the long-term effects of combined GH/GnRHa and 
2 different GH doses on insulin sensitivity and β-cell function, measured by frequently 
sampled intravenous glucose tolerance (FSIGT) tests, in children born SGA.
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At adult height, insulin sensitivity and β-cell function were similar in 67 children 
treated with combined GH/GnRHa and 43 children treated with GH only. The GH-dose 
effect on metabolic health was evaluated in a subgroup of 48 children who started GH 
treatment in early puberty (randomized to 1 or 2 mg/m2/day) with additional GnRHa for 
2 years. There was no GH dose-dependent effect on insulin sensitivity and β-cell func-
tion.
In conclusion, combined GH/GnRHa treatment has no long-term negative effects on 
insulin sensitivity and β-cell function compared with GH only. Started in early puberty, a 
GH dose of 2 mg/m2/day results in a similar insulin sensitivity and β-cell function at adult 
height as a GH dose of 1 mg/m2/day. 
chaPter 4
GH-treated SGA children with an adult height expectation below -2.5 SDS at onset of 
puberty, can benefit from additional GnRHa treatment for 2 years. We investigated 
pubertal development and growth in 76 SGA children who started GH treatment prepu-
bertal. Thirty-two children received additional GnRHa for 2 years.
Age and bone age, but also height at pubertal onset, were lower in girls and boys 
in the GH/GnRHa-group compared with the GH-group. In girls and boys treated with 
GH/GnRHa, pubertal duration after stop of GnRHa treatment was shorter than pubertal 
duration in those treated with GH only (40.9 vs 46.7 months in girls; 50.8 vs 57.5 months 
in boys). Height gain from onset of puberty until adult height, including height gain 
during 2 years of GnRHa treatment, was greater during GH/GnRHa treatment with 25.4 
cm in girls and 33.0 cm in boys. This was 6.6 cm more than in girls and boys treated with 
GH only. As a result, children treated with GH/GnRHa reached a similar adult height as 
those treated with GH only.
In conclusion, GH-treated SGA children who start puberty with an adult height expec-
tation below -2.5 SDS and are treated with additional GnRHa for 2 years, have a shorter 
pubertal duration after discontinuation of GnRHa compared to pubertal duration in chil-
dren treated with GH only. Due to adequate growth during 2 years of GnRHa treatment, 
height gain from onset of puberty until adult height is more in children treated with 
combined GH/GnRHa treatment than in children treated with GH only. Thus although 
children with GH/GnRHa treatment started puberty with a shorter stature, they reached 
a similar adult height as children treated with GH only.
chaPter 5
GH treatment results in a reduction in fat mass and insulin sensitivity, and an increase in 
lean body mass. Only short-term longitudinal changes after cessation of GH treatment 
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in subjects born SGA were available. We, therefore, assessed longitudinal changes in 
body composition, insulin sensitivity, acute insulin response, and β-cell function during 
5 years after attainment of adult height when GH treatment was discontinued. 
In 199 previously GH-treated SGA young adults, fat mass (both trunk and limb 
fat) gradually increased during 5 years after GH-cessation whereas lean body mass 
decreased. At 5 years after GH-cessation, fat mass was higher and lean body mass 
lower compared to levels at GH-cessation. During 6 months after GH-cessation, insulin 
sensitivity and β-cell function increased and the acute insulin response decreased. At 5 
years after GH-cessation, insulin sensitivity was higher, the acute insulin response lower, 
and β-cell function similar to results at GH-cessation. At 5 years after GH-cessation, 
previously GH-treated SGA young adults had a similar fat mass, insulin sensitivity, acute 
insulin response, and β-cell function, and a lower lean body mass as age-matched 
untreated short SGA young adults. Fat mass, insulin sensitivity, acute insulin response, 
and β-cell function were similar and lean body mass lower, compared to untreated SGA 
young adults with spontaneous catch-up growth and young adults born appropriate for 
gestational age. 
In conclusion, fat mass continuously increased after GH-cessation indicating the loss 
of GH benefits. At 5 years after GH-cessation, however, fat mass, insulin sensitivity, acute 
insulin response, and β-cell function were similar compared to untreated SGA and AGA 
controls. 
chaPter 6
GH treatment influences cardiovascular risk factors. Only short-term longitudinal chang-
es after cessation of GH treatment in subjects born SGA were available. We, therefore, 
assessed longitudinal changes in systolic and diastolic blood pressure (SBP and DBP), 
lipid levels, and carotid intima media thickness (cIMT) during 5 years after cessation of 
GH treatment.
In 199 previously GH-treated SGA young adults, SBP and DBP increased during 6 
months after GH-cessation and decreased thereafter. Total cholesterol, LDLc, and triglyc-
erides increased during 2 years after GH-cessation and remained similar thereafter. cIMT 
did not change after GH-cessation. At 5 years after GH-cessation, SBP, DBP, lipid levels, 
and cIMT were similar to levels at GH-cessation. At 5 years after GH-cessation, previously 
GH-treated SGA young adults had a similar SBP, DBP and cIMT, and lower lipid levels than 
age-matched untreated short SGA young adults. SBP, DBP, lipid levels, and cIMT were 
similar to untreated SGA young adults with spontaneous catch-up growth and young 
adults born appropriate for gestational age.
In conclusion, this longitudinal study during 5 years after cessation of GH treatment 
shows that long-term GH treatment in children born SGA does not only improve adult 
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height but has also no unfavorable effects on cardiovascular health in early adulthood 
and might be beneficial with regard to the lipid profile. 
chaPter 7
Some children born SGA show advanced bone age during GH treatment. ACAN gene 
mutations had been described in children with idiopathic short stature and advanced 
bone age. We set out to investigate the presence of ACAN gene mutations in children 
born SGA with persistent short stature, to develop a clinical scoring system, and to as-
sess the response to GH treatment in children with ACAN gene mutations.
Bone age was assessed in 290 GH-treated SGA children and ACAN-sequencing was 
performed in 29 children with an advanced bone age of ≥0.5 year compared to calen-
dar age. ACAN gene mutations were found in 4/29 SGA children with advanced bone 
age (13.8%). Mutations were related to the characteristics: midface hypoplasia, joint 
problems, and broad great toes. Of children with advanced bone age and 3 of these 
characteristics, 100% had an ACAN gene mutation. Of children with advanced bone age 
and 2 of these characteristics, 50% had an ACAN gene mutation, but in combination 
with a short parent (<-3.5 SDS) it rose to 100%. Children with advanced bone age hav-
ing none or only 1 of these characteristics had no ACAN gene mutation. All GH-treated 
children with an ACAN gene mutation received additional GnRHa treatment for 2 years 
from onset of puberty. At adult height, 1 girl was 5 cm taller than her mother and 1 
boy was 8 cm taller than his father with the same ACAN gene mutation. In boys, bone 
maturation was delayed by aromatase inhibitor treatment.
In conclusion, this study expands the differential diagnosis of genetic variants in chil-
dren born SGA. Our data show that the combination of persistent short stature after SGA 
birth, advanced bone age, midface hypoplasia, joint problems, and broad great toes, is 
highly suggestive for an ACAN gene mutation. Although ACAN gene mutations result in 
skeletal disorders, our data suggest that children born SGA with an ACAN gene mutation 
can benefit from GH treatment with additional 2 years of GnRHa treatment.
chaPter 8
In the general discussion we discuss our study results described in this thesis in relation 
to current literature. We emphasize on clinical implications and give directions for future 
research.
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SaMeNvattiNg
hoofDStUK 1
Dit hoofdstuk beschrijft de definities, prevalentie en mogelijke oorzaken van een 
kleine lengte en/of laag gewicht bij de geboorte (SGA, small for gestational age). Het 
geeft achtergrondinformatie over groei, puberteitsontwikkeling en de werking van 
diverse hormonale assen. De behandelingsmogelijkheden voor te kleine, SGA-geboren 
kinderen die zich rond de start van de puberteit presenteren, en de effecten van deze 
behandelingen, worden uiteen gezet. Daarnaast wordt de relatie tussen SGA, diabetes 
mellitus type 2 en hart- en vaatziekten beschreven. Aan het einde van dit hoofdstuk 
worden de doelstellingen van de studies en de indeling van dit proefschrift besproken.
hoofDStUK 2
SGA-geboren kinderen met een blijvend kleine lengte hebben baat bij behandeling met 
groeihormoon (GH). Wanneer zij een slechte lengteprognose hebben bij het begin van 
de puberteit, is additionele behandeling met GnRH-analoga (GnRHa) gedurende 2 jaar 
effectief, vooral met een dubbele dosis GH. We evalueerden de lange-termijn effecten 
van gecombineerde GH/GnRHa behandeling op de lichaamssamenstelling, bloeddruk 
en het lipidenprofiel. Daarnaast vergeleken we de effecten van 2 verschillende GH dose-
ringen (1 vs 2 mg/m2/dag) tijdens de puberteit.
Bij stop van de GH behandeling waren de vetmassa, spiermassa, bloeddruk en lipiden 
van 64 kinderen met gecombineerde GH/GnRHa behandeling vergelijkbaar met die van 
43 kinderen met alleen GH behandeling. In 47 kinderen werd het effect van verschillende 
GH doseringen tijdens de puberteit onderzocht. De vetmassa was lager in de kinderen 
met een hogere GH dosering (2 mg/m2/dag), maar de spiermassa, bloeddruk en lipiden 
waren vergelijkbaar in de 2 GH doseringsgroepen.
Deze resultaten tonen aan dat gecombineerde GH/GnRHa behandeling geen nega-
tieve lange-termijn effecten heeft vergeleken met alleen GH behandeling. Wanneer 
gecombineerde GH/GnRHa behandeling wordt gestart in het begin van de puberteit, 
leidt een hogere GH dosering (2 mg/m2/dag) tot een lagere vetmassa dan de standaard 
GH dosering van 1 mg/m2/dag.
hoofDStUK 3
SGA-geboren kinderen met een blijvend kleine lengte hebben baat bij GH behandeling. 
Wanneer zij een slechte lengteprognose hebben bij het begin van de puberteit, is ad-
ditionele behandeling met GnRHa gedurende 2 jaar effectief, vooral met een dubbele 
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dosis GH. We evalueerden de lange-termijn effecten van gecombineerde GH/GnRHa 
behandeling op de insulinegevoeligheid en β-cel functie. Daarnaast vergeleken we de 
effecten van 2 verschillende GH doseringen (1 vs 2 mg/m2/dag) tijdens de puberteit. 
Bij stop van de GH behandeling waren de insulinegevoeligheid en β-cel functie van 
67 kinderen met gecombineerde GH/GnRHa behandeling vergelijkbaar met die van 43 
kinderen met alleen GH behandeling. In 48 kinderen werd het effect van verschillende 
GH doseringen tijdens de puberteit onderzocht. De insulinegevoeligheid en β-cel func-
tie waren vergelijkbaar in de 2 GH doseringsgroepen.
Deze resultaten tonen aan dat gecombineerde GH/GnRHa behandeling geen nega-
tieve effecten heeft op de insulinegevoeligheid en β-cel functie vergeleken met alleen 
GH behandeling. Wanneer gecombineerde GH/GnRHa behandeling wordt gestart in het 
begin van de puberteit, leidt een hogere GH dosering (2 mg/m2/dag) tot een vergelijk-
bare insulinegevoeligheid en β-cel functie als de standaard GH dosering van 1 mg/m2/
dag.
hoofDStUK 4
Tot op heden was de puberteitsontwikkeling en -groei van SGA-geboren kinderen na 
staken van 2 jaar GnRHa behandeling onbekend. We vergeleken daarom de duur van 
de puberteit en de mate van pubertaire groei van 32 kinderen met gecombineerde GH/
GnRHa behandeling (GH/GnRHa-groep) met die van 44 kinderen met alleen GH behan-
deling (GH-groep).
Leeftijd, botleeftijd en de lengte bij start van de puberteit waren lager in de GH/GnR-
Ha-groep dan in de GH-groep. De duur van de puberteitsontwikkeling na staken van de 
GnRHa behandeling was korter in de GH/GnRHa-groep dan de puberteitsontwikkeling 
in de GH-groep. De lengtetoename vanaf start van de puberteit tot aan de volwassen 
lengte, inclusief de twee jaar waarin GnRHa behandeling werd gegeven, was 25.4 cm in 
meisjes en 33.0 cm in jongens. Dit was 6.6 cm meer dan de lengtetoename vanaf start 
van de puberteit tot aan de volwassen lengte in meisjes en jongens van de GH-groep. 
De volwassen lengte was vergelijkbaar in de GH/GnRHa-groep en de GH-groep.
Concluderend, SGA-geboren kinderen die rondom het begin van de puberteit starten 
met gecombineerde GH/GnRHa behandeling, hebben een kortere puberteitsontwik-
keling na staken van de GnRHa behandeling vergeleken met de puberteitsontwikke-
ling van kinderen met alleen GH behandeling. De lengtetoename vanaf start van de 
puberteit tot aan de volwassen lengte is echter groter door de adequate groei tijdens 2 
jaar GnRHa behandeling. Ondanks het feit dat kinderen in de GH/GnRHa-groep kleiner 
waren bij start van de puberteit, bereikten zij hierdoor een vergelijkbare volwassen 
lengte als kinderen in de GH-groep. 
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hoofDStUK 5
GH behandeling resulteert in een afname van vetmassa en insulinegevoeligheid en een 
toename van spiermassa. Er waren geen gegevens bekend over de lange-termijn ef-
fecten van GH behandeling op de lichaamssamenstelling, insulinegevoeligheid en β-cel 
functie na staken van de behandeling. Daarom onderzochten we dit in 199, voorheen 
met GH behandelde, SGA-geboren jongvolwassenen (SGA-GH volwassenen) gedurende 
5 jaar na staken van de GH behandeling. De gegevens op 5 jaar na staken van de behan-
deling werden vergeleken met 51 onbehandelde SGA geboren volwassenen met een te 
kleine lengte (SGA-S), 92 SGA geboren volwassenen met een normale lengte (SGA-CU) 
en 142 volwassenen met een normale geboortelengte en –gewicht en een normale 
volwassen lengte (AGA).
Gedurende 5 jaar na staken van de GH behandeling nam de vetmassa toe en de spier-
massa af. De insulinegevoeligheid steeg in de eerste 6 maanden na staken van de GH be-
handeling en bleef daarna onveranderd. Vijf jaar na staken van de GH behandeling waren 
de vetmassa en insulinegevoeligheid hoger, de spiermassa en acute insuline respons 
lager, en de β-cel functie vergelijkbaar met de waarden bij stop van de behandeling. Vijf 
jaar na staken van de GH behandeling waren de vetmassa, insulinegevoeligheid, acute 
insuline respons en β-cel functie van SGA-GH volwassenen vergelijkbaar met die van 
SGA-S, SGA-CU en AGA volwassenen. De spiermassa was lager in SGA-GH volwassenen 
vergeleken met SGA-S, SGA-CU en AGA volwassenen. 
Concluderend tonen onze resultaten een toename in vetmassa na staken van de GH 
behandeling in overeenstemming met het verlies van de lipolytische werking van GH. 
Vijf jaar na staken van de GH behandeling zijn de vetmassa, insulinegevoeligheid en 
β-cel functie van voorheen met GH behandelde SGA-geboren volwassenen vergelijk-
baar met die van onbehandelde SGA geboren volwassenen met een te kleine lengte.
hoofDStUK 6
GH behandeling beïnvloedt verscheidene cardiovasculaire risicofactoren. Er waren 
geen gegevens bekend over de lange-termijn effecten van GH behandeling op de 
bloeddruk, het lipidenprofiel en de dikte van de intima-media van de carotiden (cIMT) 
na staken van de behandeling. Daarom onderzochten we dit in 199, voorheen met GH 
behandelde, SGA-geboren jongvolwassenen (SGA-GH volwassenen) gedurende 5 jaar 
na staken van de GH behandeling. De gegevens op 5 jaar na staken van de behandeling 
werden vergeleken met 51 onbehandelde SGA geboren volwassenen met een te kleine 
lengte (SGA-S), 92 SGA geboren volwassenen met een normale lengte (SGA-CU) en 142 
volwassenen met een normale geboortelengte en –gewicht en een normale volwassen 
lengte (AGA).
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De systolische en diastolische bloeddruk namen gedurende 6 maanden na staken van 
de GH behandeling toe, maar daalden daarna. Cholesterol, LDLc en triglyceriden namen 
gedurende 2 jaar na staken van de behandeling toe, ook na correctie voor de toename 
in vetmassa, en bleven daarna onveranderd. De cIMT veranderde niet na staken van 
de GH behandeling. Vijf jaar na staken van de GH behandeling waren de systolische en 
diastolische bloeddruk, het lipidenprofiel en de cIMT vergelijkbaar met de waarden bij 
stop van de behandeling. Vijf jaar na staken van de GH behandeling waren de systoli-
sche en diastolische bloeddruk en de cIMT van SGA-GH volwassenen vergelijkbaar met 
die van SGA-S volwassenen maar de lipiden waren lager in SGA-GH volwassenen. De 
systolische en diastolische bloeddruk, het lipidenprofiel en de cIMT van SGA-GH volwas-
senen waren vergelijkbaar met die van SGA-CU en AGA volwassenen. 
Concluderend toont deze longitudinale studie gedurende 5 jaar na staken van de GH 
behandeling dat lange-termijn GH behandeling op de kinderleeftijd geen negatieve 
effecten heeft op cardiovasculaire risicofactoren op de jong volwassen leeftijd. 
hoofDStUK 7
Sommige SGA-geboren kinderen hebben of krijgen een voorlopende botleeftijd tijdens 
GH behandeling. In kinderen met een idiopathisch kleine lengte en voorlopende bot-
leeftijd werden mutaties in het ACAN gen beschreven. We onderzochten het voorkomen 
van ACAN gen mutaties in kleine, SGA geboren kinderen, ontwikkelden een klinisch 
scoringssysteem en beschreven de groeirespons tijdens GH behandeling in kinderen 
met een ACAN gen mutatie.
De botleeftijd van 290 kinderen met GH behandeling werd beoordeeld en in 29 kin-
deren met een voorlopende botleeftijd van tenminste 0.5 jaar werd diagnostiek naar 
het ACAN gen verricht. Bij 4 van de 29 kinderen (13.8%) werd een ACAN gen mutatie 
gevonden. Mutaties waren gerelateerd aan de karakteristieken: hypoplasie van het mid-
dengezicht, gewrichtsklachten en brede, grote tenen. Van de kinderen met een voor-
lopende botleeftijd en 3 van deze karakteristieken had 100% een ACAN gen mutatie. 
Van de kinderen met een voorlopende botleeftijd en 2 van deze karakteristieken had 
50% een ACAN gen mutatie. Hierbij steeg het percentage positieve bevindingen van 50 
naar 100% als tenminste één van de ouders een extreem kleine lengte had (<-3.5 SDS). 
Kinderen met een voorlopende botleeftijd en geen of slechts 1 van deze karakteristie-
ken hadden geen ACAN gen mutatie. Alle kinderen met een ACAN gen mutatie werden 
behandeld met GH en gedurende 2 jaar met additionele GnRHa behandeling. Eén meisje 
en één jongen behaalden een volwassen lengte die respectievelijk 5 en 8 cm langer was 
dan die van hun ouder met dezelfde mutatie. Behandeling met een aromatase remmer 
in jongens resulteerde in een vertraging van de botmaturatie.
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Concluderend laten onze data zien dat ACAN gen mutaties een onderliggende 
oorzaak kunnen zijn voor een persisterend kleine lengte na SGA geboorte. ACAN gen 
diagnostiek kan overwogen worden in te kleine, SGA-geboren kinderen met een voor-
lopende botleeftijd, hypoplasie van het middengezicht, gewrichtsklachten en brede, 
grote tenen. Kinderen met ACAN gen mutaties hebben baat bij gecombineerde GH/
GnRHa behandeling.
hoofDStUK 8
In de algemene discussie worden de belangrijkste resultaten van de studies in dit 
proefschrift besproken, ook in context van de huidige literatuur. Dit hoofdstuk wordt 
afgesloten met klinische implicaties en suggesties voor toekomstig onderzoek.
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what have we learNeD froM 25 yearS of growth horMoNe treatMeNt 
iN Sga?
For many years, pediatricians have been anxious that GH treatment deteriorates the 
known increased risk of metabolic problems in children born SGA. After more than 25 
years of experience with GH treatment in short children born SGA, the time has come to 
sum up the results. This chapter provides an overview of the most important findings of 
the Dutch GH trials, thereby showing that, besides the well-known effects of GH treat-
ment on growth, GH treatment affects much more than meets the eye.
gh treatment
In the Dutch IUGR-1, IUGR-2, and IUGR-3 study, children born SGA started GH treatment 
at a young age before puberty and were treated exclusively with GH. Figure 1 shows a 
schematic timeline of the most important findings during GH treatment and after cessa-
tion of treatment. An extensive number of parameters has been studied and Table 1 and 
2 summarize the results in more detail. 
The effects during treatment
The effects of GH treatment in children born SGA were thoroughly evaluated (Figure 
1 and Table 1). GH treatment improved adult height in children born SGA. Of the GH-
treated SGA children, 98% attained a height within their target height range (1). This 
represents a height gain of 11-13 cm in girls and 12-14 cm in boys. In children treated 
with GH, adult height (AH) was 0.6 SDS higher compared with untreated children. When 
GH treatment was started before puberty, AH results were similar in children treated 
with the approved GH dose of 1 mg/m2/day and those treated with a double dose of 2 
mg/m2/day (1). Children with greater spontaneous catch-up growth after birth showed 
a lower total height gain SDS during GH (2). Besides, circulating baseline free IGF-I 
and IGFBP-3 were better predictors for adult height in GH-treated SGA children than 
total IGF-I, or total IGF-I to IGFBP-3 ratio (3). This suggests a possible role for free IGF-I 
measurement in predicting the effect of GH therapy in short SGA children. Furthermore, 
short SGA children tended to have lower ALS levels compared to controls, albeit less 
reduced than IGF-I and IGFBP-3 levels (4). Determination of ALS levels before the start 
of GH treatment contributed moderately to a more accurate prediction of the growth 
response to GH treatment. 
Long-term GH treatment had no influence on the age at onset and progression of 
puberty, regardless of GH-dose (GH 1 vs 2 mg/m2/day) (5). Duration of puberty and 
pubertal height gain were not different between the GH-dose groups, and GH treatment 
had no influence on the serum Inhibin B and AMH levels (5-8).  
GH treatment improved body composition and cardiovascular profile in children born 
SGA, resulting in a decrease in fat mass, blood pressure, and serum MMP-9 levels and 
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lipid levels, and an increase in lean body mass (9-11). Besides, bone mineral density, 
which was low at start of GH treatment, normalized within 3 years (10, 12). However, GH 
treatment induced higher fasting insulin levels and glucose-stimulated insulin levels, 
indicating relative insulin resistance (13). Long-term GH treatment was not associated 
with disadvantageous changes in adiponectin, resistin, IL-6 and CRP levels, neither dur-
ing nor after GH treatment (14, 15). Preterm short SGA children had higher TSH levels 
than controls, although within the normal range (16). FT4 decreased during GH treat-
ment, but was accompanied by an increase in active T3, thereby not resulting in true 
hypothyroidism (17).
During 8 years of GH treatment, intelligence and psychosocial functioning improved 
for most children (18-20). Total IQ was significantly below average at start but had sig-
nificantly increased after 2 years of GH treatment. After 9 years of treatment, total IQ had 
become similar to levels in Dutch peers. 
The effect of cessation of GH treatment
Since we found that GH treatment affected various aspects of the metabolic and car-
diovascular profile of subjects born SGA and we know that they are at a higher risk to 
develop metabolic and cardiovascular diseases in later life, the effects of cessation of 
GH treatment needed to be evaluated (Figure 1 and Table 2). During the first 6 months 
after cessation of GH treatment, the pharmacologic effects of GH treatment on body 
composition, insulin sensitivity, blood pressure and lipid levels were lost (21, 22). After 
these initial changes, fat mass continued to increase until 5 years after cessation of GH 
treatment, but lean body mass, insulin sensitivity, and lipids remained similar (this the-
sis). After the initial increase in blood pressure, both systolic and diastolic blood pressure 
decreased and were at 5 years after cessation similar to levels at cessation of GH treat-
ment (this thesis). cIMT did not change during 5 years after cessation of GH treatment 
and was similar at 5 years after GH-cessation compared to age-matched untreated short 
SGA subjects (this thesis). At 6.5 years after GH treatment, previously GH-treated young 
adults born SGA showed a similar body composition, insulin sensitivity, and blood pres-
sure, and a more beneficial lipid profile compared to untreated short young adults born 
SGA (23, 24). This is reassuring since these findings indicate that GH treatment during 
childhood has no long-term unfavorable effects on metabolic and cardiovascular profile 
in early adulthood. However, the positive effects of GH treatment are lost and metabolic 
and cardiovascular health return to similar levels as untreated short SGA young adults. 
Since the metabolic and cardiovascular health later in adulthood are still unknown in 
both GH-treated and untreated SGA adults, longer-term follow-up of metabolic and 
cardiovascular risk factors is indicated in these predisposed subjects.
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gh treatment with or without additional gnrha treatment
In the Dutch SGA study, children born SGA started treatment at an older age. They were 
treated with GH until AH and in children who had already started puberty with an AH 
prediction below -2.5 SDS, additional GnRHa treatment for 2 years was given. Besides, 
the eff ects of two diff erent GH-doses during puberty (GH 1 mg/m2/day vs 2 mg/m2/day) 
were investigated. Figure 2 shows a schematic timeline of the most important fi ndings 
during treatment and Table 3 summarizes the results in more detail. 
The eff ects of GH treatment vs GH/GnRHa treatment 
Our data show that children who start GH treatment in early puberty can still have an 
impressive catch-up growth and GH treatment should therefore not be withheld (25). 
GH-treated SGA children who started puberty with an AH expectation below -2.5 SDS 
and were treated with 2 years of GnRHa, had a shorter pubertal duration after cessation of 
GnRHa compared with pubertal duration in children treated with GH only (26). However, 
height gain from onset of puberty until AH was greater due to adequate growth during 
2 years of GnRHa treatment. This resulted in a similar AH as children treated with GH only 
(26). Children with an AH prediction of less than -2.5 SDS at start of puberty, therefore, 
benefi t from additional treatment with GnRHa for 2 years to postpone puberty (27).
Addition of 2 years of GnRHa treatment did not adversely aff ect body composition, 
metabolic profi le, bone mineral density and quality of life (28-31). At AH, children 
treated with combined GH/GnRHa treatment had a similar fat mass, lean body mass, 
blood pressure, lipid levels and insulin sensitivity as those treated with GH only (30, 31). 
Since children with an AH expectation less than -2.5 SDS at start of puberty benefi tted 
from additional treatment with GnRHa for 2 years, and the metabolic profi le at AH of 
children treated with GH or combined GH/GnRHa was similar, additional GnRHa treat-
ment can safely be considered in children who start puberty with an AH expectation less 
than -2.5 SDS.
The eff ects of GH treatment 1 mg/m2/day vs 2 mg/m2/day 
When GH treatment is started in early puberty, only a few years of growth remain. The 
optimal GH dose during puberty and/or postponement of puberty was unknown. We 
found that boys treated with a higher GH dose of 2 mg/m2/day during puberty, reached 
a better adult height compared with boys treated with a GH dose of 1 mg/m2/day (27). A 
GH dose of 2 mg/m2/day resulted in a similar metabolic and cardiovascular profi le as GH 
1 mg/m2/day (30, 31). During 2 years of combined GH/GnRHa treatment, a GH dose of 2 
mg/m2/day resulted in a more favorable fat mass percentage than GH 1 mg/m2/day (30, 
32). We do, however, not recommend high GH dosing in all children since concerns have 
been expressed regarding the possible detrimental eff ects of persistently relatively high 
serum IGF-I levels. Nonetheless, our data show that a GH dose of 2 mg/m2/day could 
25 years of GH in SGA 185
Chapter
10
ST
A
RT
 G
H
/G
nR
H
a
A
D
U
LT
 H
EI
G
H
T
Ce
ss
at
io
n 
of
 G
H
?
Fa
t m
as
s 
in
cr
ea
se
s.
Le
an
 b
od
y 
m
as
s 
re
m
ai
ns
 s
im
ila
r.
Ad
di
tio
na
l G
nR
H
a 
fo
r 2
 y
ea
rs
 h
ad
 n
o 
ad
ve
rs
e 
e
ec
t o
n 
bo
ne
 m
in
er
al
 d
en
si
ty
.
In
su
lin
 s
en
si
tiv
ity
 d
ec
re
as
es
.
Sy
st
ol
ic
 b
lo
od
 p
re
ss
ur
e 
re
m
ai
ns
 s
im
ila
r, 
di
as
to
lic
 b
lo
od
 
pr
es
su
re
 in
cr
ea
se
s 
bu
t r
em
ai
ns
 w
ith
in
 th
e 
no
rm
al
 ra
ng
e.
Li
pi
d 
le
ve
ls
 re
m
ai
n 
si
m
ila
r, 
on
ly
 H
D
Lc
 in
cr
ea
se
s.
H
ea
lth
-r
el
at
ed
 q
ua
lit
y 
of
 li
fe
 im
pr
ov
es
.
Ad
ul
t h
ei
gh
t i
s 
si
m
ila
r.
Fa
t m
as
s 
is
 s
im
ila
r.
Le
an
 b
od
y 
m
as
s 
is
 s
im
ila
r.
In
su
lin
 s
en
si
tiv
ity
 is
 s
im
ila
r.
Bl
oo
d 
pr
es
su
re
 is
 s
im
ila
r.
Li
pi
d 
le
ve
ls
 a
re
 s
im
ila
r.
A
FT
ER
 G
H
/G
nR
H
a 
TR
EA
TM
EN
T 
W
H
IL
E 
ST
IL
L 
O
N
 G
H
G
H
/G
nR
H
a-
tr
ea
te
d 
vs
 G
H
-t
re
at
ed
 S
G
A
 a
do
le
sc
en
ts
D
U
RI
N
G
 G
H
/G
nR
H
a 
TR
EA
TM
EN
T
Sh
or
te
r p
ub
er
ta
l d
ur
at
io
n 
af
te
r G
nR
H
a-
ce
ss
at
io
n
bu
t h
ei
gh
t g
ai
n 
fr
om
 s
ta
rt
 o
f t
re
at
m
en
t u
nt
il 
ad
ul
t h
ei
gh
t w
as
 h
ig
he
r r
es
ul
tin
g 
in
 a
 s
im
ila
r 
ad
ul
t h
ei
gh
t.
AT
 A
D
U
LT
 H
EI
G
H
T
G
H
/G
nR
H
a-
tr
ea
te
d 
vs
 G
H
-t
re
at
ed
 S
G
A
 a
do
le
sc
en
ts
CE
SS
AT
IO
N
 G
nR
H
a
Th
is
 T
he
si
s
Th
is
 T
he
si
s
D
os
e-
de
pe
nd
en
t e
e
ct
 o
n 
fa
t m
as
s 
in
 fa
vo
r f
or
 G
H
 2
 m
g/
m
 /d
ay
.
D
os
e-
de
pe
nd
en
t e
e
ct
 o
n 
le
an
 b
od
y 
m
as
s
in
 fa
vo
r f
or
 G
H
 2
 m
g/
m
 /d
ay
.
In
su
lin
 s
en
si
tiv
ity
 w
as
 s
im
ila
r i
n 
th
e 
2 
G
H
 d
os
e 
gr
ou
ps
.
Bl
oo
d 
pr
es
su
re
 w
as
 s
im
ila
r i
n 
th
e 
2 
G
H
 d
os
e 
gr
ou
ps
.
Li
pi
d 
le
ve
ls
 w
er
e 
si
m
ila
r i
n 
th
e 
2 
G
H
 d
os
e 
gr
ou
ps
.
G
H
-D
O
SE
 E
FF
EC
T 
D
U
RI
N
G
 G
H
/G
nR
H
a 
TR
EA
TM
EN
T
2 2
Fi
gu
re
 2
. R
es
ul
ts
 o
f t
he
 S
G
A
 s
tu
dy
.
186 25 years of GH in SGA
be considered in a small group of short, pubertal SGA children who come to medical 
attention at such an old age that only a few years of growth remain.
genetics
Short children born SGA comprise a heterogeneous group. Bloom syndrome should 
be tested for in children with consanguineous parents, dysmorphic features (particu-
larly resembling Silver Russell syndrome), skin abnormalities, and/or serum IGF-I levels 
greater than 2.5 SD score during standard GH treatment with normal IGF binding pro-
tein-3 levels (33). Besides, ACAN gene mutations should be tested for in children born 
SGA with persistent short stature, advanced bone age and midface hypoplasia, joint 
problems or broad great toes (this thesis).
25 yearS of gh treatMeNt iN Sga
In conclusion, 25 years of experience with GH treatment in subjects born SGA has taught 
us that, besides the well-known effects of GH treatment on growth, GH treatment affects 
much more than meets the eye. Based on our studies, GH treatment has several benefi-
cial effects and is recommended in short SGA children who are otherwise at increased 
risk for short stature as adults. Additional GnRHa treatment for 2 years at start of puberty 
is recommended in children who start puberty with an expected AH below -2.5 SDS. In 
Europe, the approved GH dose for children who start GH treatment before puberty is 
1 mg/m2/day (~0.033 mg/kg/day). Since long-term effects of GH treatment and safety 
outcomes were similar between children treated with 1 or 2 mg/m2/day during puberty, 
a double GH dose of 2 mg/m2/day (~0.067 mg/kg/day) could be considered in short, 
pubertal SGA children who come to medical attention at such an old age that only a few 
years of growth remain and who do not respond sufficiently to a GH dose of 1 mg/m2/
day.
GH treatment not only improves AH and psychosocial functioning, it has also no nega-
tive effects on metabolic profile and cardiovascular risk factors until at least 5-6 years after 
its cessation. Although we have evaluated the long-term effects of GH for 5-6 years after 
cessation of treatment, the long-term effects of combined GH/GnRHa treatment after 
attainment of adult height still need to be evaluated. Besides, it remains very important 
to perform longer-term follow-up research in these patients, who have an intrinsic risk 
to develop adult-onset diseases, to elucidate the development of health and disease in 
adulthood. Future studies will also need to investigate whether GH-treated SGA patients 
show relatively greater personal and overall life achievements in adulthood. 
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Table 1. Summary of the results of the IUGR-1, IUGR-2 and IUGR-3 studies during GH treatment 
Anthropometrics
Height GH treatment led to a normalization of adult height. (1)
Children with greater spontaneous catch-up growth after birth showed a 
lower total height gain SDS during GH.
(2)
Height normalized during GH treatment. (12, 34)
Body proportions GH treatment induced a proportionate growth resulting in a normalization of 
height, sitting height, weight, head circumference, arm span, hand, tibia and 
foot size, in relation to height.
(35, 36)
Growth factors
Circulating baseline free IGF-I and IGFBP-3 were better predictors for adult 
height in GH-treated SGA children than total IGF-I, or total IGF-I to IGFBP-3 
ratio. This suggests a possible role for free IGF-I measurement in predicting 
the effect of GH therapy in short SGA children.
(3)
Short SGA children tended to have lower ALS levels compared to controls, 
albeit less reduced than IGF-I and IGFBP-3 levels. ALS might be involved in 
glucose homeostasis. Determination of ALS levels before the start of GH 
treatment contributed moderately to a more accurate prediction of the 
growth response to GH treatment.
(4)
Treatment with 2 mg GH/m2/day during 6 months resulted in higher GH, IGF-I 
and IGF-BP3 levels compared to 1 mg GH/m2/day.
(37)
In conditions in which IGF-I levels are low, such as young age and in short 
SGA children, IGFBP-3 proteolytic activity is increased to ensure IGF-I 
bioavailability.
(38)
Puberty
Long-term GH treatment had no influence on the age at onset and 
progression of puberty, regardless of GH-dose (1 vs 2 mg GH/m2/day). 
Duration of puberty and pubertal height gain were not different between the 
GH-dose groups.
(5)
Small size at birth had no effect on serum DHEAS levels before the age of 9 
yr. The incidence of premature pubarche was comparable with the normal 
population. GH treatment for 1 year had no effect on serum DHEAS levels.
(6)
Being born SGA did not impair Sertoli cell function. GH treatment did not 
result in different Inhibin B and AMH levels.
(7)
Serum AMH levels in prepubertal short SGA girls were similar to healthy 
controls, indicating that the follicle pool is not compromised due to SGA birth. 
GH treatment had no effect on AMH levels in short SGA girls.
(8)
Body composition
During long-term continuous GH treatment, BMI normalized without overall 
changes in subcutaneous fat (skinfolds measurements) compared with age-
matched references.
(9)
Fat percentage SDS decreased and lean body mass SDS remained similar 
during 6 years of GH treatment.
(10)
Cardiovascular risk factors
Blood pressure Systemic blood pressure decreased during 6 years of GH treatment. (9)
Lipid levels The atherogenic index decreased during 6 years of GH treatment. (9)
Plasma matrix 
metalloproteinase-9 
(MMP-9) levels
GH treatment had a positive, lowering effect on both MMP-9 levels and 
systolic BP SDS.
(11)
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Table 1. Summary of the results of the IUGR-1, IUGR-2 and IUGR-3 studies during GH treatment  (continued)
Anthropometrics
Inflammatory markers 
and adipocytokines
Long-term GH treatment was not associated with disadvantageous changes 
in adiponectin, resistin, IL-6 and CRP levels, neither during nor after GH 
treatment.
(14, 15)
Bone Mineral Density (BMD)
BMAD SDS increased during 6 years of GH treatment. (10)
BMD and BMAD normalized during 3 years of GH treatment. (12)
Glucose Homeostasis
Continuous GH treatment during 6 years had no adverse effects on glucose 
levels (Oral Glucose Tolerance Tests). However, GH treatment induced higher 
fasting insulin levels and glucose-stimulated insulin levels, indicating relative 
insulin resistance.
(13)
Thyroid hormone levels
Preterm short SGA children had higher, although within the normal range, 
TSH levels than controls. The level of TSH did not correlate with gestational 
age, birth weight SDS or birth length SDS. FT4 decreased during GH 
treatment, but was neither associated with an increase in TSH nor did it affect 
the response to GH treatment.
(16)
Puberty and GH treatment both induced changes in peripheral thyroid 
metabolism, resulting in more biologically active T(3) at the expense of less 
inactive rT(3), possibly mediated by IGF-I. GH treatment induced altered 
peripheral thyroid metabolism but did not result in thyroid dysfunction.
(17)
Psychological aspects
During GH treatment, IQ, behavior, and self-perception significantly improved 
from scores below average to scores comparable to Dutch peers. In addition, 
children whose height over time became closer to that of their peers showed 
less problem behavior.
(18)
GH-treated SGA adolescents had a better Quality of Life (QoL) than untreated 
adolescents born SGA, according to the disorder-specific questionnaire. 
Since the generic CHQ did not reveal such differences, a disorder-specific 
questionnaire for measuring QoL in children treated for short stature is 
preferable.
(19)
GH treatment in short children born SGA without signs of persistent catch-up 
growth was associated with significant improvement in Health-Related QoL 
and normalization of adult height.
(20)
Genetics
Short children born SGA comprise a heterogeneous group. Bloom syndrome 
should be tested for in children with consanguineous parents, dysmorphic 
features (particularly resembling Silver Russell syndrome), skin abnormalities, 
and/or IGF-1 levels greater than 2.5 SD score during standard GH treatment 
with normal IGF binding protein-3 levels.
(33)
Polymorphic variation in the IGFBP3 promoter region was correlated with 
IGFBP-3 levels, spontaneous growth and response to GH treatment in short 
SGA children.
(39)
Remaining areas
Short SGA children had a lower food intake than age-matched controls which 
increased during GH treatment.
(40)
Methylphenidate had some negative effect on growth during the first years in 
short SGA children treated with GH, but adult height was not affected.
(41)
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Table 2. Summary of the results of the IUGR-1, IUGR-2 and IUGR-3 studies after cessation of GH treatment 
Metabolic and cardiovascular health profile
During 6 months after 
GH-cessation
During 6 months after cessation of GH treatment, the GH-induced insulin 
insensitivity disappeared (Oral Glucose Tolerance Tests), the beneficial 
effect of GH on blood pressure did not change, and most adolescents had 
normal lipid levels.
(21)
During 6 months after cessation of GH treatment, longitudinal data from 
frequently sampled intravenous glucose tolerance (FSIGT) tests showed 
that the GH-induced lower insulin sensitivity increased and became similar 
to that of AGA controls. Cessation of GH treatment was, however, also 
associated with an increase in percent body fat and with a decrease in lean 
body mass, without changes in fat distribution.
(22)
During 5 years after
GH-cessation
During 5 years after cessation of GH treatment, significant changes in body 
composition, insulin sensitivity and β-cell function reflected the loss of 
GH properties. Fat mass increased, lean body mass decreased and the GH-
induced insulin resistance fully recovered. 
At 5 years after GH-cessation, FM, insulin sensitivity and β-cell function of 
previously GH-treated young adults born SGA were similar to untreated 
short young adults born SGA, indicating that long-term GH treatment in 
children born SGA has no unfavourable effect on metabolic health in early 
adulthood.
This 
thesis
During 5 years after GH-cessation, blood pressure temporarily increased, 
lipid levels increased and cIMT remained unchanged. At 5 years after 
GH-cessation, blood pressure and cIMT were similar, and lipid levels lower 
in previously GH-treated young adults born SGA compared to untreated 
short young adults born SGA. Long-term GH treatment in children born 
SGA does not only improve adult height but has also no unfavourable 
effects on metabolic and cardiovascular health in early adulthood and 
might be beneficial with regard to the lipid profile. 
This 
thesis
At 6.5 years after
GH-cessation
At 6.5 years after cessation of long-term GH treatment, previously 
GH-treated young adults born SGA had a similar glucose homeostasis, 
BMI, waist circumference, IGF-I and IGFBP-3 levels as untreated short 
young adults born SGA. Systolic and diastolic blood pressure and serum 
cholesterol were lower in GH-treated young adults. These data are 
reassuring because they suggest that long-term GH treatment does not 
increase the risk for diabetes mellitus type 2 and metabolic syndrome in 
young adults.
(23)
At 6.5 years after cessation of long-term GH treatment, previously GH-
treated young adults born SGA had a similar body composition and fat 
distribution as untreated short young adults born SGA. GH-induced 
catch-up growth had no unfavorable effect on fat mass and fat distribution 
compared with spontaneous catch-up growth. However, SGA adults 
in general might have a different body composition than healthy AGA 
controls.
(24)
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Table 3. Summary of the results of the SGA study during GH treatment with or without GnRHa 
Adult height
Excluding children with a distance to target height < 1 SDS from GH treatment is not justified. (25)
When started in adolescence, GH treatment significantly improved adult height in short SGA 
children, particularly with GH 2 mg/m2/day during puberty. When SGA children were short at 
the start of puberty, they benefitted from combined GH/GnRHa treatment.
(27)
Puberty
GH-treated SGA children who start puberty with an adult height expectation below -2.5 SDS 
and are treated with 2 years of GnRHa had a shorter pubertal duration after discontinuation of 
GnRHa compared with pubertal duration in children treated with GH only. Height gain from 
onset of puberty until adult height was, however, more due to adequate growth during 2 
years of GnRHa treatment resulting in a similar adult height as children treated with GH only.
(26)
This 
Thesis
Metabolic and cardiovascular profile
During 2 years of combined GH/GnRHa treatment, GnRHa did not adversely affect body 
composition and metabolic profile of short SGA children who came under medical attention 
at the onset of puberty. There was a dose-dependent effect on fat mass SDS), percentage 
trunk fat, lean body mass SDS, and GH and IGF1 levels in favor of treatment with GnRHa and 
the higher GH dose of 2 mg/m2/day.
(32)
At adult height, metabolic and cardiovascular parameters were similar in adolescents treated 
with combined GH/GnRHa treatment and those with GH only. Started in early puberty, a GH 
dose of 2 mg/m2/day resulted in a more favorable fat mass percentage than GH 1 mg/m2/day.
(30, 31)
This 
Thesis
Bone Mineral Density (BMD)
During GH treatment, BMD increased significantly, leading to a normal adult BMD in almost all 
patients. Two years of GnRHa in addition to GH treatment had no adverse effect on BMD.
(28)
Psychological aspects
HRQoL improved in prepubertal and pubertal short SGA children during GH treatment. 
Additional GnRHa treatment had no adverse effect on the HRQoL gain. Disorder-specific 
questionnaires were particularly appropriate to evaluate HRQoL in children treated for short 
stature.
(29)
Genetics
Mutations in the ACAN gene can be the cause of advanced bone age maturation in GH-treated 
children born SGA. ACAN-gene sequencing should be considered in children born SGA 
with persistent short stature, who show advanced bone age and midface hypoplasia, joint 
problems or broad great toes. Children with ACAN gene mutations benefit from GH treatment 
with 2 years of GnRHa treatment.
This 
Thesis
GH levels during GnRHa only
Short SGA girls lacked the normal increase in GH levels seen in puberty and had reduced 
IGF-I and IGFBP-3 levels, which might explain their reduced pubertal growth spurt. GnRHa 
treatment led to a significant reduction in GH levels. Therefore, combining GnRHa treatment 
with GH treatment might improve adult height in short SGA girls.
(42)
GnRH agonist test
GnRHa sufficiently suppressed puberty in girls and boys born SGA during 3 months of 
treatment. The GnRH agonist test falsely indicated insufficient pubertal suppression in 33% of 
the girls and 43% of the boys. 
(43, 44) 
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liSt of abbreviatioNS
AGA  appropriate for gestational age
AH  adult height
AIR  acute insulin response
ApoA-1  apolipoprotein A-1
Apo-B  apolipoprotein B
ATP III  Adult Treatment Panel III
BA  bone age
BMI  body mass index
BP  blood pressure
CA  calendar age
cIMT  carotid intima media thickness
CPP  central precocious puberty
CVD  cardiovascular disease
DBP  diastolic blood pressure
DI  disposition index 
DXA  dual-energy X-ray absorptiometry
FM  fat mass
FM%  fat mass percentage
FSH  follicle stimulating hormone
FSIGT  frequently sampled intravenous glucose tolerance test
GH  growth hormone
GHRH  growth hormone-releasing hormone
GnRH  gonadotropin-releasing hormone
GnRHa  gonadotropin-releasing hormone analog
HDLc  high density lipoprotein cholesterol
HPG-axis hypothalamic-pituitary-gonadal axis
HOMA-IR homeostasis model assessment of insulin resistance
IGF  insulin-like growth factor
IGF-I  insulin-like growth factor-I
IGFBP  insulin-like growth factor binding protein
IGT  impaired glucose tolerance
IUGR  intra-uterine growth retardation
IQR  interquartile range
LBM  lean body mass
LDLc  low density lipoprotein cholesterol
LF  limb fat
LH  luteinizing hormone
M2  breast development stage II according to Tanner
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NCEP  National Cholesterol Education Program
QOL  quality of life
SAGhE  Safety and Appropriateness of Growth hormone treatments in Europe
SBP  systolic blood pressure
sc  subcutaneous
SDS  standard deviation score
Sg  glucose effectiveness
SGA  small for gestational age
SGA-CU  born small for gestational age with spontaneous catch-up growth 
SGA-GH  previously GH-treated subjects born small for gestational age
SGA-S  born small for gestational age with short adult stature
Si  insulin sensitivity
T2DM  diabetes mellitus type 2
TC  total cholesterol
TF  trunk fat
TG  triglycerides
TH  target height
TV  testicular volume
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Research Management, MolMed, Erasmus MC 2014 1.0
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DaNKwoorD
Een klinische studie en het schrijven van een proefschrift doe je niet alleen en vele 
mensen hebben mij de afgelopen jaren geholpen. Zij hebben allemaal, op hun eigen 
manier, veel voor mij betekend en mij gestimuleerd en gemotiveerd in mijn persoonlijke 
groeiproces. Graag wijd ik aan hen de laatste pagina’s van mijn proefschrift.
Allereerst wil ik alle studiedeelnemers en hun ouders/verzorgers bedanken voor de 
jarenlange trouwe deelname aan dit onderzoek. Naast de dagelijkse inzet vergen de 
vele polibezoeken en de follow-up controles een behoorlijke inspanning van jullie. Ik 
ben iedere keer weer onder de indruk van jullie bereidheid tot deelname, geduld en 
interesse. Met vele van jullie maakte ik het behalen van de eindstreep van de groei-
hormoonbehandeling mee, en dit was iedere keer weer een feest. Zonder jullie was dit 
proefschrift, en mijn eigen eindstreep, er niet geweest. Ik wens jullie het allerbeste!
Mijn promotor, prof.dr. A.C.S. Hokken-Koelega. Beste Anita, dank voor de geweldige 
kansen en uitdagingen die u me de afgelopen jaren heeft geboden. Ik heb heel veel 
van u geleerd en met hulp van uw kennis en kritische blik is dit proefschrift geworden 
wat het is. Uw toewijding en energie voor de vele onderzoeken die u begeleidt, zijn 
bewonderenswaardig. U ondersteunt en stimuleert uw promovendi met een onvoor-
waardelijke inzet en passie, waarvoor ik zeer dankbaar ben. 
Prof.dr. A.J. van der Lelij, hartelijk dank voor uw bereidwilligheid om de rol van secretaris 
binnen de kleine commissie te vervullen.
Prof.dr. P.E. Clayton and prof.dr. S. Cianfarani, thank you for your willingness to partici-
pate in the PhD review committee and speaking at the SGA symposium. 
Dr. W.M. Bakker-van Waarde, dank voor de prettige samenwerking, uw kritische blik als 
medeauteur van enkele manuscripten en voor het plaatsnemen in de grote commissie.
Prof.dr. I.K.M. Reiss wil ik hartelijk danken voor het plaatsnemen in de grote commissie. 
Ik hoop dat we in de toekomst vaak zullen samenwerken.
Prof.dr. F. de Zegher, veel dank voor het plaatsnemen in de grote commissie.
Alle kinderartsen met wie ik heb samengewerkt aan dit onderzoek: dr. W.M. Bakker-van 
Waarde, drs. F.J.P.C.M. van der Hulst, drs. F.S. Neijens, prof.dr. C. Noordam, drs. R.J. Odink, 
dr. W. Oostdijk, dr. E.J. Schroor, dr. E.J. Sulkers, dr. C. Westerlaken en alle poli-assistenten 
van de deelnemende ziekenhuizen. Bedankt voor de prettige samenwerking, de weten-
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schappelijke bijdrage en de hartelijkheid waarmee we ontvangen werden tijdens onze 
3-maandelijkse bezoeken. Daarnaast wil ik de medewerkers van afdeling 2 Midden, de 
dagbehandeling en de polikliniek van het Sophia Kinderziekenhuis bedanken voor de 
samenwerking en de faciliteiten.
Rolph Pfundt en Stephan J.W.H. Maas, medeauteurs van het laatste manuscript in dit 
proefschrift. Hartelijk dank voor de prettige samenwerking en het geduldig beantwoor-
den van al mijn vragen.
Dr. E.L.T. van den Akker, dr. A.E. Brandsma, dr. S.W.K. de Kort, en dr. S.E. Hannema, bedankt 
voor jullie frisse blik tijdens de leerzame endocrinologiebesprekingen.
Dhr. W.H. Hackeng wil ik hartelijk danken voor het bepalen van de glucose- en insuline-
waarden van de FSIGT’s en de getoonde belangstelling voor de studies en mijn proef-
schrift. Ik heb veel bewondering voor uw trouwe inzet in al die jaren. Mevr. J. Sluimer en 
collega’s dank ik voor het uitvoeren en controleren van de DXA-scans.
Pfizer BV Nederland, in het bijzonder Joli van der Lans en Joost van Middendorp, wil ik 
bedanken voor de plezierige samenwerking, belangstelling en financiële ondersteuning 
van de SGA studie.
De Vereniging Trustfonds Erasmus Universiteit Rotterdam dank ik voor de financiële 
bijdrage aan de jaarlijkse ESPE congresbezoeken.
Het SGA Platform dank ik voor de prettige samenwerking in de afgelopen jaren. Het was 
een eer om medisch adviseur van het platform te zijn en ik ben trots dat we samen een 
mooi symposium georganiseerd hebben.
Mijn voorgangers binnen de SGA studie, Annemieke en Daniëlle. Door jullie kwam ik 
terecht in een prachtige, goed lopende studie. Jullie inzet en passie hebben voor een 
goede basis gezorgd. Bedankt voor het meedenken over nieuwe ideeën, jullie oplet-
tende en kritische blik bij het beoordelen van de manuscripten en jullie blijvende 
belangstelling. Ik wens jullie beide een prachtige carrière als kinderarts. 
Lieve researchverpleegkundigen van de groeistudies, dank jullie wel voor de fijne mo-
mentjes binnen en buiten het ziekenhuis, de teamspirit, de vele ritjes door het land en 
jullie inzet voor de studies. José, je hebt me de ruimte gegeven om te groeien en stond 
altijd klaar met eerlijke en goede adviezen. Ik weet dat ik de SGA studie bij jou in goede 
handen achterlaat! Christel, dank voor je hulp en ideeën, zonder jou was het artikel over 
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de IMTs er niet geweest. Esther, je hartelijke lach op de vroege maandagmorgen zorgde 
voor een goede start van de week. Berber en Jorien, bedankt voor jullie enthousiasme 
en de fijne tijd samen bij de endo. Janneke, mijn vriezerbuddy, Marianne en Joke, heel 
hartelijk bedankt voor de fijne samenwerking in de afgelopen jaren.
Ik wens jullie allemaal heel veel geluk en succes in de toekomst!
Mijn lieve collega’s van de Stichting Kind en Groei, Akvile, Conny, Elise, Eva, Gladys, Ineke, 
José, Mariëlle, Momoko, Laura, Layla, Lydia, Nienke, Renske, Rosadinde, Sander, Sandra, 
Sinddie, Stephany, Sunita en Trudie. Jullie zagen mij in het begin zo weinig dat de deur 
pas na het duidelijk noemen van mijn naam en bezoekreden werd geopend. Gelukkig 
richtte ik me op de SGA studie en voelde ik me al snel helemaal thuis bij jullie. Eerst op 
de rumoerige bovenverdieping, later op de rustige benedenverdieping. Het is zo fijn om 
leuke collega’s te hebben die zorgen voor een plezierige werksfeer. Dank jullie wel voor 
alle theetjes, taartjes, lunches op het balkon, etentjes en hilarische uitjes. Ik heb een 
prachtige tijd gehad bij jullie!
Ineke, bedankt voor al je hulp, steun en wijze woorden. Je inzet voor alle promovendi 
en voor het symposium op die speciale en spannende dag, zijn bewonderenswaardig! 
Mariëlle, zorgzaam en betrokken. De PWS kinderen, en ik als collega, hebben het met 
je getroffen. Rosadinde, hartelijk en oprecht, dank voor de prachtige uitnodiging voor 
het symposium! Sander, altijd rustig en kalm tijdens SPSS/ESPE-stress, dank voor je vele 
hulp en humor. 
Lieve Justine, wat was het speciaal om jou te begeleiden tijdens je wetenschapsstage 
bij de studie waar je zelf als deelnemer aan mee hebt gedaan! Je vrolijke goedemorgen, 
enthousiasme, betrokkenheid en harde werken heb ik zeer gewaardeerd.
Lieve endo-meiden, Florentien, Gerthe, Judith, Kirsten, Laura, Layla, Lin, Nienke, Petra, 
Renske, Sinddie, Stephany en Yvonne. Bedankt voor het enthousiasme, de gezelligheid 
en de adviezen. Altijd tijd om over onderzoek te discussiëren maar zeker ook voor 
biosavondjes en etentjes. Dank voor vele mooie momenten, het endolied zal ik nooit 
vergeten! Lieve Laura, dank dat ik bij jou even mocht ‘oefenen’. Samen schaatsen en 
hardlopen, je enthousiasme en vrolijkheid werkten aanstekelijk!
Alle onderzoekers van de SOV. De activiteiten, ski/survival-weekenden, borrels en diners 
met jullie hebben voor een fantastische tijd gezorgd!
Lieve Lidewij en Dorian, skihelden, zonder jullie stond ik nog steeds boven aan die 
idioot steile skipiste, op een net iets te hoge berg in Valkenburg, of compleet verdwaald 
in een zeer donkere grot... Jullie stimuleerden mij niet alleen om deze hindernissen te 
nemen, maar ook om alle onderzoeksuitdagingen aan te gaan. Lieve Lidewij, dank voor 
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je vertrouwen en eindeloos goede adviezen. Heel veel succes, je wordt een fantastische 
kinderarts, en we zetten onze etentjes gewoon voort!
Mijn lieve SOV-bestuursgenootjes, Lisette, Robin en Esther. Lisette, na pittige over-
legmomentjes dook ik vaak even je kamer in waar je altijd klaar zat met een kop thee 
en bemoedigende woorden. Robin, met jouw nuchtere blik en relativeringsvermogen 
werd ieder (SOV-)probleempje opgelost. Esther, enthousiast en met een frisse blik het 
SOV-bestuur ingestapt waardoor ik wat afstand kon nemen. Lieve meiden, bedankt voor 
de geweldige tijd! 
Oud-collega’s uit het Elisabeth ziekenhuis Tilburg, ik kijk met veel plezier terug op mijn 
eerste stappen als arts bij jullie. Dank dat jullie mij stimuleerden om onderzoek te gaan 
doen.
Alle lieve vrienden en vriendinnen buiten het Sophia, bedankt voor alle niet-promotie 
gerelateerde afleidingen. Zonder de weekendjesweg, mooie reizen in binnen- en bui-
tenland, heerlijke etentjes met de Sch(r)ans on tour, muzikale momentjes in Beeg met 
borrels bij Aurora, lieve kaartjes die hun weg naar Rotterdam vonden, musical-avondjes, 
de vele theetjes en Limburgse vlaai, waren de afgelopen jaren niet zo leuk geweest. 
Dank dat jullie me helemaal in Rotterdam nog steeds komen opzoeken! Lieve Eronne, 
met iemand op vakantie gaan die de cover en lay-out van haar proefschrift nog moet 
goedkeuren, is een ware uitdaging. Dank voor je geduld en humor, ik heb ervan genoten.
Mijn paranimfen.
Lieve Dorian, vanaf het begin van mijn promotieonderzoek stond je naast me en ik 
ben ontzettend blij en trots dat je ook op die spannende dag als paranimf naast me 
wilt staan. We hebben ontelbare theetjes gedronken en taartjes gegeten, pratend over 
de ups-and-downs van het onderzoeksleven en zo veel meer. Jouw luisterend oor, 
positiviteit, vertrouwen, lieve woorden en fijne knuffels hebben ervoor gezorgd dat dit 
proefschrift uiteindelijk af is gekomen. Zonder jou was het niet gelukt! Ik hoop dat onze 
vriendschap nog jaren zal voortduren. Dank dat je aan mijn zijde staat! 
Lieve Sanne, ♪ You see in blue when I see everything in red ♪, maar dat heeft ons nooit 
weerhouden van heel veel gezellige momenten. Blauw en rood samen geven een hele 
mooie kleur paars! Of we nu in Beeg, Maastricht, Nijmegen, Londen, Iowa, Tilburg, Zee-
land, Luxemburg, Rotterdam of Brussel zijn, onze gesprekken zetten we gewoon voort 
waar we ze, soms weken eerder, gestopt zijn. Je bent altijd zo betrokken, geïnteresseerd 
en behulpzaam, en ik ben ontzettend trots dat je mijn paranimf bent! Onze reis naar 
New York en Washington was de kers op de cheesecake, en ik hoop dat er nog vele 
mooie momenten, in Nederland en ver daarbuiten, mogen volgen!
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Mijn lieve familie in het hoge noorden en het diepe zuiden. Dank voor het hartverwar-
mende samenzijn. Joke en Klaas, dank dat jullie altijd voor mij klaar staan, als er verhuisd 
of geklust moet worden, de verwarming ’s nachts kapot springt, mijn band lek is of ik 
gewoon even zin heb in een middagje tuin. Dank voor jullie belangstelling en de vele 
gezellige weekenden in Rotterdam. Lieve Jasmijn, mijn petekind, je tovert altijd een lach 
op mijn gezicht. Er komen nu weer wat meer samen-momentjes aan, beloofd!
Lieve mama en papa, ik heb veel geleerd in de afgelopen 4 jaar maar jullie weten niet 
half hoeveel ik van jullie heb geleerd. Jullie hebben me altijd gestimuleerd maar nooit 
gepusht, iets waardoor ik ontzettend gegroeid ben. Dank jullie wel voor jullie oneindige 
steun en liefde. Ik ben trots jullie dochter te zijn!
Mijn allerliefste zussen, Daniëlle en Kimberley. Wat ben ik trots de middelste van onze 
drie-eenheid te zijn. Lieve Daan, als mijn grote zus volgde ik vaak jouw voorbeeld, in 
schoolkeuze en muziekinstrument, maar niet in studie. Ondanks dat je in een hele 
andere branche zit en we een eindje uit elkaar wonen, ben je altijd geïnteresseerd en 
behulpzaam. Je hebt een prachtig gezin waar ik vaak van mee mag genieten. Lieve Isis 
en Vesper, jullie zijn mijn zonnetjes in het zuiden! 
Lieve Kim, de jongste en zo vaak en veel bemoederd. Je kwam me gezellig achterna naar 
Rotterdam en wat was het heerlijk de afgelopen jaren hier met jou te mogen delen. Je 
oprechtheid, humor, opbeurende woorden en lekkere maaltijden hebben me altijd veel 
goed gedaan. Ik kan me geen lievere zussen voorstellen.
‘I am part of one terrific sister act’
Manouk
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Growth hormone (GH) treatment effectively 
induces catch-up growth and improves 
adult height in short children born small for 
gestational age (SGA). Besides this visual 
effect, GH treatment also has several other 
effects which occur inside the body. 
This doctoral thesis presents the effects of GH treatment, with or without 
additional gonadotropin-releasing hormone analog (GnRHa) treatment, on 
metabolic and cardiovascular risk factors. The effects of GnRHa treatment, in 
addition to GH treatment, on pubertal development are described. Further, the 
long-term effects of discontinuation of GH treatment are assessed in young 
adults born SGA. Finally, a new genetic cause for persistent short stature after 
SGA birth is revealed. 
The results presented in this thesis illustrate that there is more to GH treatment 
than meets the eye.
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